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Summary 
Human and bovine respiratory syncytial viruses (HRSV and BRSV), along with 
pneumonia virus of mice (PVM) are the members of the genus Pneumovirus in the 
subfamily Pneumovirinae of the family Paramyxoviridae. Although both HRSV and 
BRSV have been associated with important diseases in human and livestock, there is no 
clearcut description of the molecular aspects of their pathogenesis. For HRSV, the lack 
of a suitable study model is one of the main reasons hampering the study of aspects of 
pathogenesis of the virus. HRSV infects a wide range of animal models, however most 
of the common laboratory animal models are not sufficiently permissive to study the 
infectivity of the virus. 
PVM naturally infects mice and causes a disease indistinguishable from that of 
HRSV in humans. Two strains of PVM have been described: strain 15 (Warwick) which 
is not pathogenic and strain J3666 which is highly pathogenic. The main difference 
between these two strains lies in the organisation of the gene encoding the attachment 
(G) glycoprotein. The G gene in strain J3666 has two ORFs. The larger second ORF 
codes for the G glycoprotein and is located downstream of the first ORF which has no 
known function. The strain 15 G gene also contains two ORFs but in this case both the 
first and main ORFs overlap each other. 
The aim of the project was to investigate the molecular basis for pathogenesis of 
PVM as a model for pneumoviruses. As a first step, the pathogenesis of PVM strain 
J3666 was revaluated and the effect of consecutive tissue culture passages on the 
pathogenicity of the virus was examined. It was shown that consecutive passages of 
PVM strain J3666 caused attenuation of the virus. To investigate the possible mutations 
causing the attenuation the majority of the virus genome was sequenced from three 
passage stocks where the transition from pathogenic to non-pathogenic occurred.  No 
differences in the genome sequences for the three passage stocks were found.  However, 
sequence analysis of individual clones of the SH and G genes of the viruses showed 
evidence that the stocks contained a mixed population of sequences. 
A robust reverse genetics system was established to rescue recombinant PVM 
from cDNA using co-transfection of plasmids coding for the ribonucleoprotein complex 
of the virus (N, L, M2-1 and P proteins) and a cDNA copy of the virus genome cloned 
under the control of the bacteriophage T7 RNA polymerase. Using this system, four 
viruses differing in their G gene organisation were generated and used to infect mice to 
study the effect of mutations on pathogenicity.  It was shown that the viruses with the G 
gene of strain 15 (Warwick) lacking the first ORF manifest a modest increase in their 
pathogenicity compared to the non-pathogenic PVM strain 15(Warwick) parent. The 
recombinant viruses containing the G gene organisation of strain J3666 showed the 
highest level of pathogenicity. 
The reverse genetics system was used to study the role of the first ORF in G 
glycoprotein expression. Using a dicistronic minigenome construct, the effect of the 
presence or absence of the first ORF in both the strain 15 and strain J3666 G gene 
organisation was studied.  It was shown that the presence of the first ORF of the G gene 
in the strain 15 (Warwick) suppressed the expression of the G protein, while the first 
ORF in the strain J3666 did not have any significant effect on G protein expression. 
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1.1  PVM and RSV: An overview and virus taxonomy 
Pneumonia virus of mice (PVM) was first purified from apparently healthy mice 
in 1938 during an attempt to isolate viruses from mice with “various acute non-
influenzal diseases of the respiratory tract” (Horsfall & Hahn, 1940). The lung extract of 
healthy mice, which were used as the control system, caused transmissible pulmonary 
consolidations in mice intranasally infected with the extract (Horsfall & Hahn, 1940). A 
wide range of mammalian hosts including humans, primates, rodents and rabbits were 
reported being seropositive against PVM (Horsfall & Curnen, 1946; Pringle & Eglin, 
1986). A recent study showed the presence of a viral agent closely related to PVM 
capable of producing acute pneumonia in dogs. The canine virus was isolated from 
nasal and pharyngeal swab specimens and tested using a pool of human respiratory 
syncytial virus (HRSV) monoclonal antibodies consisting of four monoclonal antibodies 
against P, N, M2 and F proteins. Testing the canine virus against the antibodies, 
individually, indicated that the agent reacts with the P and M2 monoclonal antibodies, 
but not with N and F antibodies. Sequencing of PCR fragments amplified from the N 
gene of the canine virus indicated 96% - 97% alignment to the N gene of PVM, and a 
fragment amplified from the L gene was found to be 96% identical to the L gene of 
PVM (Renshaw et al., 2010).  
About 2 decades after the description of PVM,  HRSV was isolated in 1956 
from a symptomatic chimpanzee with coryza during an outbreak of illness (Chanock et 
al., 1957). This virus, chimpanzee coryza agent (CCA), was subsequently shown to be a 
serious human pathogen (Chanock et al., 1957). HRSV is now recognised as the most 
important viral pathogen of serious respiratory tract infection in paediatrics, and is 
responsible for both upper and lower respiratory tract infections (Collins et al., 2001). 
Annually, a large range of patients including infants, neonates, immunocompromised 
patients, and elderly people are infected with the virus (Collins et al., 2001). 
The similarity between the cytopathology of HRSV and Newcastle disease virus 
(NDV) was the first evidence suggesting relatedness of the two viruses (Kisch et al., 
1962). Later, despite the lack of neuraminidase (NA) and hemagglutination (HA) 
activities in HRSV, the possibility of the classification of HRSV into the “Parainfluenza 
group” was suggested (Waterson & Hobson, 1962). Based on the virus morphology and 
the lack of neuraminidase and hemagglutination activities and to distinguish it from 
3 
 
other members of the family Paramyxoviridae, HRSV was classified separately in the 
genus pneumovirus, of the family Paramyxoviridae (Venkatesan et al., 1983). 
The family Paramyxoviridae, one of the largest families of viruses, includes 
major contagious and infectious viruses causing a wide range of disease in humans and 
animals. The family Paramyxoviridae contains two subfamilies: Paramyxovirinae and 
Pneumovirinae. The subfamily Pneumovirinae is distinguished from Paramyxovirinae 
based on their morphologically different nucleocapsid. However, the major differences 
between them are the number of encoded proteins and a different form of attachment 
glycoprotein  (Lamb & Kolakofsky, 2001). In turn, the family Paramyxoviridae is 
related to other families of virus having single component negative sense RNA genomes 
as part of the order Mononegavirales. 
The sub-family Paramyxovirinae includes the genera avulavirus, henipavirus, 
respirovirus, rubulavirus, and morbillivirus, and the subfamily Pneumovirinae contains 
the genera pneumovirus and metapneumovirus (Table 1.1). There are three members 
described in the genus pneumovirus: human respiratory syncytial virus (HRSV), bovine 
respiratory syncytial virus (BRSV) and murine pneumonia virus (MPV). HRSV is the 
type member of the genus and has two known subtypes: genotype A and B. MPV, 
traditionally known as pneumonia virus of mice (PVM), is the murine counterpart of 
HRSV. Most information known is about HRSV as the type member of the genus. In 
the description of pneumoviruses below, differences between PVM and HRSV, and also 
difference between the two HRSV genotypes are indicated where it is required. A 
summary of the classification of the family Paramyxoviridae is given in Table  1.1. 
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Family Subfamily Genus Type species 
Paramyxoviridae 
Paramyxovirinae 
avulavirus  Newcastle disease virus (NDV) 
Henipavirus  Hendra virus (HeV) 
morbillivirus  measles virus (MeV) 
rubulavirus  mumps virus (MuV) 
respirovirus  Sendai  virus (SeV) 
Pneumovirinae 
pneumovirus 
human respiratory syncytial virus 
(HRSV) 
metapneumovirus  avian metapneumovirus (AMPV) 
Table  1.1 Classification of family Paramyxoviridae based on the reclassification of International 
Committee on the Taxonomy of Viruses (ICTV) in 2009 (ICTV, 2009). The type member of each 
genus is provided separately under type species column. 
HRSV was classified into two distinct subtypes A and B by using a cross 
protection experiment with related glycoproteins (Mufson et al., 1985). Mufson and 
colleagues (1985) used a collection of monoclonal antibodies against the G, F, M, N and 
P proteins of RSV strain Long and examined seven different viruses isolated at different 
times. The main difference was observed in the G glycoproteins in which the two 
subtypes shared one of the six epitopes that was tested. In the same study differences in 
the epitopes of the F, M and N proteins were reported:  one of the two epitopes 
examined in the F glycoprotein, two of six epitopes in the M protein, and one of six in 
the N protein were different between subtypes A and B (Mufson et al., 1985). In 
another study 26 different HRSV strains were classified into three groups which were 
defined as common, more common and rare strains (Anderson et al., 1985). 
Soon after isolation of bovine respiratory syncytial virus (BRSV) the serologic 
relatedness between HRSV and BRSV was shown which suggested a taxonomical 
relationship between the two viruses (Doggett et al., 1968; Paccaud & Jacquier, 1970). 
Subsequently, PVM was classified as another member of the genus mainly because of 
the morphological similarities with human and bovine RS viruses (Berthiaume et al., 
1974).  
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1.1.1 General features of the virion  
Both PVM and HRSV are enveloped viruses surrounded by the lipid bilayer 
which is derived from the host cell plasma membrane. The fusion (F) and attachment 
(G) glycoproteins project from the surface of the viral envelope. A small hydrophobic 
(SH) protein is the third viral surface protein. However, due to its hydrophobic nature 
and small size the SH protein is not readily detectable on the virus surface. The matrix 
(M) protein forms a protein layer between the envelope and the nucleocapsid. The 
nucleocapsid consists of the virus genomic RNA (vRNA) tightly packaged into the 
nucleocapsid protein and surrounded by the RNP complex. The virus structure is 
depicted in Figure 1.1 and different parts of the virus are annotated. 
The virion of HRSV and PVM show a pleomorphic appearance with sizes 
ranging from 100 to 350 nm. The filamentous forms range from 60 to 200 nm in 
diameter and a length of up to 10 µm (Bachi & Howe, 1973; Lamb & Kolakofsky, 
2001; Norrby et al., 1970). PVM particles are 100-120 nm in diameter with a length of 
2-3 µm in the filamentous forms, and 80-120 nm in diameter in the spherical 
morphology (Compans et al., 1967; Gallaspy et al., 1978). 
 
Figure  1.1 pneumovirus structure. The attachment (G) and fusion (F) glycoproteins, lipid 
membrane, the matrix (M) protein, and ribonucleoprotein complex (RNP complex) are indicated. 
As described above, no HA or NA activity has been reported for HRSV 
(Richman et al., 1971). However, this characteristic is not a general feature of 
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pneumoviruses; Ling and Pringle (1989b) using a hemagglutination inhibition 
experiment showed that G glycoprotein of PVM has intrinsic hemagglutination effect 
on murine red blood cells. Ling and Pringle (1989b)  also reported that a monoclonal 
antibody directed against the G glycoprotein of PVM strain 15 (Warwick) strongly 
inhibited PVM from agglutinating murine erythrocytes. 
The lack of a suitable animal model for HRSV has hampered the study of 
different aspects in the pathogenesis of the virus. Occasionally BRSV, the bovine 
counterpart of HRSV, has been used to study the pathogenesis of pneumoviruses. PVM, 
has also been proposed as a good candidate to investigate unknown aspects of 
pneumovirus-host interaction. 
1.2 Molecular biology and replication cycle of pneumoviruses 
The replication cycle of pneumoviruses starts by binding of the virus at the 
cellular surface components, which is mediated by the G and/or F glycoproteins 
(section  1.2.1). Virus entry to the cell happens after the attachment and is mediated by 
the F glycoprotein which initiates fusion between the viral envelope and the cellular 
membrane. Following the fusion process, the nucleocapsid complex containing the viral 
genome is released into the cytoplasm (section  1.2.1.3). The viral RNA (vRNA) is used 
as a template in the RNA synthesis process involving transcription and replication. The 
transcription process involves synthesis of messenger RNA (mRNA) and the replication 
cycle involves the synthesis of a complimentary copy of vRNA (cRNA) which acts as 
the antigenomic RNA. The cRNA is then transcribed to the vRNA by the viral RNP 
complex (Section  1.2.4). In contrast to Sendai virus, PVM has been shown to be capable 
of growth in enucleated BS-C-1 cells indicating that nuclear functions provided by the 
cell are not necessary for the virus replication (Cash et al., 1979). The HRSV and PVM 
genomes comprise 10 genes separated by intragenic sequences.  
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Figure  1.2 Comparison between RSV and PVM vRNA. There are 10 genes across the genome 
responsible for coding 11 or 12 known proteins respectively. The name of each gene is 
indicated. Numbers in brackets refer to the number of nucleotides in the intergenic regions. The 
size of P2 and M2-2 genes and proteins are provided and separated from the number 
representing the size of P1 and M2-1 by “/”. 
During virus replication, at least 11 proteins are synthesised and processed: 
these are the viral structural proteins (M, SH, F, and G), nucleocapsid complex proteins 
(N, L, P and M2-1 proteins), and non-structural proteins (NS-1, NS-2, and M2-2). The 
replication cycle of pneumoviruses is completed by the assembly and release of the 
virus (Section  1.2.5.1). A schematic structure of the vRNA of PVM strain 15 Warwick 
and HRSV strain S2 is depicted in Figure  1.2. 
1.2.1 Attachment and entry 
HRSV uses glycosaminoglycan (GAG) proteins for attachment to the host cells 
with HRSV entry estimated to have a half life of 30 min (Techaarpornkul et al., 2002). 
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There is no report on the entry rates of other members of the Paramyxoviridae. The 
process of attachment of HRSV to host cells is not clearly understood. Two major 
glycoproteins of HRSV, glycoprotein G (the large glycoprotein) and glycoprotein F, 
have been shown to be responsible for the attachment and virus docking on the host 
cells. 
The G glycoprotein of HRSV was shown to be responsible for virus attachment 
(Levine et al., 1987). Subsequently, it was shown that monoclonal antibodies directed 
against the HRSV G glycoprotein are capable of preventing virus entry (Martinez & 
Melero, 1998). The observation that viruses lacking the gene encoding the G protein are 
able to infect in vivo and in vitro has raised question about the role of the G protein in 
virus attachment (Karron et al., 1997; Martinez & Melero, 1998). It has been proposed 
that the F protein may be able to attach to the cell surface through an unknown 
mechanism. 
1.2.1.1 G glycoprotein 
The G glycoprotein is a type II glycoprotein with a hydrophobic region near its 
N terminus. The G glycoprotein is smaller than, its counterpart, the HN glycoprotein, 
among the members of Paramyxovirinae, and its length varies from 282 to 319 amino 
acids among different strains of the HRSV (Lamb & Kolakofsky, 2001). No cellular 
receptor has been identified for the G glycoprotein, though there is evidence that cell 
surface GAG are important in the virus binding and infection (Feldman et al., 1999). 
The G glycoprotein appears not to be an essential glycoprotein for virus growth. HRSV 
lacking the G glycoprotein can grow efficiently in Vero cells but their growth was 
impaired in HEp-2 cell lines (Teng et al., 2001). 
Maturation of the G glycoprotein occurs in the endoplasmic reticulum and Golgi 
compartments of the cell. The G glycoprotein produces homo-oligomers in the 
endoplasmic reticulum and O-glycosylation follows after the oligomerisation in the 
trans-Golgi compartment (Collins & Mottet, 1992). 
The G protein of HRSV has an Mr of 36000 in its non-glycosylated state. Its 
glycosylated form is reported to have an Mr of 84000-90000 under reducing SDS-PAGE 
electrophoresis conditions. Recently a new form of the G glycoprotein of HRSV grown 
in human airway epithelium (HAE) reported, and described as a dimer of the Mr  90000 
form or a highly glycosylated form of the G protein with extensive O- linked 
glycosylation (Figure  1.3.A) (Kwilas et al., 2009). About 58% of the mass of the mature 
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G protein is occupied by O- and N-linked carbohydrates (55% O-linked and 3% N-
linked). The external portion of the G protein contains between 77 and 91 potential sites 
for the attachment of O-linked oligosaccharides depending on the strain. There are four 
sites reported for the attachment of N-linked glycoproteins (Lambert, 1988; Teng & 
Collins, 2002; Wertz et al., 1985). The number of potential N-glycosylation sites varies 
between different strains: four N-glycosylation sites were reported for strain A2 whereas 
there are eight N-glycosylation sites reported for the Long strain (Teng & Collins, 
2002). The O- and N-glycosylation sites make two distinct domains in the structure of G 
glycoprotein separated by a short central domain which is highly conserved among 
different HRSV strains. 
The central region of the HRSV G protein overlaps a stretch of four cysteine 
moieties, clustered in a 13-residue stretch (from amino acids 164 to 176) positioned 
close to each other which makes disulfide bonds between each other in a 1:4 and 2:3 
organisation (Teng & Collins, 2002). This generates a cysteine noose in the G 
glycoprotein structure. The fact that this domain is highly conserved among different 
strains of HRSV has led to the suggestion that it is a potential receptor binding domain 
of the virus. However, a recombinant HRS virus lacking the cysteine noose in the G 
protein was capable of efficient growth in vivo. The poor growth of the virus lacking G 
gene in vivo suggests the presence of other regions on the G glycoprotein that may play 
an important function in virus infectivity (Teng & Collins, 2002). The conserved region 
contains a CX3C chemokine motif at amino acid positions 182–186 (Harcourt et al., 
2006; Tripp et al., 2001).   
Figure  1.3 shows the schematic structure of the G protein (Figure  1.3.A), and 
compares G protein of different strains of HRSV with PVM (Figure  1.3.B). As it is 
depicted in the Figure  1.3.A, the hydrophobic region of the HRSV G protein lies 
between residues 38 to 66. In the G protein of HRSV strain A2 amino acids 38-63,  and 
in the G protein of PVM strain J3666 amino acids 37-59 serve as both signal sequence 
and the transmembrane anchor Figure  1.3.B. 
A temperature sensitive form of HRSV derived from HRSV strain B1 termed 
strain cp52, lacks both SH and G genes and instead contains a fusion between SH 
(Section  0) and G genes with 91 nucleotide in length and has five amino acid coding 
changes in F and L. The HRSV strain cp52 has been extensively used in HRSV studies 
to analyse the SH and/or G gene functions in the virus pathogenesis (Karron et al., 
1997). 
10 
 
The presence of abundant amounts of proline residues in the primary sequence 
gives another unique feature to the pneumovirus G glycoproteins. Approximately 30 
proline residues (approximately 10% of the total residues) are gathered at the carboxy 
terminus of the G glycoprotein. The presence of high proportions of serine, threonine, 
proline residues and extensive O-linked carbohydrates are features that the G 
glycoprotein shares with various mucinous glycoproteins (Wertz et al., 1985). 
G1 and G2 glycoproteins were reported as two different forms of the G 
glycoprotein for PVM strain 15 (Warwick), with G2 derived from G1 (Ling & Pringle, 
1989b). The estimated relative molecular mass for G1 and G2 glycoproteins of PVM 
strain 15 (Warwick) was calculated as 76400 and 62000, respectively. The molecular 
mass after removal of both N- and O- linked oligosaccharides were very close to each 
other. The relative molecular mass for G glycoproteins reported by Ling and Pringle 
(1989b) is listed in Table  1.2. 
 
 Glycosylated 
form 
N-linked sugars 
removed 
O-linked sugars 
removed 
Removal of both N- and O-
linked sugars 
G1 76400 58400 57600 39600 
G2 62000 48200 51000-58600 37200-44800 
Table  1.2 The relative molecular mass of G glycoproteins of PVM strain 15 (Warwick) adapted 
from (Ling & Pringle, 1989b).  
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A 
 
 
 
B 
 
PVMJ3666 
PVM15 W  
PVM15 ATCC 
HRSVA2 
HRSVB1 
 
 
PVMJ3666 
PVM15 W  
PVM15 ATCC 
HRSVA2 
HRSVB1 
 
 
PVMJ3666 
PVM15 W  
PVM15 ATCC 
HRSVA2 
HRSVB1 
 
 
PVMJ3666 
PVM15 W  
PVM15 ATCC 
HRSVA2 
HRSVB1 
 
 
PVMJ3666 
PVM15 W  
PVM15 ATCC 
HRSVA2 
HRSVB1 
 
 
PVMJ3666 
PVM15 W  
PVM15 ATCC 
HRSVA2 
HRSVB1 
 
 
PVMJ3666 
PVM15 W  
PVM15 ATCC 
HRSVA2 
HRSVB1 
 
MGRNFEVSGSIT-NLNFERTQHPDTFRTGVKVNQMCKLIAGVLTSAAVAVCVGVIMYSVF 
----------------------------------MCKLIAGVLTSAAVAVCVGVIMYSVF 
MGRNLEVSGSIT-NLNFERTQHPDTFRTVVKVNQMCKLIAGVLTSAAVAVCVGVIMYSVF 
MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAMIISTSLIIAAII 
MSKHKNQRTARTLEKTWDTLNHLIVISSCLYRLNLKSIAQIALSVLAMIISTSLIIAAII 
                                  : .:   .*:  *: :...:*: ::: 
 
---TSNHKANST----QNATTRNSTSTP----PQPTAGLPTTEQG-------TIPRFTKP 
---TSNHKANST----QNATTRNSTSTP----PQPTAGLPTTEQG-------TIPRFTKP 
---TSNHKANST----QNATTRNSTSTP----PQPTAGLPTTEQG-------TIPRFTKP 
FIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQLGISPSNPSEITSQITTILASTTP 
FIISANHKVTLTTVTVQTIKNHTEKNITTYLTQVPPERVSSSKQPTTTSPIHTNSATTSP 
   ::***.. *    *  ... ... .      *   :..::         *    *.* 
 
PTKTATHHEITEPVKMATPSEDPYQCSSNGYLDRPDLPENFKLVLDVICKPPGPEHHNTS 
PTKTATHHEITEPVKMATPSEDPYQCSSNGYLDRPDLPENFKLVLDVICKPPGPEHHNTS 
PTKTATHHEITEPVKMATPSEDPYQCSSNGYLDRPDLPENFKLVLDVICKPPGPEHHNTS 
GVKSTLQSTTVKTKNTTTTQTQPSKPTTKQRQNKPP-------------SKPNNDFH--- 
NTKSETHHTTAQTKGRTTTSTQTNKPSTKPRLKNPP-------------KKPKDDYH--- 
 .*:  :   .:.   :*.. :. : :::   ..*              . *  :.*    
 
CYEKREINPGSVCPDLVTMKANMGLNNGGGEDAAPYIEVTTLSTYSNKRAMCVHNGCDQG 
CYEKREINPGSVCPDLVTMKANMGLNNGGGEDAAPYIEVTTLSTYSNKRAMCVHNGCDQG 
CYEKREINPGSVCPDLVTMKANMGLNNGGGEDAAPYIEVTTLSTYSNKRAMCVHNGCDQG 
-FEVFNFVPCSICSNNPTCWAICKRIPNKKPGKKTTTKPTKKPT---------------- 
-FEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPT---------------- 
 :*  :: * *:* :    .:      .      .  : *. .*                 
 
FCFFLSGLSTDQERAVLELGGQQAIMELHYDSYWKHYWSNSNCVVPRTNCNLTDQTEILF 
FCFFLSGLSTDQERAVLELGGQQAIMELHYDSYWKHYWSNSNCVVPRTNCNLTDQTEILF 
FCFFLSGLSTDQERAVLELGGQQAIMELHYDSYWKHYWSNSNCVVPRTNCNLTDQTEILF 
-------LKTT-KKD------------------------------PKPQTTKSKEV---- 
-------TKTTNKRD------------------------------PKTPAKTTKKE---- 
        .*  :.                               *..  . :.:      
 
PRFNNKNQSQCTTCADSAGLDNKFYLTCDGLLRTLPLVGLPSLSPQAYKAVPTQTTGTTT 
PRFNNKNQSECTTCADSAGLDNKFYLTCDGLLRTLPLVGLPSLSPQAYKAVPTQTTGTTT 
PRFNNKNQSQCTTCADSAGLDNKFYLTCDGLLRTLPLVGLPSLSPQAYKAVPTQTTGTTT 
PTTKPTEEPTINTTKTNIITTLLTSNTTGNPELTSQMETFHSTSSEG-NPSPSQVSTTSE 
TTTNPTKKPTLTTTERDTSTSQSTVLDTTTLEHTIQQQSLHSTTPEN-TPNSTQTPTASE 
.  : .::.  .*   .                *     : * :.:  .. .:*.. ::  
 
APTSESRHPTPAPRRSKPLSRKKRALCGVDSGREPKPTMPYWCPMLQLFPRRSNS 
APTSETRHPTPAPRRSKPLSRKKRALCGVDSSREPKPTMPYWCPMLQLFPRRSNS 
APTSETRHPTPAPRRSKPLSRKKRALCGVDSSREPKPTMPYWCPMLQLFPRRSNS 
YPSQPSSPPN-TPRQ---------------------------------------- 
-PSTSNSTQN-TQSHA--------------------------------------- 
 *:  .   . :  .                                        
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Figure  1.3.A Schematic structure of the G glycoprotein of HRSV. The structure of the G 
glycoprotein of HRSV, based on the description by Collins and colleagues (2001). The 
cytoplasmic tail (CT) and transmembrane domain (TM) are shown with blue and red colours, 
respectively. The presence of proline residues is shown by small dark blue circles. The O- 
glycosylation (blue spikes) and N- glycosylation (red spikes) sites are indicated. The conserved 
area is indicated between amino acid residues 164 and 176. The cysteine noose is shown by 
dotted lines and the di-sulphide binds are shown between cysteine molecules. B. Comparison of 
G protein sequences among pneumoviruses. HRSV strain A2 and B1 (as indicated) are 
compared with PVM strains (J3666, Warwick –shown as PVM 15 W, and 15 – shown as PVM 
15 ATCC). The predicted transmembrane domain across the molecule is indicated in red. The 
conserved area in the G protein of HRSV is indicated in cyan. The cysteine residues 
responsible for the cysteine noose are indicated in yellow. The presence of a potential furin 
cleavage site (Arg-X-(Lys/Arg)-Arg) in the G protein of PVM strains is indicated with green 
background. The “*” character indicates positions which have a single, fully conserved residue. 
The “:” character represents strongly and “.” characters indicates weakly conserved residues 
(Thompson et al., 2002). The prediction for the transmembrane domains was made using the 
HMMTOP server (Tusnady & Simon, 2001). The schematic structure of the G glycoprotein (A) 
and the sequences (B) are presented from N terminus to C terminus. 
PVM_15_W   3’ UCCUAUUCAUGAUAGGAUAACCUUGGUUUGCUCUGGACAUCUCGUCGAGUGUGUUCUCUU 
PVM_J3666  3’ UCCUAUUCAUGAUAGGAUAACCUUAGUUUACUCUGGACAUCUCGUCGAGUAUGUUCUCUU 
              ************************ **** ******************** ********* 
 
PVM_15_W      GGUGUUCGACUGAAGUGGAUCAUACCCUUCCUUGAAUCUUCACUCACCGUCGUAAUGGUU 
PVM_J3666     GAUGAUCAACUGAAGUGAAUCAUACCCUUCCUUGAAACUUCACUCACCGUCGUAAUGGUU 
              * ** ** ********* ****************** *********************** 
 
PVM_15_W      AAACUUGAAACUCUCUUGAGUCGUAGGACUGUGUAAAUCCUGACAACAUUUUUCACUUGG 
PVM_J3666     AAACUUGAAACUCUCUUGAGUCGUAGGACUGUGUAAAUCCUGACCACA-UUUUCACUUGG 
              ******************************************** *** *********** 
 
PVM_15_W      UUUACACAUUCGAAUAACGUCCACACGAGUGUUCACGACGACACCGUCAAACACACCCCC 5’ 
PVM_J3666     UUUACACAUUCGAAUAACGUCCACACGAGUGUUCACGACGACACCGUCAAACACACCCCC 5’ 
              ************************************************************   
Figure  1.4 Comparison of the nucleotide sequence (genomic sense) of the G gene of PVM 
strain 15 (Warwick) and PVM strain J3666. A uridine insertion in the sequence of PVM strain 15 
(Warwick) changes the open reading frame for the PVM strain 15 and causes a premature stop 
in protein synthesis. In the strain J3666, the open reading frame starts from the same place of 
the strain 15 (Warwick) and protein synthesis continues to the main stop codon of the ORF at 
position 1273 of the gene (not shown). PVM strain J3666 and PVM strain 15 (Warwick) are 
shown as PVM_J3666 and PVM_15_W respectively. Start codons are shown in green and stop 
codons are indicated in red. The mutation site is shown in yellow. The “*” character indicates 
positions which have a single, fully conserved residue. 
1.2.1.1.1 Second open reading frame in the PVM G gene 
Analysis of the sequence of the G gene of the non-pathogenic strain 15 
(Warwick) and the pathogenic strain J3666 showed that the G protein was encoded by 
the second ORF in the mRNA. This was also seen with the HRSV G gene. In strain 
J3666 G mRNA a small (37nt) ORF is located upstream of the major G protein coding 
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ORF. The strain J3666 G protein contains a cytoplasmic domain followed by a putative 
transmembrane domain. In contrast, the strain 15 (Warwick) G mRNA contains a first 
ORF which overlaps the G protein – coding major ORF. The strain 15 (Warwick) G 
protein does not contain a significant intracellular domain preceding the transmembrane 
region (Randhawa et al., 1995). The difference in gene organisation in the G protein 
coding ORFs of the two viruses is the result of the presence of an additional nucleotide 
in a string of U residues (4 in strain J3666 and 5 in strain 15 G mRNA) which results in 
a frame shift (see Figure  1.4). The organisation of the G gene of both viruses is shown 
diagrammatically in Figure  1.5. 
A short open reading frame (ORF) of 15 codons was described overlapping the 
start of major ORF of the HRSV G gene (Wertz et al., 1985). The function of the ORF 
or the function of its possible product has not been clearly described.  
 
Figure  1.5 Comparison of the G mRNA organisation in PVM strain 15 Warwick and PVM strain 
J3666. There is a second open reading frame in PVM strain 15 Warwick overlapping the main 
open reading frame. In PVM strain J3666, first ORF is upstream and separate from the second 
ORF (Randhawa et al., 1995). The numbers refer to the nucleotide position in the G gene mRNA. 
The G gene is presented from 5’ to 3’. 
1.2.1.1.2 Proteolytic processing of G glycoprotein 
It was first reported by Spring and Toplin (1983) that the “75K glycoprotein” (G 
glycoprotein) of HRSV is susceptible to tryptic digestion in vitro producing two 
fragments with Mr value of 40,000 and 29,000. However, the authors reported that 
digestion of a pool of HRS virus with trypsin, chymotrypsin, or elastase does not have 
any effect on the virus infectivity in vitro (Spring & Tolpin, 1983). Recently, it was 
reported that Vero grown viruses predominantly contain a form of G glycoprotein with 
Mr of 55,000 which lacks its C terminus whereas viruses grown in HEp-2 cells 
possessed the G glycoprotein with a relative molecular mass of 90,000 (Kwilas et al., 
2009). In the same report, it was shown that the virus grown in Vero cells is less 
infectious in vitro. The data indicated a vulnerability of the G glycoprotein to be 
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processed post-translationally, and the virus grown in cells capable of producing 
truncated G glycoprotein are less infectious and less dependent on GAG. The 
pathogenicity of viruses with the G glycoprotein lacking its C terminal has remained 
unclear. 
A soluble form of the HRSV G glycoprotein (Gs) is formed by initiation of 
translation from an alternative start codon in the G mRNA. This produces a protein 47 
residues shorter than the full-length G protein and this is processed further by 
proteolytic enzymes which digest  at amino acid residue at positions 66 and/or 75 
(Hendricks et al., 1988; Roberts et al., 1994). Roberts and colleagues (1994) reported a 
further processing possibility generating a third form which is also secreted. The precise 
role of the Gs form is unclear but it has been implicated in some aspects of 
pathogenicity. 
Ling and Pringle (1989b) reported a shorter form of the G glycoprotein in cells 
infected with PVM. Krempl and colleagues (2007) reported the presence of the same 
form of the G glycoprotein in infected cells. In both reports no secreted form of PVM G 
glycoprotein was detected. Thus, the shorter form of the G glycoprotein of PVM is 
thought to be not the counter part of the secreted G glycoprotein produced in cells 
infected with HRSV. 
1.2.1.2 Fusion (F) glycoprotein: 
The fusion (F) protein of RSV, similar to the fusion proteins of other members 
of the family Paramyxoviridae, is a type I transmembrane surface protein which 
mediates membrane and envelope fusion. The HRSV F protein  is synthesised as a large 
precursor polypeptide F0 with a length of 574 amino acids, which is activated by 
cleavage at two separate sites by a furin-like cellular endoprotease to produce two 
glycoproteins (F1 and F2) which are linked together by disulfide bonds (Johnson & 
Collins, 1988).  
The first cleavage site in the HRSV F protein is at residue 109 and consists of an 
arginine-rich sequence (RARR). The second cleavage site is at residue 136 and consists 
of a lysine and arginine-rich sequence (KKRKRR), with a 27 amino acid gap between 
the two sites. The second site at position 136 is equivalent to the cleavage site found in 
the other F proteins of members of the Paramyxoviridae family (Zimmer et al., 2001). 
A polypeptide of 27 amino acids in length (pep27) is released upon the proteolytic 
cleavage. The exact function for the polypeptide is not known. However, it has been 
15 
 
reported that the BRSV pep27 protein is related by sequence and function to tachykinins 
( 1.3.2.1) (Zimmer et al., 2003). There are three N-glycosylation sites in pep27 and it has 
been shown that mutation in at least one of the sites increases syncytia formation 
suggesting that differential glycosylation of pep27 may modulate fusion (Rawling et al., 
2008). 
The F proteins in Paramyxoviridae have three main hydrophobic domains: one 
appears in the N terminal of the F0 and acts as the signal peptide for translocation to the 
endoplasmic reticulum, the second is the fusion peptide and is close to the C-terminus 
of the F1 region, and the third is located at the N-terminus of the F2 region. The HRSV 
F protein is capable of attaching to cells and producing syncytia independently without 
the presence of the G glycoproteins. This is in contrast with the situation for the 
Paramyxoviruses where the presence of attachment HN protein is essential for docking 
of the virus (Rawling et al., 2008). 
Similar to the F protein of RS viruses, the F protein of PVM is a glycosylated 
protein which is activated by cleavage into F1 and F2 polypeptides. The presence of 
both F1 and F2 proteins in infected cells was described by Ling and Pringle (1989b). 
The results identified an F(1,2) glycoprotein with a mobility slower than that of F1 and 
two different forms of F1 with different motilities (Mr value of 20000 and 12000). This 
led to a proposal of two possible structures for the PVM F protein: the first one is the 
common F structure like the other Paramyxoviridae members in which F0 is processed 
and cleaved to F1 and F2 fragments which happens rapidly for the PVM F protein. The 
F2 protein was proposed to be very small, with Mr value of 5000 (Ling & Pringle, 
1989b). 
1.2.1.3 Uncoating 
The uncoating process involves the release of the ribonucleoprotein complex 
(RNP) from the virus particle into the cytoplasm. This involves removal of the M 
protein layer from the RNP complex. Asenjo and colleagues (2008) have demonstrated 
that the liberation of M protein from the RNP needs phosphorylation of the P protein  at 
the serine residue at position 54. Administration of LiCl inhibits the cellular kinase 
responsible for the phosphorylation and causes accumulation of P protein but not M 
protein in cytoplasmic inclusion bodies which suggests involvement of M protein with 
the RNP. 
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1.2.2 Genome structure and organisation 
A clear description of HRSV genome, its polarity and the number of mRNA 
encoded from the genome was reported by Huang and Wertz (1982). Figure  1.2 
compares genome structure of HRSV and PVM. HRSV possesses a monopartite single 
stranded negative sense genome with a length varying from 15140 to 15225 nucleotides 
(in HRSV strain B1). In PVM the genome length ranges from 14885 to 14887 
depending on the strain. Table  1.3 provides the genome length for different members of 
the pneumovirus genus. 
 
Virus Strain Nucleotide length 
Gene bank accession 
number 
PVM J3666 
14885 
14885 
NC_006579 
AY743909 
PVM 15 (Warwick) 14887 AY743910 
PVM 15 (ATCC) 14886 AY729016 
HRSV A2 15222 M74568 
HRSV Line 19 15191 FJ614813 
HRSV S2 15190 U39662 
HRSV B1 15225 NC_001781 
HRSV cp52 13933 AF013255 
BRSV A51908 15140 NC_001989 
Table  1.3 Comparison between HRSV, BRSV and PVM genome length. The nucleotide length 
and the relevant accession number in the gene bank are provided for each of the virus species.  
Unlike the situation with other members of the order Mononegavirales,  the 
genome of pneumoviruses do not follow the rule of six which requires the number of 
nucleotide of the genome to be divisible by number 6 (Samal & Collins, 1996). The 
vRNA in HRSV contains a complementary structure in both the 3’ and 5’ ends of the 
molecule (Mink et al., 1991). The leader region (Le), a 44 nucleotide region at the 3’ 
end of the genome, controls transcription, whereas replication is under the control of the 
trailer complement region (TrC), a 155 nucleotide region at the 5’ end of the genome. 
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Both trailer and leader sequences are highly conserved among different members of 
pneumoviruses. The leader and trailer regions are complementary and show 81% 
homology. However, despite the presence of the complementary structures, it was 
reported that the HRSV genome has a linear structure (Cowton et al., 2006). Among the 
conserved nucleotides the first 10 nucleotides are identical and nucleotides 11-26 share 
81% of similarity. Complete transcription of the vRNA results in production of 
complementary RNA (cRNA) which acts as the antigenome to mediate the genome 
replication (see  1.2.5). 
 The conserved nucleotides in the leader region are responsible for the efficiency 
of replication and transcription of the genome, and provide the possibility of balancing 
between transcription and replication. In the 3’ leader region the nucleotide at position 4 
has been shown to be particularly important in determining the frequency of replication 
compared to transcription. The presence of a G residue at this position yielded higher 
levels of transcription while in contrast the presence of an A residue reduced both 
transcription and replication to 25% of wildtype levels (Fearns et al., 2002). This and 
additional mutational analysis data suggest that the leader region is a critical cis-acting 
element which determines the rates of transcription and replication. Generally, the 
role(s) of the nucleotides in the leader region can be divided into three groups: 1. 
residues important for RNA replication but not transcription (1U, 2G, 6U and 7U); 2. 
residues important for both transcription and replication (3C, 5C, 8U, 9U, 10U and 
11U); 3. residues less important for transcription and replication and which tolerate 
alteration (residues 12-26). 
In the genome, each gene is flanked by a gene start and gene end sequence and a 
highly variable intragenic region separates genes from each other. The sequence of both 
gene start and gene end are not conserved among viral species, but the gene start is 
highly conserved and gene end is semi-conserved within each virus genome. Collins 
and Wertz (1985b) have( mapped and reported the gene start sequences in HRSV as 5’-
GGGGCAAAU-3’ and the semi-consensus gene end sequence as 5’-AGU(U/A)A(N)1–
4-poly(A)-3’ in the complementary RNA sense, and 3’-UCA(A/U)U(N)1-4-poly(U)-5’ in 
the genomic RNA sense. Table  1.5 compares the gene end sequence of HRSV strain 
A2. Transcription efficiency (Section  1.2.4.3) is controlled by the nucleotide 
arrangement of the sequences (Harmon et al., 2001). In PVM the gene start sequence is 
more variable in comparison with other members of pneumoviruses (Table  1.4)  
(Dibben & Easton, 2007). 
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HRSV genes are transcribed to produce 10 mRNA molecules responsible for 
synthesis of the structural (SH, G, F, M, N, P and L) and non-structural (NS1, NS2, M2-
1, and M2-2) proteins.  
 
Gene name Gene sequence 
NS1 
NS2 
M  
N 
P 
SH 
G 
F 
M2 
L 
 
AGGACAAGU 
AGGACAAGU 
AGGACAAAU 
AGGAUAAAU 
AGGAUAAAU 
AGGAUAAAU 
AGGAUAAGU 
AGGACAAAU 
AGGAUGAGU 
AGGAUCAAU 
****  * * 
Table  1.4 Alignment of the sequences of gene starts in PVM. Sequences are provided in their 
genomic order. The consensus nucleotides are indicated by a “*” sign (Thompson et al., 2002). 
Gene name and sequence Termination efficiency 
NS1             UCAAUUAUAUUUUG 
NS2             UCAUUAAAUUUUAA 
N               UCAAUUAUUUUUUA 
P               UCAAUGUUUUUUUC 
M               UCAAUUAUUUUUUA 
SH              UCAAUUAAUUUUUA 
G               UCAAUGAAUUUUUG 
F               UCAAUAUAUUUUGU 
M2              UCAAUAAAUUUUCC 
L               UCAAUAAUUUUUAA 
                *** *    ***   
+ 
+ 
++ 
++ 
++ 
+++ 
++ 
+ 
+ 
+ 
Table  1.5 Comparison of gene end sequence in HRSV strain A2. Termination efficiency is 
shown with +, ++, and +++ signs indicating inefficient (15 to 40%), efficient (65 to 80%), and 
highly efficient (95%) respectively (Harmon et al., 2001). The consensus nucleotides are indicated 
by a “*” sign (Thompson et al., 2002). 
1.2.3 RNA dependent RNA polymerase complex 
Transcription and replication in the subfamily Pneumovirinae is mediated and 
controlled by viral proteins (N, P, L and M2-1) and cis-acting genomic factors. 
Although the HRSV N, P, and L proteins are capable of directing transcription and 
replication functions, the presence of the M2-1 protein is essential to obtain fully 
processed transcription. Transcription requires interplay of the N, P, L and M2-1 
proteins. It has been suggested that replication does not require the activity of the M2-1, 
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but it requires the M2-2 protein for switching from transcription to replication (Melero, 
2006). 
1.2.3.1 Nucleocapsid (N) protein of pneumoviruses 
The nucleocapsid protein encoded by HRSV is 391 amino acids in length. The N 
protein, similar in function to the N protein of other members of the family, makes 
stable complexes with the vRNA to form the nucleocapsid structure, and binds to the 
replication intermediate cRNA to protect them against RNase activity and possibly to 
prevent formation of secondary RNA structures. The N protein is considered the major 
component of the virus particle. The N protein interacts with the vRNA in association 
with the virus P protein, and it appears that the fully phosphorylated form of the P 
protein is essential for obtaining a stable P:N complex (Castagne et al., 2004). It has 
been shown that when the N protein is expressed in eucaryotic or procaryotic hosts, it 
binds to the cellular RNA structures non-specifically and forms a nucleocapsid-like 
structure which is visible using electron microscopy. Moreover, the N protein is capable 
of self binding to produce ring-like structures (Murphy et al., 2003). 
The N protein in Paramyxovirinae has a modular structure (Karlin et al., 2003). 
Sequence similarity between the N protein of PVM and the N protein of 
Paramyxovirinae suggests structural similarities between N proteins (Barr et al., 1991). 
Two main domains were defined for the N protein: Ncore and Ccore. The Ncore occupies 
about two thirds of the amino-terminus of the N protein and contains in HRSV the 
region necessary for production of N:RNA and N:N structures (Murphy et al., 2003; 
Murray et al., 2001). The Ccore is essential for interaction with the P protein (Karlin et 
al., 2003). Figure  1.6 shows domains of the N protein of HRSV which are important in 
P and N interaction and the RNA binding domains. 
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Figure  1.6 The HRSV N protein structure. The potential P binding sites amino acids 48 to 65, 
241 to 260 and 301 to 335 are shown with turquoise colour. The region with a potential effect on 
helical stability is shown in pink colour (amino acids 121 to 160). The predicted functions of N 
terminus (amino acids 1 to 92) and C terminus ends of the protein (amino acids 200 to 392) are 
identified. Adapted from Murphy et al., (2003).  
There is a high level of similarities (60%) in amino acid sequence between the N 
protein of PVM and its HRSV counterpart. The C terminus (residues 245 to 315) is 
highly conserved (96% identity) suggesting a conserved function of this domain (Barr et 
al., 1991). 
During HRSV infection, inclusion bodies are formed in the cytoplasm of 
infected cells. There are believed to be the result of aggregations of the P and N 
proteins. The presence of RNA (both genomic and antigenomic polarities) has also been 
shown in these inclusion bodies (Garcia-Barreno et al., 1996; Garcia et al., 1993)  
1.2.3.2 Phosphoprotein (P) protein of pneumoviruses 
The phosphoprotein of HRSV with 241 amino acids is highly conserved 
between strains. Using a panel of mutations and a minigenome system, the function of 
the P protein of BRSV has been analysed thoroughly (Khattar et al., 2001). The P 
protein is highly structured and regulates the transcription and/or replication process. 
Amino acids 41 to 60 of the P protein appear to negatively regulate the replication 
process. It has been shown that the removal of a phosphorylation site on the P protein of 
BRSV (232S) appears not to have any effect on transcription (Khattar et al., 2001), 
confirming previous reports (Villanueva et al., 2000). Barik and colleagues (1995)  had 
previously suggested that phosphorylation of P protein at position 232 was essential for 
viral transcription and virus assembly. More recently, phosphorylation of threonine at 
position 108 has been shown to be responsible for the interaction of the P and M2-1 
proteins (Asenjo et al., 2006). 
A putative calcium binding domain (229-DESSDNDLSLEDF-241) has been 
proposed for the P protein of BRSV. The binding of calcium to this domain results in 
21 
 
conformational changes and exposure of hydrophobic residues allowing interaction with 
target protein(s) (Ikura, 1996; Khattar et al., 2001). Mutations in the calcium binding 
domain resulted in deficiency in binding to the N protein. It is noteworthy that the 
mutations did not affect the affinity of P protein to L protein (Khattar et al., 2001). 
Based on the immunoprecipitation studies done by Garcia-Barreno and 
colleagues (1996), the C terminus of the P protein appears to be essential for interaction 
with the N protein when both proteins are expressed in vivo with the first 6 amino acids 
from the C terminus being the most important in the interaction with the N protein 
(Garcia-Barreno et al., 1996). Slack and Easton (1998), using a yeast two hybrid 
system, identified two distinct sites near the C terminus of the P protein which were 
important in N and P protein interaction. Confirming the importance of the C terminus 
of the P protein in its interaction with N protein, two point mutations in the C terminus 
were identified which were responsible for producing temperature sensitivity for the 
interaction between the P and N proteins (Lu et al., 2002). 
In addition to the full length P protein, it has been shown that a protein (P-2) 
with Mr of 19,000 is produced from an internal in-frame start codon from the P protein 
mRNA of HRSV strain RSN-2 in vitro (Caravokyri & Pringle, 1992).  
The P protein of PVM (295 amino acids) is longer than that of HRSV. The 
homology between the two proteins is scattered across the molecule but suggests two 
conserved sites divided by a non-conserved region in the middle of the molecule (Barr 
et al., 1994). The precipitation of the P protein of HRSV with monoclonal antibody 
raised against PVM P protein suggested an antigenic relatedness between these two 
proteins (Ling & Pringle, 1989a). 
A second and internal ORF of the P protein in PVM with a product of 137 
amino acids was identified (Barr et al., 1994). The function of this protein is unknown. 
A reverse genetics approach by Dibben and Easton (2008) indicated that the P-2 protein 
of PVM was not essential for transcription or replication. 
1.2.3.3 Large polymerase (L) protein of pneumoviruses 
The large protein of HRSV is 2165 amino acids in length, with Mr of 250,226 
for strain A2 (Collins et al., 1987). The L protein is rich in leucine and isoleucine amino 
acids and in neutral pH has an estimated positive charge of +75 (Melero, 2006). 
Aligning five sequences from the order Mononegavirales, Poch and colleagues (1990) 
suggested six conserved regions in the L protein. Based on this comparison the main 
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catalytic domains of L protein were predicted to lie within the conserved blocks which 
were flanked by non-conserved sequences with the hinge function. The function of each 
domain was predicted based on the analogy and the biophysical characteristic of 
conserved amino acids and their surrounding residues, and it was suggested that region 
III acts as the active site; lysine residues within regions II and IV acts as ribonucleotide 
binding domains; a highly conserved region inside domain II acts as the template 
recognition site; and region VI acts as the polyadenylation or protein kinase site. Region 
III of the L polymerase contains the GDNQ motif which is present in the all DNA and 
RNA polymerase molecules (Poch et al., 1990; Poch et al., 1989; Stec et al., 1991). It 
was suggested that   a GDN motif is a modified form of the GDD polymerase motif and 
was suggested as the common ancestor of polymerase proteins (Kamer & Argos, 1984; 
Stec et al., 1991). 
1.2.3.4 M2-1 (22K) protein 
The HRSV M2-1 protein, previously called the 22K protein and a unique protein 
to the subfamily of  Pneumovirinae, is 194 amino acids in length and is one of the most 
important regulatory proteins of the virus affecting control of gene transcription and 
genome replication (Dibben et al., 2008). When first identified, it was believed the M2-
1 protein was a second matrix protein as it was dissociated from N protein in the same 
situation similar to that of the M protein (Collins & Wertz, 1985a; Huang et al., 1985). 
The main function of the M2-1 protein was first discovered by Hardy and Wertz  
(1998), and described as a transcriptional antitermination factor. Using EM analysis, the 
M2-1 protein was described as a tetramer with a Mr of 89,000 and with a diameter of 
7.6 nm. Using a panel of mutants, the oligomerisation domain was mapped across 
amino-acid residues 32-63 which form a potential α-helix structure (Tran et al., 2009). 
On a one dimensional SDS-PAGE system two different forms of M2-1 protein have 
been shown, while on the two dimensional SDS-PAGE system more than two forms 
have been reported (Routledge et al., 1987). More recently, it has been reported that the 
difference in the mobility of the two forms shown in the one dimensional SDS-PAGE 
system is due to differences in the phosphorylation of the M2-1 protein with the slower 
being phosphorylated and the faster form not being phosphorylated (Hardy & Wertz, 
2000). The phosphorylation site has been mapped by two groups individually. Using a 
mass spectrophotometry technique, Cartee and Wertz (2001)  identified the 
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phosphorylation sites as serine 58 and serine 61. In contrast, site directed mutagenesis 
confirmed the phosphorylation sites as threonine 56 and serine 58 (Cuesta et al., 2000). 
The M2-1 protein has a zinc binding domain known as Cys3–His1 motif (C7-
X7-C15-X5-C21-X3-H25). The cysteine and histidine residues in this motif have been 
predicted to be important in maintaining the readthrough ability of the RNP complex in 
a sub-genomic HRSV based system bearing the M-SH gene junction (Hardy & Wertz, 
2000). An M2-1 protein mutated at cysteine residues at positions 7 and 15, and histidine 
residue at position 25 was not able to act as a potent transcription factor in the RNP 
complex (Hardy & Wertz, 2000).  
Amino acid residues 59 to 80 of the M2-1 protein share a similarity of 95% 
among HRSV and BRSV strains. The similarity of this region in comparison with the 
region in PVM is only 45%. However, in the PVM M2-1 protein, residues 70 to 80 
show a higher level of similarity (90%) with the same region of the M2-1 protein of 
other members of the genus. The aromatic and hydrophobic nature of the amino acid 
residues in this region, and the high level of conservation among other strains and 
species of the genus suggest that this region may be the RNA binding domain of the 
molecule (Cuesta et al., 2000). 
1.2.4 Transcription and gene expression 
The HRSV genome contains a single promoter located in the leader region 
which controls RNA synthesis (Dickens et al., 1984). For the RNA synthesis in 
transcription or replication, two different models are hypothesised. In the first model, 
transcription and replication start at the same site of the leader sequence. Having been 
transcribed, the RNA faces three possibilities: 1. the synthesis of an immature RNA that 
dissociates from the template near the leader region, 2. RNA being packaged into the N 
protein and forms a stable complex which results in the synthesis of cRNA, and 3. RNA 
associates with the N protein and makes a stable complex, but RNA elongation ends at 
the leader region and reinitiates at the gene start region. In the second model, it is 
proposed that transcription and replication start at distinct but overlapping sites of the 
leader regions. Nucleotides 3C, 5C, 8U, 9U, 10U, and 11U of the leader sequence are 
the common elements of the two promoters (see Section  1.2.2 for description on the 
leader sequence). Nucleotides 1U, 2G, 6U, and 7U of the leader sequence are involved 
in the recognition of the RNP complex for replication complex and the gene start 
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signals for the transcription initiation (Fearns et al., 2002). There are other mechanisms 
proposed for transcription initiation which are reviewed by Cowton et al. (2006). 
It has been suggested that the transcriptional complex having been bound to the 
leader region, starts scanning the genome for the gene start sequence and initiates 
mRNA synthesis from the NS1 gene (Cowton & Fearns, 2005). The cis factor for 
termination of gene transcription is the gene end sequence (Section  1.2.2) (Harmon et 
al., 2001). It has been shown that if the polymerase does not recognise the gene end 
signal, it will result in the production of a polycistronic RNA containing the intergenic 
junction (Dickens et al., 1984). 
One of the fundamental differences between the genomic structure of PVM and 
HRSV is the overlap of the M2 and L genes seen in HRSV. The L gene shares its 5’ 
sequence with 3’ end of M2 gene. In PVM, however, both M2 and L genes form 
separate and distinctive genes on the genome (Figure 1.1) (Collins et al., 1987). 
1.2.4.1 Gene expression gradient 
Early reports indicated that after termination in transcription, the RNP complex 
dissociates from the cRNA templates and a proportion of the RNP complex restart 
transcription by relocating to the promoter sequence in the 3’ end of vRNA. The 
remaining proportion continues transcription of the next gene  (Dickens et al., 1984). 
This stop-start process generates a gradient of transcription with mRNAs representing 
leader proximal genes being more abundant than those from leader-distal genes. The 
gradient of expression of HRSV genes was confirmed by Barik (1992) in which the 
concentration of individual viral mRNA molecules were calculated using a slot blot 
assay and the molar ratio of mRNA was calculated against the NS1 mRNA. The 
percentage of mRNA for each gene of RSV is shown in Table  1.6. 
 
Gene NS1 NS2 N P M SH G F M2-1 L 
Molar ratio 100 95 90 68 52 32 21 18 15 3 
Table  1.6 Percentage molar ratio of HRSV mRNA indicating the genome expression gradient 
(Barik, 1992). 
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1.2.4.2 mRNA capping   
Neither the vRNA nor cRNA contain a 5’ cap structure. However, mRNA 
molecules are capped (m7G(5')ppp(5')Gp) and polyadenylated (Barik, 1993). Barik 
(1993), using radioactive S-adenosyl-methionine, showed that the methyl group, but not 
the G residues, is added by host enzymes. In the same study it was shown that both the 
cap structure formation and the cap methylation are coupled to transcription and on-
going transcription is required for cap formation and methylation and that the cap itself 
does not have any effect on transcription.  
More recently, it has been reported that the L protein of vesicular stomatitis 
virus (VSV), a member of family Rhabdoviridae within the order Mononegavirales, is 
responsible for capping of pre-mRNA molecules (Li et al., 2006), and specifically that 
the region V of the L protein is responsible in the pre-mRNA capping process (Li et al., 
2008b). Mutational analysis has shown that the capping process happens not in the 
conventional way of mRNA capping, but in a unique way using histidine residue in the 
V domain of the L protein (known as the HR motif) (Ogino et al., 2010). It is likely that 
a similar process occurs in pneumoviruses with the L protein carrying out the capping 
process. The proposed mechanism for capping mRNA is shown in Figure  1.7 in 
comparison with the normal cellular capping process. 
 
Figure  1.7 The process involving cap synthesis in eukaryotes and in VSV. A. In eukaryotic cells 
the γ phosphate of  pre-mRNA is removed by the action of RNA 5′-triphosphatase (RTPase) (1). 
In the next steps (2 and 3) a GMP is transferred by a guanylyltransferase (GTase) enzyme 
action to the pre-mRNA to produce the 5’ cap structure. B. In VSV the L protein mediates both 
reactions and removes two phosphate groups from the tri-phosphate-pre-mRNA structure (1a) 
and transfers a GDP to the pre-mRNA structure by its RNA:GDP polyribonucleotidyltransferase 
(PRNTase) activity (2a and 3a). Adapted from Ogino et al. (2010). 
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1.2.4.3 Transcription termination and polyadenylation 
Harmon and colleagues (2001) have summarised the cis factors involving in the 
transcription termination in three categories: the two conserved regions of the Gene End 
sequence (the 3’-UCAAU-5’ and the U track) and the central region which is located 
between the conserved regions (Section  1.2.2). Analysis of the gene end sequence of the 
M gene of HRSV vRNA has shown that nucleotides at positions 2 to 6 are important for 
transcription termination, whereas the nucleotides at positions 1 and 7 are not important 
to obtain efficient transcription termination. At position 8 of the gene end sequence, an 
A or U residue allows termination. The presence of four U residues is necessary for 
efficient transcription termination, and genes of HRSV with shorter U residues have 
been shown to fail to produce mRNA efficiently and produce readthrough polycistronic 
RNA templates (Harmon et al., 2001). Poly-adenylation occurs when the polymerase 
complex reaches to the gene end sequence. The presence of a U rich sequence in the 
gene end directs the RNP complex to generate the poly A sequence. 
In contrast with the gene start sequence, the gene end sequence is not well 
conserved among the pneumoviruses. In PVM the gene end sequence consists of 
uAGUuAnnn(A)n and in HRSV it consists of AGU(U/A)Annnn(A)n (Chambers et al., 
1991; Melero, 2006). The gene end sequence is followed by the non-conserved 
intergenic sequence (Chambers et al., 1991). It was shown that the length or structure of 
the intergenic sequence does not affect the termination of transcription (Kuo et al., 
1996). This finding was challenged with another report describing the importance of the 
M/SH gene junction variation in the expression of the SH (Moudy et al., 2004). Moudy 
and colleagues (2004) reported the P/M gene junction as the most variable gene junction 
with no detectable variation in the gene expression. 
1.2.5 Genome replication 
It has been proposed that the RNP complex which carries out genome 
replication is the same complex used in transcription. However, the switch from 
transcription to replication is not completely understood. The study of Sendai virus, a 
paramyxovirus, has suggested that the abundance of the N protein is important in 
controlling the switch between the RNA transcription and replication processes. The 
presence of the N protein in the cytoplasm of the infected cells may cover the gene end 
and gene start signals, and as a result the RNP complex does not respond to the gene 
end signals and instead reads through the cRNA (Vidal & Kolakofsky, 1989). 
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 As for transcription, genome replication is controlled by the leader (Le) 
sequence of the genomic RNA to synthesis cRNA and the complementary sequence of 
trailer region of the vRNA (TrC) to synthesis vRNA from the cRNA template 
(Figure  1.8). Figure  1.9 shows the Le region from several pneumoviruses, and 
Figure  1.10 compares the Le and the TrC regions of HRSV. Genome replication 
requires switch of the RNP complex from transcription phase to the replication 
(Figure  1.8). 
Recently, it has been shown that the HRSV RNP complex tends to start RNA 
synthesis with a purine residue and specifically it prefers adenosine to start vRNA or 
cRNA synthesis. Deletion of the first nucleotide of  the template RNA or introduction of 
a mutation substituting a U residue in the template urges the RNP complex to start the 
RNA synthesis from the first available pyrimidine residue in the template (the third 
nucleotide residue of the template) (Noton et al., 2010). The RNP polymerase binds to 
the nucleotides 3, 5, 8, 9, 10 and 11, facing its active site towards nucleotides 1 and 2. 
The RNA polymerase then uses ATP molecule to start RNA synthesis independently of 
the template to start synthesis of RNA (Noton et al., 2010). It has been suggested that 
the de novo addition of ATP to the nascent RNA in HRSV is mediated by the same 
secondary ATP binding site which was recognized in the VSV L protein (Massey & 
Lenard, 1987; Noton et al., 2010). 
Initiation of the assembly of the nascent RNA before the RNP complex reaches 
to the first intergenic region increases the possibility of the read-thorough RNA 
synthesis and hence leads to replication rather than transcription (Vidal & Kolakofsky, 
1989). Further studies on Sendai virus have confirmed coupled packaging of the nascent 
RNA with the RNP complex making the replication occur with a higher processivity in 
comparison to transcription (Gubbay et al., 2001). In a recent study of HRSV, Noton 
and colleagues (2010) observed that if the RNA synthesis begins at position 3 of the 
leader sequence it fails to proceed more than 50 nucleotides. They have linked this 
phenomenon to the possibility of the attachment of the N protein to the first two 
nucleotides of the leader sequence during coupled RNA synthesis and packaging 
process, with the binding of the N protein ensuring processivity of RNA synthesis 
during replication. 
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Figure  1.8 HRSV genome replication. The RNP complex (depicted as a compartment in blue 
and red colors) recognizes the genomic leader (Le) sequence or the trailer complementary 
sequence (TrC) sequence to dock on the RNA template and starts RNA synthesis. The blue 
arrows show the direction that the RNP complex moves. The Le and leader complementary 
sequences (LeC) are shown in red color. The trailer (Tr) and TrC sequences are shown in green 
color. The red compartments of the RNP complex represent P, N, and M2-1 proteins, and the 
blue compartment represents the large polymerase protein.  
 
 
 
 
 
 
 
PVM15(Warwick)      UGCGCUUUUUUACGUAU--UGUUUUGAUAGUUGGACUUUUUUCAAUCCUGUU-- 
PVM15(ATCC)         UGCGCUUUUUUACGUAU--UGUUUUGAUAGUUGGACUUUUUUCAAUCCUGUU-- 
PVMJ3666            UGCGCUUUUUUACGUAU--UGUUUUGAUAGUUGGACUUUUUCAAUCCUGUUC-- 
BRSV                UGCGCUUUUUUACGCAUAUUGUUUGGACAUGUAGGUUUUUUCUAGCCCCG---- 
HRSVB1              UGCGCUUUUUUACGCAUGAUGUUUGAACGUGUAAGCCUUUUUUACCCCGU---- 
HRSVA2              UGCGCUUUUUUACGCAUGUUGUUUGAACGUAUUUGGUUUUUUUACCCCGU---- 
HRSV19              ----CUUUUUUACGCAUGUUGUUUGAACGCAUUUGGUUUUUUUACCCCGUUUAU 
                        ********** **  *****  *    *     ****  *  *        
  
Figure  1.9 Genomic sequence of the leader domain of pneumoviruses. The leader sequence of 
members of genus pneumovirus are compared together. The genomic sequence of the RNA is 
shown. See Table  1.3 for the accession numbers of the sequences in the genebank. The 
identical nucleotides are shown in yellow. The “*” character indicates positions which have a 
single, fully conserved residue (Thompson et al., 2002).  
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cRNA_Leader      UGCUCUUUUUUUCACAGUUUUUGAUUAUAGAGCAUUAAAU--- 
vRNA_Leader      UGCGCUUUUUUACGCA--UGUUGUUUG-AACGUAUUUGGUUUU 
              *** ******* * **  * *** **  *  * ***   * 
Figure  1.10 Comparison between leader sequence in the genome and antigenome of HRSV. 
The leader sequence of genome is indicated by vRNA_Leader and the genome sequence of the 
antigenome is indicated by cRNA_Leader. The “*” character indicates positions which have a 
single, fully conserved residue (Thompson et al., 2002). 
1.2.5.1 M2-2 protein 
The M2-2 protein (with a Mr value of 9-10,000) is synthesised from the second 
ORF of the M2 gene, partially overlapping the M2-1 open reading frame (Ahmadian et 
al., 1999; Collins et al., 1996a; Collins & Wertz, 1985a). From three tandem AUG 
codons at the 5’ end of the M2-2 ORF, only the first and the second codons can be used 
to synthesise the M2-2 protein which is functional in the minigenome system (Cheng et 
al., 2005). Expression of the M2-2 ORF from the M2 mRNA requires termination of the 
expression of the first ORF and re-initiation of expression of the second ORF (M2-2) in 
a process called coupled translation (Ahmadian et al., 2000). In the coupled translation 
process the overlapping sequence between M2-1 and M2-2 directs the ribosome towards 
the initiation signal of the M2-2 ORF, with an efficiency determined by the sequence 
upstream of the overlap region (Gould & Easton, 2007). 
In a HRSV sub-genomic mini-replicon system, it was shown that the M2-2 
protein acts as a negative regulatory protein in RNA synthesis (Collins et al., 1996a; 
Hardy & Wertz, 1998). It has been suggested that the M2-2 protein maintains the 
balance between the genome replication and transcription (Bermingham & Collins, 
1999). In cells infected with HRSV strain A2 there is a rapid increase in mRNA 
production until it levels off, whilst in cells infected with a HRSV strain A2 lacking the 
M2-2 gene an initial delay was observed in the mRNA synthesis followed by a sudden 
increase in the level of mRNA higher than that of the wildtype which led to an 
accumulation of mRNA. In contrast, in comparison with the wildtype virus there was a 
significant reduction in the accumulation of cRNA with the M2-2 deleted virus  
(Bermingham & Collins, 1999). It has been also reported that over-expression of M2-2 
protein in HRSV infected cells completely inhibits virus growth (Cheng et al., 2005). 
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In HRSV, the M2 mRNA overlaps the beginning of the L gene by 68 nt. 
Transcription from the L gene start sequence frequently terminates at the M2 gene end 
sequence which  has the effect of down regulating expression of the L gene mRNA and 
hence the level of L protein (Collins et al., 1987). Comparison between mRNA and 
protein synthesis of an M2-2 deleted recombinant HRSV and rescued HRSV strain A2 
are similar (Jin et al., 2000a). Attenuation of HRSV with deleted M2-2 in BALB/c mice 
and cotton rats has also been reported (Jin et al., 2000a). 
1.2.6 Virus assembly and release 
Similar to other members of Paramyxoviridae, assembly of HRSV occurs in the 
cytoplasm of the infected cells in assembly sites close to the plasma membrane. The 
virus glycoproteins are transferred to the assembly sites of the infected cells using 
cellular proteins. 
Assembly in Paramyxoviridae occurs in two steps; assembly of the RNP 
complex and assembly of the envelope. The assembly of RNP complex to the RNA 
occurs during replication of the new genomic RNA. 
1.2.6.1 Matrix (M) protein 
The matrix (M) protein of pneumoviruses acts as a connecting layer between the 
viral nucleocapsid and the viral membrane. Its interaction with different viral proteins 
including N, G, F and M2-1 has been demonstrated. There are two main functions 
reported for the M protein; switching off viral transcription and directing virus assembly 
towards budding. It has been shown for members of the order Mononegavirales that the 
M protein is essential for virus budding, suggesting it has intrinsic capabilities of 
directing virus budding (Mebatsion et al., 1996; Mebatsion et al., 1999; Teng & Collins, 
1998). The cytoplasmic domain of the G protein, in particular the first 6 amino acids 
and especially serine at position 2 and asparagine at position 6, play a major role in the 
interaction of G and M proteins (Ghildyal et al., 2005). The interaction between the F 
and M proteins is independent from the interaction between the G and M proteins 
(Ghildyal et al., 2005). This suggests that there are separate domains on the M protein 
responsible for interaction with F and G glycoproteins. 
It has been shown that the first 110 amino acids from the N-terminus of the N 
protein are responsible for the interaction between M and N proteins (Li et al., 2008a). 
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1.2.6.2 Virus release 
Sample titration from the apical and basolateral surfaces of polarised human 
airway epithelial (HAE) cells grown on 0.4 µm semipermeable membranes indicated 
that virus budding occurs from the apical surface of cells and the virus is released into 
the luminal periciliary fluid and/or possibly into overlaying mucus layer in vivo. This 
would result in a “vectorial pattern”, forming a circular form of infection with each 
initial focal point in the centre and radial spread of the progeny HRSV into adjacent 
cells (Zhang et al., 2002). 
1.3 Pneumovirus pathogenicity 
1.3.1  Virus factors affecting pathogenicity  
Pathogenesis in viruses is frequently multifactorial, and requires interaction 
between many viral and host proteins. Other factors such as regulatory sequences may 
also play a role. For example, certain attenuated derivatives of HRSV have a 4C 
nucleotide substitution at their leader position which has been shown to affect the 
amount of genome replication (Section  1.2.2). Other viral factors affecting the 
pathogenicity are described below (Fearns et al., 2002). 
1.3.1.1 Non-structural (NS) protein 1 and 2 
The HRSV non-structural proteins 1 and 2, previously known as 11K and 14K 
proteins, are found in abundance in the infected cells, but in little amounts associated 
with virion extracts. Therefore, they are designated as non-structural proteins (Huang et 
al., 1985). The NS1 and NS2 proteins are unique to pneumoviruses and lack 
counterparts among other negative strand non-segmented RNA viruses. The NS1 gene 
of HRSV strain A2 is 552 nucleotides in length and encodes a polypeptide of 139 amino 
acids. The NS2 gene is 503 nucleotides in length and encodes a polypeptide of 124 
amino acids in length (Collins & Wertz, 1985b). The NS1 and NS2 gene positions close 
to the leader/promoter region makes them the most abundantly transcribed genes in 
HRSV infected cells (Collins & Wertz, 1985b; Glazier et al., 1977). 
In a novel experiment, recombinant rabies viruses carrying either the BRSV 
NS1 or NS2 genes were generated to assess the ability of these genes to confer reduced 
sensitivity to interferon. The data showed that both NS1 and NS2 can inhibit the IFN 
response in the host cell but that both act together synergistically for the greatest effect 
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(Schlender et al., 2000). It has been proposed that the NS1 and NS2 proteins may also 
contribute to host specificity by exerting the greatest effect on the IFN systems of the 
relevant host animal (Bossert & Conzelmann, 2002; Schlender et al., 2000). 
The importance of NS1 and NS2 proteins in antagonizing the host innate 
immune response was also analysed using recombinant BRSV virus deleted in either or 
both of the genes (Schlender et al., 2000). It was shown that BRS recombinant viruses 
lacking NS1, NS2 or both proteins grow efficiently in Vero, HEp-2 and BSR-T7/5 cells. 
However, their growth was reduced by 100-fold in MDBK cells, suggesting further that 
NS1 and NS2 proteins are IFN antagonists. The evidence from the experiment was 
confirmed by co-cultivating Vero cells with MDBK cells in a two-chamber culture 
system in which the chambers were isolated from each other by a permeable filter. The 
analysis showed that cells responded to soluble factors released from MDBK cells by 
inhibition of the growth of the viruses. A similar result was observed with macrophages 
as the effector (Schlender et al., 2000; Valarcher et al., 2003).   
The function of NS1 and NS2 proteins in virus replication and plaque 
morphology of HRSV strain A2 was analysed by Jin and colleagues (2000). It was 
shown that the presence of the NS1 and NS2 genes in the HRSV genome is not essential 
for recombinant virus recovery or replication in vivo or in vitro (Jin et al., 2000b). 
However, deletion of NS1 and/or NS2 genes in the recombinant viruses resulted in the 
generation of smaller plaque morphology and 100-fold reduction in virus replication in 
Vero and HEp-2 cells. Replication of the recombinant viruses in the lower respiratory 
tract of cotton rats was also reduced (Jin et al., 2000b). 
The function of the NS1 and NS2 proteins and their impact in virus replication 
and interferon antagonism in PVM strain 15 (ATCC) was studied by Buchholz et al. 
(2009). It was shown that the deletion of either the NS1 or NS2 genes did not affect the 
ability of the recombinant PVM to grow in interferon negative Vero cells. However, 
recombinant viruses lacking NS1 or NS2 genes did not grow in mouse embryonic 
fibroblast cells (Buchholz et al., 2009). 
1.3.1.2 Effect of the G glycoprotein in pneumoviruses pathogenesis 
The G glycoprotein of pneumoviruses has been identified as one of the major 
determinant factors of pathogenesis. As noted earlier (Section  1.2.1.1) the structural 
similarity between the CX3C motif of the G glycoprotein and fractalkine chemokine 
suggests an interaction between the CX3C motif and CXCR1 (fractalkine receptors) 
33 
 
which enables the G glycoprotein to mimic fractalkine function (Tripp et al., 2001). 
This function of the G protein was attributed to the CX3C motif of the G protein (2006). 
Mice infected with recombinant HRSV deficient in the CX3C motif or lacking the G 
gene showed significantly higher levels of pulmonary CX3CR1+, CD4+ and CD8+ cells 
than in mice infected with the HRSV strain A2 (Harcourt et al., 2006). These data 
suggest the importance of the G glycoprotein in controlling the influx of cytotoxic CD8+ 
T cells, which have an important role in controlling the infection and virus clearance. 
HRSV G protein stimulation of naive spleen cells induces IL4 and CXCL1 
production (Harcourt et al., 2006). The mechanism of this function of the G protein has 
not been identified, but this is attributed to the interaction between the G protein and 
extracellular heparin molecules, or the interaction between the cysteine noose and 
fractalkine receptors (Harcourt et al., 2006). 
The conserved cysteine rich region of the G glycoprotein acts as an 
antiinflamatory factor to antagonize the proinflammatory effect of F glycoprotein 
(Polack et al., 2005). The G glycoprotein has also been shown to change cytokine 
production of the infected cells by blocking production of inflammatory cytokines, 
decreasing nuclear translocation of NF-κB. The similarity between the GCRR domain 
of the G protein (see  1.2.1.1) and the fourth sub-domain of TNFR1 suggests an 
interaction between these two molecules which may explain the G gene contribution in 
immunomodulatory function (Langedijk et al., 1998). 
More recently it has been shown that the G glycoprotein inhibits TLR 3 and 4 
mediated type I interferon response by modulating the TICAM-I pathway (Shingai et 
al., 2008). The down regulation of IFN-β in MLE-15 cells (mouse lung epithelial cells) 
infected with a recombinant virus lacking the G gene was related to down regulation of 
interferon stimulated gene-15 (ISG-15) protein which its expression of which rapidly 
increases in response to viral infections (Moore et al., 2008). In cells infected with 
recombinant HRSV lacking G gene, the mRNA and expression levels of suppressor of 
cytokine signalling 3 (SOCS3) were significantly higher in comparison with cells 
infected with the wildtype HRSV or HRSV lacking NS1 and NS2 genes (Moore et al., 
2008), indicating the effect of the G protein in inhibiting the innate immunity cellular 
signalling pathway. 
The fast release of the Gs from the infected cells (after 24 hr of infection) helps 
the virus to modulate both cellular and humoral immunity by using the Gs as a decoy 
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for anti-G specific neutralising antibodies and as an imitative protein for CX3C 
chemokine in controlling monocyte trafficking (Collins & Graham, 2008). 
G glycoprotein activates the humoral response. However, the antibody response 
to the G glycoprotein is sub-group specific (Section  1.1) and cross reactivity between 
anti-G antibodies rarely happens (Oshansky et al., 2009). In contrast, anti-F antibodies 
are effectively capable of neutralizing the virus (Kao et al., 1984; Melero et al., 1997; 
Trudel et al., 1991). 
1.3.1.3 Effect of the F glycoprotein in pneumoviruses pathogenesis 
Unlike other paramyxoviruses, cleavage of the pneumovirus F protein is not a 
key determinant of pathogenicity and virus virulence. In contrast with the G 
glycoprotein, the HRSV F glycoprotein has been reported to interact with toll like 
receptor 4 (TLR4) and activates the signalling pathway leading to up-regulation of 
TNFα, IL-6 and IL-12 production (Collins & Graham, 2008; Oshansky et al., 2009). 
Antibody response is against two types of F protein: the mature form which is 
present on the virus particles and the immature form which is the unfolded form of the F 
protein. The immature form does not contain all of the epitopes necessary for 
neutralisation (Lopez et al., 1998). Early release of the immature form from lysed 
infected cells results in an inefficient antibody response (Oshansky et al., 2009). The 
major neutralising antibodies are against F protein. 
It has been reported that the F protein in HRSV strain Line 19 is more 
mucogenic than its counterparts in HRSV strain A2 or HRSV strain Long (Moore et al., 
2009). Moore and colleagues (2009) have shown that BALB/cJ mice infected with a 
chimeric HRSV virus strain A2 carrying the F gene from the strain Line 19 showed 
lower IFN-α production, higher lung viral load, higher lung IL-13 level, higher airway 
mucin production level and higher airway hyper responsiveness than those were 
infected with recombinant HRSV strains A2 and Long. In comparison with the 
sequence of the F protein in the strains A2 and Long, the F protein of HRSV strain Line 
19 contains 4 unique amino acid substitutes in its sequence (Moore et al., 2009). 
The importance of pep27 of BRSV and the furin like cleavage sites of the F 
protein (Section 1.2.1.2) in BRSV replication in the cell culture has been investigated 
(Zimmer et al., 2002). Although the pep27 or the furin cleavage sites are not required 
for efficient virus growth in the cell culture (Zimmer et al., 2002), in a separate study 
(Valarcher et al., 2006), it was shown that calves infected with recombinant viruses 
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carrying mutations in the furin cleavage sites of the F protein or lacking the pep27 
demonstrate a less gross and microscopic pulmonary pathology in comparison with the 
calves infected with the recombinant viruses carrying the authentic F glycoprotein. 
Small hydrophobic (SH) protein 
The SH protein is a small (64 amino acids for HRSV strain A2, subgroup A, and 
65 amino acid for HRSV subgroup B) and highly conserved transmembrane 
glycoprotein transcribed and translated from the SH gene. The amino acid sequence of 
the SH protein is highly conserved among both HRSV subtypes (Carter et al., 2010).  
The SH protein was shown to be non-essential in HRSV replication and was 
categorised as an accessory protein of HRSV (Bukreyev et al., 1997; Whitehead et al., 
1999). The SH protein accumulates in different forms (designated SH0, SHp, SHt and 
SHg) inside infected cells.  SH0 is the non-glycosylated and full length form of the SH 
protein with a relative molecular mass of 7,500, SHg contains an N-linked carbohydrate 
side chain (Mr 13,000-15,000), SHp has more modification by addition of 
polylactosaminoglycan oligosaccharides to the N-linked side chain (Mr 21,000-65,000) 
and SHt is distinct nonglycosylated form of the SH protein with a shorter N-terminus as 
its translation starts from the second start codon of the SH gene (Anderson et al., 1992; 
Collins & Mottet, 1993). The N-linked glycosylation sites and the central hydrophobic 
region are highly conserved among HRSV and BRSV subtypes (Anderson et al., 1992). 
Lipid rafts in the cellular secretary pathway such as the endoplasmic reticulum, Golgi 
compartment and cell surface are the main sites that SH protein is observed in 
abundance in the infected cells. The appearance of SH protein in viral filamentous 
structures is minimal (Rixon et al., 2004). 
The function of the SH protein is not clearly known. However, an anti-apoptotic 
function has been reported (Fuentes et al., 2007), and large plaque formation 
phenomenon seen in SH deleted recombinant HRSV is attributed to the anti-apoptotic 
function of the SH protein (Bukreyev et al., 1997; Techaarpornkul et al., 2002). 
There is evidence that the SH protein is phosphorylated via a MAPK p38-
dependent pathway during the virus infection cycle, and the phosphorylated SH protein 
is linked with a pentamer homo-oligomer structure (Rixon et al., 2005). Observations 
using electron microscopy techniques suggest the presence of pentamer and hexamer 
homo-oligomer viroporin channels formed by the SH glycoprotein (Carter et al., 2010; 
Gan et al., 2008; Kochva et al., 2003). The function of these channels in the viral and 
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cellular life cycle, their effect on the apoptosis (Lang et al., 2005), and the possibility of 
their contribution in the virulence remains to be clarified. 
Deletion of the SH gene from recombinant HRSV viruses did not have any 
significant effect on the virus growth in vitro (Bukreyev et al., 1997). However, a 
deleted SH recombinant virus showed 40-fold reduction in replication in the lower 
respiratory tract of chimpanzees infected with the virus and the chimpanzees showed 
less rhinorrhea in comparison with the chimpanzees receiving the wild-type HRSV 
(Whitehead et al., 1999). 
Sequence analysis of the SH gene among clinical isolated showed little or no 
sequence variability (Chen et al., 2000), indicating conservation of SH gene among the 
clinical isolates and suggesting an evolutionary importance of the SH gene for 
maintaining viral pathogenicity. 
The expression of MIP, MCP-1, and IP-10 was related to the biological function 
of G and/or SH glycoproteins. The mRNA expression level for MIP, MCP-1 and IP-10 
was reported as being higher in the bronchoalveolar lavage (BAL) cells of mice infected 
with HRSV strain cp52 than those of mice infected with HRSV strain B1. The 
difference between the expression levels was related to the lack of biological activity of 
G and/or SH glycoproteins in the strain cp52 (Tripp et al., 2000a). 
1.3.2 Host factors affecting pathogenicity 
There are host factors that may affect the severity of disease associate with  
HRSV infection. The importance of these host factors in the infection of HRSV was 
observed by Prince et al. (1979). To develop a mice model for HRSV infection, 20 
strains of inbred mice were infected with HRSV strain Long (Prince et al., 1979). 
Among the infected mice strains  the CBA/CaCHN strain of mice was reported as the 
most resistant while the strain DBA/2N was reported the most permissive strain (Prince 
et al., 1979). In a separate study, Anh et al. (2006) tested susceptibility of 6 different 
strains of mice (129/Sv, BALB/c, C3H/HeN, C57BL/6, DBA/2 and SJL) to PVM 
infection. the strain SJL showed the most resistance to PVM infection while the rest 
showed high susceptibility to the infection with a greater degree for the strain 129/Sv 
which was followed by the strains DBA/2, C3H/HeN, BALB/c and C57BL/6 in order.  
The host factors affecting the pathogenicity related with HRSV infection may 
include age, gender, race, congenital heart disease, bronchopulmonary dysplasia, 
immunosuppression or immunodeficiency, narrow airways, premature birth, low birth 
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weight and the level of immunity of individuals during the time of infection (Collins & 
Graham, 2008; DeVincenzo, 2005; Leader & Kohlhase, 2003; Oshansky et al., 2009; 
Walsh et al., 1997; Welliver, 2003). The relation of nucleotide polymorphism in certain 
genes with severity of disease caused by HRSV also has been examined. These include 
genes involved in immune response including genes encoding cytokines and 
chemokines (including IL-4, IL-8, IL-10, IL-13, IL-18, RANTES/CCL5), or surface and 
signal transduction elements (including TLR-4, CD14, IL-4R, CX3CR1, CCR5 and 
surfactant proteins) (Amanatidou et al., 2006; Awomoyi et al., 2007; Collins & 
Graham, 2008; Hull et al., 2003; Miyairi & DeVincenzo, 2008; Paulus et al., 2007; 
Puthothu et al., 2007).  
1.3.2.1 The effect of tachykinins on respiratory disease 
Mammalian tachykinins are traditionally categorized as neurotransmitters. They 
all are short polypeptides (about 11 amino acids) processed and post-translationally 
modified from longer polypeptides (Page, 2005). Despite early reports indicating 
production of tachykinins solely from neural cells, there are several reports suggesting 
the production of tachykinins in other tissues and cells including inflammatory sites, 
macrophages, eosinophils, lymphocytes, and dendritic cells (Bost & Pascual, 1992; 
Killingsworth et al., 1997; Weinstock et al., 1988).  There are also reports showing the 
presence of tachykinins in the peripheral circulation and even in placental tissue (Page, 
2005; Page et al., 2000). The tachykinins in these cells exert their effects in different 
regulatory and inflammatory mechanisms. 
Five tachykinin peptides have been identified in mammals; substance P (SP), 
neurokinin A (NKA), neuropeptide K (NKK), neuropeptide-  (NKY), and neurokinin 
B (NKB). All of the tachykinins share a similar C-terminal of                                    
Phe-X-Gly-Leu-Met-amid where X is an aromatic or hydrophobic amino acid (Hietala 
et al., 2005). The conserved C terminal region acts as the central activation factor to 
activate tachykinin receptors  (Page, 2005). At least three receptors have been reported 
to interact with tachykinins: the neurokinin-1, neurokinin-2 and neurokinin-3 receptors 
(NK-1R, NK-2R, and NK-3R). It has been shown that different tachykinins have 
different affinities in binding to the receptors, as SP binds to NK-1R more efficiently 
than the others. NKA and NKB bind to NK-2R and NK-3R with a higher affinity in 
comparison with the others (O'Connor et al., 2004; Page, 2005).  
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SP was first discovered in 1931 and was subsequently isolated from bovine 
hypothalamus and characterized in 1971. In humans and animals, SP increases 
ventilation (Saaresranta & Polo, 2002). It has been shown that SP has a broncho-
constriction effect in vitro, though no such effect is reported in vivo (Saaresranta & 
Polo, 2002).  The amount of SP in HPLC purified tracheal and lung extracts has been 
measured at 13.0 and 5.4 pmol/g tissue, respectively (Groneberg et al., 2006). 
It seems likely that human respiratory inflammation causes SP and NKA 
production from neuronal or non-neuronal cells located in the respiratory system. In 
guinea pig models, 24 hr after allergen challenge the amount of SP and NKA was 
increased 3- to 4-fold. In a study on NK-1R depleted animal models it was shown that 
deletion of the receptor did not have any significant effect on the accumulation of 
inflammatory factors such as antigen specific IgE and inflammatory cells in 
bronchoalveolar lavage (BAL) fluids (Tournoy et al., 2003). The effect of tachykinins 
in signal transduction in respiratory systems and its importance in the inflammation 
remains to be understood (Groneberg et al., 2006).  
It has been shown that SP is produced in association with the G and/or SH 
glycoproteins in lungs of mice acutely infected with HRSV (Tripp et al., 2000b). In this 
study the level of SP in the BAL of naïve mice was measured by a competitive ELISA 
test and compared to those of HRSV strain B1 and HRSV strain cp52 infected mice 
(Karron et al., 1997). It was shown that that SP was significantly lower in the group of 
mice infected by cp52. The absence of G and SH glycoproteins in the strain cp52 
suggested that either or both of the glycoproteins contributed to the alteration of the 
level of SP detected.  
1.3.3 Long lasting HRSV infection 
The contribution of HRSV to chronic obstructive pulmonary disease (COPD) 
has been sought for some time. As with acute respiratory disease caused by HRSV the 
main site of inflammation in COPD is the small airways where obstruction and 
inflammation happens upon the infection (Wilkinson et al., 2006). The infection of a 
recombinant HRSV expressing GFP persisted for more than one month in well 
differentiated human airway epithelium (WD-HAE) culture, with normal cilia 
movement and no obvious cytopathology or syncytia formation (Zhang et al., 2002). 
This suggested that long term infection may be possible.  
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Two reports have described long-lasting pneumovirus infection in vivo. To 
investigate the mechanisms involved in latency, persistency or immune evasion, no 
virus was detected in broncho alveolar fluid isolated from BALB/c mice infected with 
HRSV, while the virus was detectable in lung homogenates of the mice using PCR after 
100 days of post infection (Schwarze et al., 2004). The mice did not demonstrate any 
signs of infection during the period. In a similar study BRSV was isolated directly from 
tracheobronchial and mediastinal lymph nodes of  calves infected with BRSV in up to 
71 days post infection (Valarcher et al., 2001). 
1.3.4 Using PVM to study the pathogenesis of HRSV 
Generally speaking, mouse models are not fully permissive to HRSV infection. 
Mice least sensitive to HRSV are  CBA/CaHN and the most sensitive are DBA/2N 
(Byrd & Prince, 1997). In comparison with mice, cotton rats are more permissive to 
HRSV infection replicating to a 100 times greater titre than that in DBA/2N mice (Byrd 
& Prince, 1997; Prince et al., 1978). However, the lack of reagents in characterising the 
details of the immunity against HRSV infection is one of the major limiting factors in 
HRSV studies in cotton rats. The availability of congenic, transgenic and knock-out 
strains of cotton rats is another limiting factor in HRSV studies (Byrd & Prince, 1997). 
Another limitation in using mice models of HRSV is the difference between human and 
mice eosinophils in their response to disease (Rosenberg et al., 2009). Considering that 
eosinophils play an important role in the HRSV infection, using mouse models in 
studying HRSV pathogenesis may not reflect the aspects of the eosinophil’s 
contribution in the virus pathogenicity. 
Another alternative way to study the pathogenesis of HRSV is studying the 
pathogenesis of PVM in mice and extrapolating the findings to HRSV. PVM infection 
in mice reflects the same pathology  as HRSV infection in human patients. It has been 
reported that intranasal inoculation of mice with 250 pfu of PVM in a volume of 50 µl 
causes fatal disease in mice (Cook et al., 1998). In contrast, a virus load of 104 – 106 pfu 
is necessary to infect mice (Cannon et al., 1987; Easton et al., 2004; Taylor et al., 
1984). Moreover, the pathogenic PVM develops clear symptoms including weight loss, 
abnormal gait, and tremor during its replication in mice which makes monitoring the 
progress of the disease simpler without the need for obtaining histopathology samples. 
As in HRSV infection in human tissues, PVM infection in mice is accompanied 
by an influx of granulocytes into the lower respiratory system. Production of eosinophil 
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attractants like MIP-1α, eotaxin and RANTES is a common feature between the 
infection caused by PVM in mice and the infection of HRSV in human tissues, and  
using a gene microarray expression of MIP-2 (mouse orthologue for IL-8) and MCP-2 
has been shown (Bonville et al., 2006; Domachowske et al., 2000a; Domachowske et 
al., 2000b).  
1.3.5 Aims 
The main challenge in the study of pathogenesis of HRSV is the lack of a 
suitable animal model. Mouse models are partially permissive for HRSV infection but 
the study of the pathogenicity can be achieved only through histopathological analysis. 
PVM is genetically close to HRSV and displays a pathology in mice which resembles 
that of HRSV in humans. It therefore has been proposed that the PVM infection in mice 
may be suitable model for the study of pneumoviruses in their host.  
The aims of this project were: 
• To establish a reverse genetics system for PVM which could be used to 
study the effects of specific mutations on pathogenicity. 
• To investigate the pathogenicity in mice of a series of stocks of PVM 
which had been progressively passaged in tissue culture and to determine 
the nucleotide sequence of the genes of pathogenic and non-pathogenic 
viruses. This data would be compared with the published sequences of 
pathogenic and non-pathogenic PVM strains. 
• To introduce specific mutations into the G gene of recombinant PVM 
viruses and determine the effect on pathogenicity in mice. 
• To investigate possible consequences of specific mutations associated 
with pathogenicity on molecular processes such as the level of gene 
expression. 
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CHAPTER 2  
 
 
MATERIALS AND METHODS 
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2.1 Solutions 
2.1.1 AEC peroxidase substrate 
AEC (3-amino-9-ethylcarbazole) was dissolved in DMSO at a concentration of 
3.3 mg/ml and kept frozen in small aliquots at -20˚C until the time of use. 20 mM of 
CH3COONa (pH 5.6) and 0.6ml AEC solution were added to water in order, and 16 μl 
of H2O2 was added to the mixture prior to use to have a final volume of 10 ml of the 
substrate. 
2.1.2 ABTS Substrate 
ABTS (2,2'-azino-bis-[3-ethylbenzothiazoline-6-sulfonic acid]) substrate was 
prepared by dissolving 100 mg of ABTS (SIGMA) in 100 ml of buffer. To prepare the 
buffer 1.67 g of the buffer powder (Roche; consists of sodium perborate, citric acid, and 
disodium hydrogen phosphate) was dissolved in 100 ml of distilled water. 
2.1.3 Carbonate coating buffer 
Coating buffer contained 0.34% (w/v) Na2CO3 (anhydrous), 0.57% (w/v) 
NaHCO3, pH 9.6. The pH was adjusted using NaHCO3. 
2.1.4 Luria-Bertani broth and agar media 
10 g of tryptone, 5 g of yeast extract and 10 g of NaCl were dissolved in one 
litre of water. Bacteriological agar (10 g/l) was added to prepare LB agar.  After being 
autoclaved the solution was aliquoted in appropriate tubes or dishes. 
2.1.5 Ketamine and xylazine cocktail 
To obtain the anesthetic condition in mice a ketamine/xylazine cocktail was 
used.  The mixture contained 10 mg/ml of the anesthetic ketamine and 1.8 mg/ml of the 
analgesic xylazine dissolved in sterile phosphate buffered saline (PBS). Adult BALB/c 
mice were anaesthetized by intraperitoneal injection with 150 µl of the mixture. 
2.1.6 Phenol:chloroform mixture 
A mixture of phenol (50% v/v) and chloroform (50% v/v) was used to purify 
DNA from protein contaminants. 
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2.1.7 SDS-PAGE sample buffer 
For preparing 10 ml of 4x sample buffer, 3 ml of 20% (w/v) SDS solution, 3 ml 
of glycerol, 1.6 ml of β-mercaptoethanol and 0.006 g bromophenol blue were mixed 
together. The solution was made prior to use and kept at 4˚C for short term storage. 
2.1.8 SDS-PAGE electrophoresis buffer 
SDS-PAGE electrophoresis buffer (1x) was made by dissolving 25 mM Tris, 
250 mM glycine (pH 8.3) and 0.1% (w/v) SDS in distilled water. 
2.1.9 TAE Buffer 
Tris-acetate (TAE) buffer was specifically used to run low melting agarose gels.  
To make 50x of Tris acetate buffer 242 g of Tris base, 57.1 ml glacial acetic acid and 
100 ml of 0.5 M EDTA (pH 8.0) were mixed together and dissolved into one litre of 
distilled water. 
2.1.10 TB solution 
TB solution composed 10 mM PIPES, 55 mM MnCl2 and 15 mM CaCl2 and 250 
mM KCl. After dissolving the PIPES CaCl2 and KCl in distilled water and adjusting the 
pH to 6.7, MnCl2 was added to the solution. The solution was prepared freshly prior to 
use and filter sterilized. 
2.1.11 TBE Buffer 
Tris-borate (TBE) buffer was prepared in a 10x concentrated format. The 
concentrated solution was diluted to 1x to prepare the working concentration. To make 
the 10x concentrated solution 54 g of Tris base, 27.5 g of boric acid and 20 ml of 0.5 M 
EDTA (pH 8) were dissolved in one litre of distilled water. 
2.1.12 TBS and TBST buffers 
50 mM Tris and 150 mM NaCl were mixed together and the final volume was 
adjusted to 1L. For making 1X TBST 1 ml of Tween-20 was added to 1X TBS. 
2.1.13 X-Gal and IPTG solutions 
A 20 mg/ml stock of X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galacto-
pyranoside) in DMF (dimethylformamide) was prepared. The solution was kept at -20˚C 
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and stored in the dark. A 100 mM stock solution of IPTG (isopropyl-β-D-
thiogalactopyranoside) in distilled water was prepared filter sterilized and kept at -20˚C 
and in the dark until the time of usage. 
2.2 Cell culture and classic virology techniques 
2.2.1 Viruses and cell lines 
BS-C-1 (African green monkey kidney cell lines) and BSR-T7/5 (BHK21 cells 
expressing bacteriophage T7 RNA polymerase) cells were obtained from Dr. R. Ling, 
pneumovirus Laboratory, University of Warwick (Buchholz et al., 1999). All cell lines 
were grown at 37˚C in Glasgow minimum essential medium (GMEM) supplemented 
with 10% fetal calf serum (FCS), 2 mM glutamine, 100 units/ml penicillin and 100 
µg/ml streptomycin. A maintenance medium with the same amount of antibiotics and L-
glutamine, but with 2% FCS was prepared and used to keep cells. 
PVM strain J3666 and PVM strain 15 (Warwick) were obtained from Prof.  A. 
Easton, pneumovirus Laboratory, University of Warwick.  
2.2.2 Mammalian cell culture 
BS-C-1 cells were grown to confluence in Glasgow modified Eagles’ medium 
(GMEM) supplemented with 10% fetal bovine serum (FBS), Penicillin (100 units/ml), 
streptomycin (50 mg/ml) and L-glutamine (2 mM final concentration). After obtaining 
confluence, cells were detached from the surface by washing with trypsin 1:250 prior to 
dispersal in growth medium to obtain a single cell suspension. The cell suspension was 
divided between tissue culture dishes to have a final suspension of cells containing 
5x105 cells/ml.  The tissue culture dishes were incubated at 37°C in 5% (v/v) CO2 and 
air. 
For the BSR-T7/5 cell line, the same procedure was repeated. GMEM medium 
supplemented with Geniticin (Invitrogen) to a final concentration of 1 mg/ml was used 
to cultivate the cells. 
2.2.3 Freezing of mammalian cells 
Mammalian cells were frozen in a mixture of 90% serum plus 10% DMSO. 
Freshly prepared confluent cells were detached from the growth surface and pelleted at 
low speed. The cells were resuspended in freezing mix which had been freshly prepared 
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and filter sterilized prior to use.  The number of cells and the volume of freezing 
mixture were adjusted to approximately 5x105 per ml. The suspension was placed into 
cryo-tubes in 1 ml aliquots. The cryo-tubes were moved to a 1˚C freezing container (Mr. 
Frosty™, Nalgene Labware) to control the reduction of the temperature to a rate of 1˚C 
for every minute. The freezing container containing the samples was moved to a -70˚C 
freezer. The frozen samples were moved to the gas phase of liquid nitrogen for longer 
storage. 
2.2.4 Transfection of mammalian cell lines using Lipofectamine 2000 
Lipofectamine 2000 (Invitrogen) was used to transfect BSR-T7/5 cells. Briefly, 
sub-confluent BSR-T7/5 cells were freshly prepared in 10 cm2 tissue culture plates the 
day before transfection. Prior to transfection, the medium was replaced with GMEM 
supplemented with 2% FBS. The DNA mixture (see Sections  4.7 and  5.11 for the 
quantities) and Lipofectamine 2000 were mixed separately in 250 µl of OPTIMEM® 
(Invitrogen). For each 1 µg DNA, 3 µl of Lipofectamine 2000 was used. After a 
minimum of 5 min of incubation at room temperature, both the diluted DNA and the 
transfection agent were mixed together. The mixture was incubated for a minimum of 
30 min, and then added drop-wise to the prepared cell culture. 
2.2.5 Transfection of mammalian cell lines using Turbofect 
The medium bathing the cells was replaced with GMEM containing 2% (v/v) 
FBS immediately prior to the transfection. The DNA to be transfected was resuspended 
in 400 µl of OPTIMEM® (Invitrogen). For every 1 µg DNA 1.5 µl of Turbofect was 
used. The desired amount of Turbofect reagent was added to the DNA suspension and 
mixed thoroughly. After 15 to 20 min incubation at the room temperature the 
DNA:Turbofect mixture was added to the cell culture medium. 
2.2.6 Virus cultivation 
Roller bottles containing sub-confluent BS-C-1 cells were infected with PVM 
virus in such a way to obtain a final moi of 0.05 pfu/cell. Both PVM strain J3666 and 
strain 15 (Warwick) were incubated at 31˚C until 80-90% cell destruction was achieved. 
At this point the roller bottles were frozen and thawed. The freeze and thaw cycle was 
followed by scraping the attached cells into the medium using sterile glass beads. The 
suspension of virus and cell lysates were kept at -70˚C in small aliquots.  
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2.2.7 Micro-plaque assay 
Serial dilutions of virus were prepared in the maintenance GMEM medium 
containing 2% (v/v) FBS immediately before the titration and kept on ice during the 
assay. Freshly prepared sub-confluent BS-C-1 cells in a 96-well plate were used to 
quantify the titre of the viruses (section  2.2.1). The medium bathing cells was replaced 
with 100 µl of the virus dilutions in triplicates. Cells were incubated for 1 hr at 31°C to 
complete adsorption. The adsorption was followed by washing cells to remove unbound 
viruses, and the cells were overlaid with maintenance medium. The titre of all of viruses 
was measured at 31˚C after 24 hr incubation. Cells were fixed with 1:1 (v/v) mixture of 
chilled methanol and acetone for 30 min at room temperature. The fixed cells were 
washed with PBS 3 times, and incubated with 1/40 dilution of the monoclonal antibody 
(26/C3/B5) which is specific for the P protein of PVM (Ling & Pringle, 1989a). The 
mAb was diluted in PBS containing 1% gelatin (Ling & Pringle, 1989a). The cells were 
incubated with the antibody for 1 hr at 37˚C. After removing antibody, the cells were 
washed 3 times with PBS. Goat anti-mouse antibody (BioRad) was used as the 
secondary antibody and cells were incubated with 1:2000 concentration of this for 1 hr. 
The incubation was followed by washing the cells 3 times with PBS. The washing 
process was followed by addition of AEC peroxidase substrate (section  2.1.1) and plates 
were observed until a brown color was developed. The number of plaques represented 
by brown cells was counted and the titre of virus stock was calculated. 
2.3 Molecular biology techniques 
2.3.1 Plasmid DNA extraction 
QIAGEN® plasmid preparation columns were used to prepare stocks of DNA. 
Briefly, for DNA preparation in mini scale, 5 ml of an overnight bacterial culture grown 
in LB broth supplemented with the appropriate antibiotic (mainly Ampicillin at final 
concentration of 100 µg/ml) was used. Bacterial cells were pelleted by centrifugation at 
2500 g for 5 min and resuspended in 250 μl of buffer P1 (provided in the kit). The cells 
were lysed by the addition of 250 μl of buffer P2 (provided in the kit). The tube 
containing the lysate was inverted 4-6 times to mix the solution thoroughly. The 
mixture was neutralized using 350 μl of buffer N3 (provided in the kit), and centrifuged 
at 18000 g for 15min. The supernatant was transferred to a QIAprep spin column and 
centrifuged down for 1 min to remove the solution from the column leaving the DNA in 
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the column. The column was washed using 0.75μl of buffer TE and centrifuged for 
1min. DNA was eluted using 50μl of the elution buffer provided in kit (EB buffer, 
provided in the kit). 
For larger scale DNA preparation (maxi-preparation), 500 ml of freshly prepared 
bacterial culture was used. A cell lysate was obtained by adding 10 ml of P2 buffer to 
10 ml of resuspended cells in P1 buffer. The lysate was neutralized using 10 ml of 
chilled P3 buffer. A QIAGEN-tip 500 column was equilibrated by applying 10 ml of 
QBT buffer (provided in the kit). The supernatant was transferred to the column and 
washed twice by adding 30 ml of QC buffer (provided in the kit). The buffer was passed 
through the column by gravity. DNA was eluted in 15 ml of buffer QF (provided in the 
kit) and precipitated using 10.5 ml of isopropanol. The DNA pellet was washed in 5 ml 
of 70% ethanol, air dried and reconstituted in an appropriate volume of buffer EB 
provided in the kit. 
2.3.2 DNA Digestion  
To carry out a single or double digestion with a restriction endonuclease, the 
appropriate amount of DNA was diluted into the appropriate buffer for the enzyme 
according to the manufacturers’ instructions. BSA was added to the DNA mixture if 
required. At the final step the relevant enzyme(s) were added to the mixture and the 
reaction was incubated according to the enzyme manufacturers’ instructions. 
2.3.3 Gel extraction 
To prepare DNA fragments from agarose gels, the DNA was separated by 
electrophoresis in a 1% agarose gel in 1x TBE buffer. The desired fragment was excised 
from the agarose gel using a new razor blade or scalpel blade. Gel extraction was 
carried out using a QIAGEN® gel extraction kit following the manufacturer’s 
instruction. Briefly, the excised gel was dissolved at 65°C in the QG buffer (provided in 
the kit) at pH 7.5. The solution containing the DNA fragment was passed through the 
silica membrane column provided. The DNA trapped in the column was eluted with the 
buffer provided. 
2.3.4 DNA ligation and low melting point agarose dependent ligation 
T4 DNA ligase (Fermentas) was used to ligate DNA fragments together. To 
avoid repeated freeze and thaw the 10x ligation buffer provided with the enzyme was 
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aliquoted in 2 µl volumes and used only once. DNA fragments ready to be ligated 
(insert and vector) were mixed with water, buffer and enzyme to achieve 20 µl of 
reaction in total. The reaction mix was incubated at 16˚C for 2 hr. In ligations of two 
fragments with cohesive ends, the molar ratio of insert and vector was adjusted in such 
a way that insert was 3 times more than the vector. For ligation of fragments with blunt 
ends 3-fold excess of vector was used. Aliquots of the ligation product were used in 
transformation of Escherichia coli (E. coli)(section  2.3.6). 
In situations where it was not possible to get an appropriate concentration of a 
DNA fragment after gel purification, low melting point (LMP) Agar (TopVision® 
Genetic Quality LMP, Fermentas) was used. LMP agarose gels were prepared in 1x 
TAE buffer. The electrophoresis was conducted at 4˚C. The desired fragment was 
excised from the gel and the agarose containing the DNA was melted at 60˚ C . The 
molten agarose was added directly to ligation reaction. The concentration of LMP 
agarose was calculated not to exceed 5% of total volume (20 µl) of the ligation mix. 
Finally, the ligation tube was incubated at appropriate temperature, either at 16°C for 3 
hr, or at 4˚C for overnight ligation. 
2.3.5 Preparation of competent bacterial cells 
Competent bacterial cells were produced using the method of Inoue, et. al. 
(1990). A freshly prepared E. coli liquid culture originating from one single colony, was 
grown at 18-20˚C in a 250 ml volume of LB medium until the optimal turbidity was 
achieved (A600 = 0.6). The cultures were centrifuged at 2500 g for 10 min at 4˚C in 50 
ml volumes, and pellets were   resuspended in 20 ml of ice cold TB solution, 
individually. The suspensions were incubated in an ice bath for 10 min and bacteria 
were pelleted as before. The pellets were gently resuspended in 5 ml of TB solution 
individually. DMSO was added with gentle swirling to a final concentration of 7% 
(v/v). Following incubation in an ice bath for 20 min, the cell suspension was dispensed 
into 100 or 200 μl aliquots. The aliquots were immediately frozen using liquid nitrogen 
and kept at -70˚C until required. 
2.3.6 Heat-shock based transformation of E. coli 
The competent cell aliquots were thawed in an ice bath. The DNA suspension 
was added in a volume less than 10% of the volume of competent cell solution and 
mixed gently prior to incubation on ice for 45 min. The incubation was followed by a 
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heat shock at 42˚C for 1 min. Sterile LB medium was added to make 1 ml of bacterial 
suspension and this was transferred into a sterile polypropylene tube and incubated at 
37˚C with vigorous shaking. The transformed bacteria were grown on LB agar plates 
containing the appropriate antibiotic. 
2.3.7 RNA isolation 
RNA was isolated using Trizol-LS® (Invitrogen) reagent and manufacturer’s 
instructions were followed thoroughly. To minimize the effect of cell culture passages 
on the sequence of viruses, the RNA extraction was performed directly using virus 
stocks with known titre. The number of the passages of the virus is specified where 
required. The yield of RNA extracted from 0.25 ml of virus suspension was enough for 
RT-PCR experiments ( 2.3.10). 
2.3.8 pBS-T vectors preparation 
EcoRV digested pBlueScript II vectors (2961 bp) were purified from a 1% 
agarose gel (Section  2.3.3). T residues were added to the 3’ ends of the fragment in a 
polymerase reaction containing 5 units of Taq DNA polymerase, 100 µM of dTTP and 
Taq DNA polymerase buffer (Fermentas) containing 1.5 mM Mg2+. The reaction was 
conducted at 72˚C for 2 hr. The reaction product was phenol:choloroform purified 
(Section  2.1.6) and self ligated to remove the digested DNA lacking the 3’T residues. 
The linear fragment of pBS-T, with an estimated molecular weight of 3000 bp, was 
visualized and purified on a 0.7% agarose gel. 
2.3.9 Blue and white colony screening 
From IPTG and X-Gal stocks (Section  2.1.13), 1 ml of each was added to 1 litre 
of molten LBA (Section  2.1.4) ready to be dispensed into 10 cm diameter bacterial 
culture dishes. The appropriate antibiotic for selection was added, mixed evenly and 
poured into the dishes. 
2.3.10 Reverse transcription polymerase chain reaction (RT-PCR) 
For producing cDNA from viral RNA templates RevertAid™ H minus reverse 
transcriptase (Fermentas) was employed. The reaction was set following the 
manufacturer’s guidance. Briefly, RNA samples (0.1 – 5 ng), gene specific (10 µM) or 
random primers (0.2 µg or 100 µM) and RNase free water were mixed together to 
50 
 
obtain 12.5 µl of the mixture. At this point, the sample was heated to 65˚C for 5 min and 
chilled on ice immediately. The reaction buffer containing DTT, RiboLock™ RNase 
inhibitor (Fermentas), dNTPs (100 µM of each dATP, dCTP, dGTP and dTTP) and 200 
units of the reverse transcriptase were added to the mixture to end up having a total 
volume of 20 µl. The sample was incubated at 25˚C if random primers were used and 
was followed with incubation of samples at 42˚C for 60 min. Otherwise the sample was 
incubated for 43˚C for 60 min. To clear the cDNA product from RNA templates, 
incubation of the sample with RNase H (Fermentas) for 30 min was carried out, and 
was followed by stopping the RNase reaction at 65˚C for 30 min. The cDNA was 
phenol:chloroform (section  2.1.6) purified and ethanol precipitated, and was used 
appropriately in PCR reactions.  
2.3.11  Polymerase Chain Reactions (PCR) 
The polymerase chain reaction technique was employed for three major 
purposes: 
1. Amplification of specific DNA fragments from DNA or cDNA templates using 
standard PCR procedure for detection, cloning or sequencing purposes. 
2. Introducing site-specific mutations into a target plasmid DNA. 
3. Ligase independent adhesion of DNA fragments; which was achieved using 
overlap PCR technique. 
The use of PCR technique in site specific mutation and overlap PCR is 
explained separately in sections  2.3.12,  2.3.13 and  2.3.14. In the standard PCR for 
sequencing and detection, Taq DNA polymerase (Fermentas) enzyme was employed 
unless otherwise specified. For PCR to produce DNA for cloning purposes, Pfu DNA 
polymerase (Fermentas) was used. To minimize the error rate in DNA amplification, the 
proofreading KOD DNA polymerase (Novagen) was employed to produce DNA 
fragments from single-stranded cDNA templates for sequencing purposes. It is specified 
in the text if a sequence was obtained from DNA fragments amplified with KOD DNA 
polymerase enzyme. 
 For the standard PCR, the reaction mixture was prepared following the 
manufacturers’ guidance. Each PCR mixture contained 100 µM of appropriate pair of 
primers, the appropriate PCR buffer, 2 mM of Mg2+ salt, and dNTP mix (100 µM of the 
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each of dATP, dCTP, dGTP, and dTTP). Primers were designed using Lasergene 
PrimerSelect software. In the primer design, extra care was taken to avoid secondary 
structure formation, intra molecular interaction and GC content less than 50%. Most of 
the primers were designed ending at their 3’ end with C or G rich content to prevent 
“breathing of 3’ ends” unless the situation was inevitable. The PCR condition was 
adjusted according to enzyme manufacturers’ instructions. 
2.3.12 Quick change site-directed mutagenesis 
Quick change site-directed mutagenesis was carried out using a suitable 
proofreading polymerase enzyme. For fragments less than 5kb, Pfu polymerase 
(Fermentas) was used, and for fragments with longer length, Phusion polymerase (NEB 
Biolabs) was used. The thermocycler machine was programmed to run 18 cycles to 
amplify DNA based on the enzyme manufacturers’ instructions. The extension time was 
calculated for each enzyme specifically (2 min per 1 kb for Pfu polymerase, and for 30 
seconds for Phusion polymerase). Thereafter, the reaction mixture was digested with 
DpnI enzyme to remove the parental DNA. Aliquots of the DpnI digested mixture were 
used to transform competent E. coli. 
2.3.13 Primer design for Quick change site-directed mutagenesis 
Primers designed for the mutagenesis reaction had three main characteristics: 
they were complementary and designed to anneal to the same sequence on opposite 
strands of the plasmid; they had the mutation site embedded in the middle of the primer; 
and they were not shorter than 25 base pairs with a Tm of not less than 78˚C. The Tm was 
calculated using the equation: Tm= 81.5 + 0.41(%GC) - 675/N - %mismatch. 
The “%mismatch” was defined as zero for calculating Tm for primers intended to 
introduce insertions or deletions, and for mutagenesis was calculated by dividing the 
number of nucleic acids to the total length of the primer and multiplied to 100. An 
annealing temperature of 55˚C was used uniformly. 
2.3.14 “Round the horn” site directed mutagenesis PCR 
This technique was designed based on the standard PCR. The primers used in 
this mutagenesis technique were designed in a way that they abut at the 5’ ends 
(Figure  2.1), and ligation of the fragments amplified with these primers would produce 
the plasmid carrying the desired mutation or lacking a specific part of the template 
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plasmid to induce a deletion. Before running the PCR reaction the primers were 
phosphorylated at their 5’ ends using T4 polynucleotide kinase (Fermentas). The PCR 
reaction was carried out as described in section  2.3.11. The resulting PCR product was 
digested with DpnI to remove the parental, methylated, plasmid template. The PCR 
product was separated on an agarose gel and the desired fragment was excised from the 
gel. The purified DNA was ligated to itself using T4 DNA ligase (Fermentas). The 
ligation mixture was used to transform competent E. coli, and the recombinant bacteria 
were grown in the presence of the appropriate antibiotic.  Single colonies were isolated 
from the culture plates and plasmid DNA was isolated for confirmation of insertion of 
the described mutation. 
 
Figure  2.1 “Round the horn” site directed mutagenesis PCR.  A. The pair of primers was 
designed at both sides of the deletion site. The deletion site is depicted in dotted lines. B. 
Primers carrying the mutagenesis sites were designed abut each other. The tail of the primers 
carrying the mutated sequence is depicted in light blue color. After completion of the DNA 
amplification, pre-phosphorylated primers were ligated together to obtain the full plasmid. 
2.3.15 DNA sequencing 
All sequencing samples were prepared individually in 0.5 ml tubes or in 96 well 
sequencing grade plates. It was ensured the samples were containing the advised 
amounts of template DNA and primer. The samples were sent to the genomics facilities 
of university of Warwick, department of life sciences, and they were sequenced using 
Sanger sequencing method. The sequencing was performed using ABI PRISM 3130xl 
Genetic Analyser systems. 
2.3.16 Nucleotide similarity searches 
MUSCLE on-line software (available on EBI server: 
http://www.ebi.ac.uk/Tools/sequence.html) was used to find sequence similarities 
between DNA fragments. Seqman from the DNA star laser gene suit (Lasergene) was 
used to compile sequencing results. 
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2.3.17 SDS - polyacrylamide gel electrophoresis (SDS-PAGE) 
To prepare a mini SDS-PAGE gel (BioRad Protean III gel), the components 
(Table  2.1.A) were mixed and the gel was cast into the sealed mould. About two third of 
the cast was filled with the resolving gel (Table  2.1.A) and the edge of the gel was 
levelled and covered with isopropanol to remove air bubbles from the gel liquid and to 
prevent the gel from oxidation. The ready stacking gel mix (Table  2.1.B) was added to 
the mould containing polymerised and washed resolving gel. At this point the teflon 
comb was inserted between the two glass sheets and into the liquid gel to prepare wells. 
The gel was left until complete polymerisation was achieved in the stacking gel. Then 
combs were removed and the wells were washed with distilled water to remove any 
non-polymerised acrylamide. The electrophoresis unit was assembled based on the 
manufacturer’s instruction and filled with the SDS-PAGE electrophoresis buffer 
(section  2.1.8).  Samples were prepared in the electrophoresis sample buffer 
(section  2.1.7), and boiled for 5 min or incubated at 37˚C for 30 min, and the samples 
were applied into the prepared wells. A voltage of 8 volt/cm was applied to the unit 
until the bromophenol blue dye reached to the resolving gel. A voltage of 15 volt/cm 
was applied until the bromophenol blue dye reached to the bottom of the gel. 
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A 
Ingredients 
Amount required 
for 10 ml of 8% 
resolving SDS-
PAGE gel 
Amount required for 
10 ml of 10% 
resolving SDS-PAGE 
gel 
Amount required for 
10 ml of 12% 
resolving SDS-PAGE 
gel 
H2O 4.6 4 3.3 
30% Acrylamide / 0.8% 
bisacrylamide mix 2.7 3.3 4 
1.5 M Tris (pH 8.8) 2.5 2.5 2.5 
10% SDS 0.1 0.1 0.1 
10% ammonium 
persulfate 0.1 0.1 0.1 
TEMED 0.006 0.004 0.004 
 
B 
Ingredients Amount required for 10 ml of 5% stacking SDS-PAGE gel 
H2O 1.4 
30% Acrylamide mix / 0.8% 
bisacrylamide 0.33 
1.5 M Tris (pH 6.8) 0.25 
10% SDS 0.02 
10% ammonium persulfate 0.02 
TEMED 0.002 
Table  2.1 Ingredients to prepare a 8%, 10% and 12% SDS-PAGE electrophoresis gel. 
Ingredients were mixed in order and poured into the prepared and sealed cast as it is explained 
in the text. A. Ingredients for preparing the resolving gel. B. Ingredients for preparing the 
stacking gel. 
2.3.18 Western blot  
A Trans-Blot® SD semi-dry electrophoretic transfer cell was used. Prior to the 
transfer, the SDS-PAGE gel was trimmed and equilibrated with transfer buffer (24 mM 
Tris base, 192 mM glycine, and 20% methanol) for 5 min. Whatman papers and 
polyvinylidene fluoride (PVDF) membranes were cut to the dimensions of the gel. The 
PVDF membrane was soaked in methanol for 2 min and thereafter was soaked in the 
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transfer buffer. A stack of Whatman papers was made and soaked with the transfer 
buffer. These were placed on top of the anode electrode. Any air bubbles trapped 
between the soaked membranes were removed. The PVDF membrane and the gel were 
placed on the stack of the Whatman papers, leaving the gel on top of the PVDF 
membrane. More Whatman papers soaked with transfer buffer were then placed on the 
gel. Air bubbles between the layers were removed and the cathode plate was placed 
carefully on the stack leaving the stack in the space provided between the cathode and 
the anode. Constant voltage of 10 volt was used to perform the transfer for 20 min and 
the PVDF membrane was then removed for further processing. 
A blocking procedure was performed on the membrane with 5% bovine serum 
albumin (BSA) mixture in TBS (Section  2.1.12) in a rocking platform, at room 
temperature for 1 hr. The blocking was followed by washing the membrane in TBST 
(Section  2.1.12)  3 times each for 15 min. The membrane was then incubated with 
rabbit anti-GFP polyclonal antibody (Abcam) diluted 1:5000 in TBS containing 5% 
BSA for 1 hr. The membrane was then rinsed as before and incubated with horse radish 
peroxidase (HRP)-conjugated goat anti-rabbit antibody at 37°C and for 1 hr. The 
membrane was rinsed, and incubated with Lumi-Light western blotting substrate 
(Roche) for 5 min according to the manufacturer’s guidance. The membrane was blot-
dried and transferred to a radiography cassette. X-ray medical film (Fuji) was exposed 
to the membrane for different periods of time. The exposed films were developed using 
a Curix 60 Agfa film developing machine. 
2.3.19 Fluorescent detection of PVM P protein 
A monolayer of the BS-C-1 cells were prepared on a sterile glass coverslip and 
subsequently infected as required for the experiment. The cells were fixed at room 
temperature for 30 min using an ice cold methanol:acetone (50:50) mixture. 
Subsequently, the cells were washed 3 times with PBS for 15 min each time. The cells 
were then incubated in 5% BSA in PBS for 1 hr. The incubation was followed by 3 
washes, each for 15 min as before. Monoclonal antibody against the PVM P protein, 
designated 26/3/B5, (Ling & Pringle, 1989a) was used at a 1/40 dilution in PBS. The cells 
were incubated with the antibody for 1 hr. The incubation was followed by 3  washes with 
PBS as before. The coverslips were then incubated with anti mouse Alexa® Fluor 488 goat 
anti-mouse IgG (Invitrogen), (1:3000) diluted in PBS containing 1% (w/v) BSA. From 
this point, the experiment was carried out in the dark. The coverslips were washed in 
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PBS 3 times, each for 15 min and incubated with  0.2 µg of DAPI (Sigma) in PBS for 5 
min, and were washed 3 times as before and,  air-dried, and mounted onto glass slides 
using Vectorshield (Vector laboratories) and sealed and fixed using fast dry nail 
varnish. 
Fluorescence was analysed using a Leica SP2 confocal microscope linked to a 
DM RE7 upright microscope. AlexaFluor488 was excited at 488 nm and the emitted 
light between 505 and 550 nm was recorded. DAPI was excited at 405 nm and the 
emitted wavelength between 410 and 550 mm was collected. Images were analyzed 
with Leica software. 
2.4 Reporter genes assay 
The eGFP and Luciferase genes were employed as the reporter genes in the 
experiments (Chapter 3). To quantify the expression level of GFP and the activity of 
luciferase, GFP and luciferase assays were used. 
2.4.1 GFP ELISA 
The required numbers of wells (ELISA Immulon 2HB plates) were coated with 
a 1:3000 dilution of 1 mg/ml stock of goat anti-GFP polyclonal IgG antibody 
(Rockland) in coating buffer (Section  2.1.3). The binding process was carried out at 4˚C 
overnight. After binding, the wells were washed with PBS/Tween (0.1% Tween 20 in 
1x PBS) 3 times. Irrelevant non-specific interactions were blocked using 0.2 ml of 
blocking buffer (1% BSA in PBS) for 2 hr at room temperature.  The ELISA plate was 
dried and after being wrapped in cling film, and stored at -20˚C until required. 
Prior to the usage of coated ELISA plates, the antibody coated wells were re-
hydrated with 0.2 ml/well of PBS/Tween. Standard GFP (Clontech) was prepared in the 
blocking buffer from 300 to 0 pg concentrations, and used to plot a standard curve to 
quantify the amount of GFP in each sample. Thereafter, desired samples and the 
previously prepared GFP standards were added to wells. After 1 hr of incubation at 
37˚C a rabbit anti-GFP polyclonal antibody (Abcam) was diluted to 1:32000 in 
PBS/Tween (0.1% Tween 20 in 1x PBS) and was added to the wells. After 1 hr 
incubation at 37˚C the wells were was hed with PBS/Tween.  Anti-rabbit goat HRP 
conjugated antibodies (Bio Rad) were diluted to 1:1000 in PBS/Tween (0.1% Tween 20 
in 1x PBS) and added to the wells. The ELISA plate was incubated for 1 hr at 37˚ C, 
followed by 5 washes with PBS Tween. The ABTS substrate was added until a visible 
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green color appeared in wells treated with standard amounts of GFP. The absorbance 
was measured using a Labsystems Multiskan RC plate reader machine at a wave length 
of 405 nm. The OD405 of samples were converted to concentrations using the standard 
curve using the Labsystems Multiskan software. 
2.4.1.1 Rabbit anti-GFP polyclonal antibody 
Rabbit anti-GFP polyclonal IgG known as Ab290 (Abcam) was diluted in water 
to obtain a 1:80 dilution of the antibody. The antibody-water mixture was diluted in 
glycerol to obtain a 1:1 mixture of antibody and glycerol with a final concentration of 
1:160 of the antibody. The solution was kept at -20˚C in small aliquots until the time of 
usage. 
2.4.2 Luciferase activity assay 
Prior to the measurement of luciferase activity, the wells containing transfected 
cells were washed with PBS and lysed in Luciferase Cell Culture Lysis Buffer (CCLR) 
reagent (25 mM Tris-Phosphate, 2 mM DTT, 2 mM 1,2-diaminocyclohexane-
N,N,N’N’-tetraacetic acid, 10% glycerol, and 1% Triton® X-100). Cells were scraped 
from the surface of the wells into the CCLR buffer. This material was centrifuged for 1 
min at 18000 g. Finally, 10 μl of cell lysate was transferred to each opaque well of 
white luminescence micro-wells (LumiNunc, Nunc), and 50 μl of luciferase assay 
reagent (Promega) was added to the wells containing the cell lysate. The light intensity 
was measured immediately for a period of 10 seconds using a Luminoskan® Ascent 
microplate luminometer (Thermo Scientific) immediately after addition of the luciferase 
assay reagent. 
2.5 Animal studies 
In this research 4-8 weeks old BALB/c male or female mice were obtained from 
in-house facilities and Charles river laboratories. The mice obtained from Charles river 
laboratories were specific pathogen free (SPF) and were used to breed mice in the in-
house facilities. To study the pathogenesis of PVM, BALB/c mice were anesthetized 
with intraperitoneal injection of ketamine and xylazine cocktail (Section  2.1.5), and 
after obtaining full anesthetic condition were infected intranasally with 50 µl of the 
known titre of virus suspension. A group of control mice were inoculated intranasally 
with PBS. The weights of mice in each group were monitored on a daily basis. Clinical 
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examination was performed every day and signs of infection were recorded using the 
scoring system (Table  2.2) developed by Cook, et. al. (1998). Mice were euthanized by 
cervical dislocation if weight loss exceeded 25%. Experiments were conducted for a 
minimum of 14 days, and at the end of the experiment, all of the remaining mice were 
euthanized by cervical dislocation. Subsequently, the lungs were removed for virus 
isolation. Removed tissues were kept at -70˚C until the day required for analysis.  
Clinical score Clinical signs 
1 Healthy with no signs of illness 
2  
Consistently ruffled fur, especially on neck, Piloerection, 
breathing may be deeper and mice less alert 
3 Laboured breathing. Frequently showing tremors and lethargy 
4 
Abnormal gait and reduced mobility. Laboured breathing. 
Frequently emaciated. May show cyanosis of tail and ears 
5 Death 
Table  2.2 Clinical scoring system from (Cook et. al. 1998). Five categories were defined: 
Categories 1 and 6 were defined as healthy and dead respectively. Categories 2 was defined as 
sick. Category 3 was defined as sicker. Category 4 was defined as very sick with the signs of 
cyanosis and abnormal gait in the infected mice.  
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3.1 Introduction 
As discussed in chapter 1, PVM has at least two distinguishable strains. PVM 
strain 15 (Warwick) has been shown to be non-pathogenic and PVM strain J3666 and 
PVM strain 15 deposited with the ATCC were reported as being pathogenic (Anh et al., 
2006; Cook et al., 1998; Domachowske et al., 2004; Krempl & Collins, 2004; 
Rosenberg et al., 2005). Sequence analyses identified several differences between the 
two pathogenic and the non-pathogenic strains raising the possibility of the contribution 
of the sequence differences to the pathogenesis that were observed (Krempl et al., 2005; 
Thorpe & Easton, 2005). Among these, the differences in the G gene, encoding the 
attachment glycoprotein of the virus, have been linked with the pathogenesis (Krempl et 
al., 2005; Krempl et al., 2007; Randhawa et al., 1995).  
In many cases the passage of viruses in tissue culture leads to a loss of 
pathogenicity (Claassen et al., 2005; Cohen et al., 1989; Dardiri, 1969; Hearn et al., 
1966; Taylor et al., 1993). PVM strain 15 (ATCC) has been continuously passaged in 
mice since its deposition, whereas PVM strain 15 (Warwick) has been extensively 
passaged in BS-C-1 cells in tissue culture. It is possible that the passage of the virus in 
tissue culture has led to the loss of pathogenicity in mice (Cook et al., 1998; Krempl & 
Collins, 2004). To investigate this, virus stocks were prepared following sequential 
passage of the pathogenic strain J3666 in tissue culture and the pathogenicity was 
investigated in mice. Stocks of the pathogenic PVM strain J3666 which had previously 
been passaged exclusively in mice were prepared by sequential passage in BS-C-1 cells. 
Initial analysis showed that five passages in tissue culture did not eliminate the ability 
of the virus to induce a fatal pneumonia in mice (Prof. A. J. Easton, personal 
communication).  
3.2 Evaluation of the pathogenicity of a working stock of PVM strain 
J3666 
It was necessary to prepare a reference stock of PVM strain J3666 for the 
experiments in this study. A working stock of PVM strain J3666 was prepared by taking 
as a seed stock virus which had been passaged 3 times in BS-C-1 cells and which 
retained pathogenicity. This was then used to prepare a large volume of a single stock 
by growth in BS-C-1 cells as described in section  2.2.6. The titre of the virus was 
calculated as 1.6 x 106 pfu per millilitre. On the basis of previous data, it was 
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anticipated that 500 pfu of PVM was likely to be a lethal dose (A. Easton, personal 
communication). This was taken as the initial starting point and two-fold dilutions of 
virus were prepared for infection of mice. 
Each group contained typically five mice. Following infection with the various 
dilutions of PVM strain J3666, as described in section  2.5, mice were checked daily. 
The body weight and the clinical score for each group in the experiment were recorded. 
The daily difference of the body weight throughout the experiment compared to that of 
the first day of the experiment and expressed as a percentage was calculated for each 
group. The data are shown in Figure  3.1. The clinical score for each mouse was 
monitored daily based on the scoring system described in section  2.5. The mean clinical 
score was calculated for each group and the data are shown in Figure 3.2. 
 
Figure  3.1. Weight loss of BALB/c mice infected with different amounts of PVM strain J3666 
passaged 4 times in BS-C-1 cells. After inoculation with different doses of virus, mice were 
examined daily and the percentage of their body weight compared to day one was determined 
for each group and expressed as a percentage. Weight loss is presented until the first animal in 
any group died or was humanely killed. The data shown is representative of two independent 
experiments. The amount of virus (pfu) in each 50 µl inoculum: 500 pfu , 250 pfu , 125 
pfu , 62.5 pfu , 31.2 pfu , and 15.5 pfu .  
For the groups that were inoculated with 500 and 250 pfu of PVM, weight loss 
began on day 6, and progressed quickly. At day 11 post-infection, one of the mice in the 
group infected with 250 pfu died due to the severe symptoms of the infection. The 
severity of disease for mice inoculated with either 500 pfu or 250 pfu was sufficiently 
extensive on day 11 that all animals were humanely killed to prevent further suffering 
(Figure 3.2), as required by the Home Office license under which this work was done. 
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The group which received 125 pfu of the virus first showed weight loss on day 6 
post infection, as for the groups receiving 500 and 250 pfu. However, the rate of weight 
loss subsequently proceeded at a slower pace. The rate of weight loss in this group of 
mice reached 25.47% on day 11 post infection day and began to recede on day 13 as the 
mice recovered. The mice did not achieve the starting weight by the end of the 
experiment, and one of the mice did not recover from the infection (Figure  3.1). 
Mice in the groups inoculated with 62.5 and 31.2 pfu of virus were the last to 
show onset of weight loss which first occurred on day 9. The weight loss was transient 
and mild, with a maximum of 9.48% for the mice treated with 62.5 pfu. This group of 
mice recovered quickly from the infection. The group of mice infected with 31.25 pfu of 
the virus, however, did fully recover to their original weight by the end of the 
experiment (Figure  3.1). Mice treated with 15.6 pfu of PVM did not show any weight 
loss. These data demonstrated that an inoculum containing 250 pfu of this virus stock 
was a lethal dose for BALB/c mice. 
In mice infected with 500 pfu and 250 pfu inocula, the signs of disease started 
from days 5 and 6 post infection and progressed rapidly until day 9 when the mice were 
culled for humane reasons. The onset of clinical signs of disease  in the group of mice 
infected with 125 pfu was on day 7 post infection. In the group infected with 125 pfu, 
the signs of disease progressed until day 10 when they reached a plateau and the mice 
started recovering from day 12 post infection. In the groups infected with 62.5 and 31.2 
pfu the signs of disease started on day 10. The group infected with 62.5 pfu fully 
recovered while the group infected with 31.2 pfu showed the lowest clinical score until 
the end of the experiment. Clinical signs of disease  were not observed in the group 
infected with 15.5 pfu (Figure  3.2). 
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Figure  3.2. Clinical score of BALB/c mice infected with different amounts of PVM strain J3666 
passaged 4 times in BS-C-1 cells. The scoring system described in section  2.5 was used to 
show the severity of infection in mice infected with PVM strain J3666. Mean clinical score for 
each group of mice was calculated and shown in the graph. The data shown is representative of 
two independent experiments. Clinical score is presented until the first animal in any group died 
or was humanely killed. The amount of virus (pfu) in each 50µl inoculum: 500 pfu , 250 pfu 
, 125 pfu , 62.5 pfu , 31.2 pfu , and 15.5 pfu . 
3.3 Effect of consecutive passages of PVM strain J3666 on the 
pathogenicity of the virus 
As described above, passage in tissue culture has been shown to reduce 
pathogenicity of many viruses and it was of interest to investigate this for PVM. If it 
was possible to generate stocks of non-pathogenic virus from a pathogenic virus it may 
be possible to investigate the changes responsible for the altered characteristics. The 
virus that was tested by Cook and colleagues (Cook et al., 1998) had been subjected to 
5 continuous passages in cell culture after being isolated from mice lungs and retained 
its pathogenicity (Prof. Andrew Easton, personal communication). In the work 
presented here, the ability of the virus from the same number of passages and other 
virus stocks from further consecutive passages (from passage 6 to 10) to generate 
disease in mice was tested. 
For this purpose successive passages from the stock virus (passage 4) described 
in section  3.2, were made on BS-C-1 cells, and the number of passages was extended to 
10. The viruses were kept at -70˚C until the day of challenge. The titre of the stock 
prepared from each passage was calculated and BALB/c mice were infected with 5000, 
500 and 250 pfu of virus in an inoculum volume of 50 µl. 
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As can be seen in Figure  3.3, virus from passages 5 and 6 were capable of 
producing clinical signs of disease and weight loss when 5000 pfu was administered. 
The progress of weight loss and clinical signs  were more rapid in the passage 5 
compared to the passage 6. In mice infected with passage 5 virus, as for passage 6 virus, 
weight loss and clinical signs of disease started in day 6. The weight loss alongside the 
clinical syndrome proceeded quickly and led to very severe disease in passage 6, but in 
passage 6 from day 6 onwards clinical signs and weight loss progressed until day 10. At 
day 10, both infection and clinical symptoms reached a plateau, and started to increase 
from day 10 onwards resulting a second phase of the infection with more severe signs. 
Similar to passages 5 and 6, the onset of clinical signs of disease and weight loss in the 
group infected with passage 7 virus was day 6, and the symptoms reached to a plateau 
in the same period of time as in passage 6, but in contrast with passage 6 virus, mice 
started to recover quickly from day 10 onwards indicating the virus after 7 successive 
passages has lost its virulence (Figure  3.3.A and B). 
Mice inoculated with passage 4 virus (Section 3.2) demonstrated clinical signs 
and weight loss from day 5 when they were inoculated with 500 pfu of the virus 
(Figures 3.1 and 3.2). Comparing the results with those obtained from mice inoculated 
with the same amount of virus from passage 5 indicates that the the onset of clinical 
manifestations is on the same day and the virulence of the virus from both passages are 
similar. However, comparison between the clinical signs demonstrated by mice 
inoculated with 250 pfu of the passages 4 and 5 indicate that the virus in passage 5 is 
less virulent than the virus in passage 4, as the mice inoculated with passage 5 started 
recovering from the infection while mice inoculated with passage 4 did not recover.  
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Figure  3.3. Weight loss and clinical score of mice infected with 5000, 500 and 250 pfu of PVM 
passages 5 (A & B), 6 (C & D) and 7 (E & F). The body weight differences (A, C & E) and 
clinical scores (B, D & F) were monitored on a daily basis.. Weight loss is presented until the 
first animal died or was humanely killed because of the severe symptoms. The data shown is 
representative of two independent experiments. The inocula were 5000 pfu , 500 pfu 
, and 250 pfu . 
In the groups of mice infected with 500 pfu of the passage 5 virus stock the 
clinical score did not begin to rise until day five post infection (Figure  3.3.C). Clinical 
signs and weight loss developed quickly among the mice within the group (Figure  3.3.C 
and D). In contrast with the results achieved from passage 5, no sign of disease 
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appeared in the groups in which mice were infected with 500 pfu of passages 6 and 7 
virus stocks, indicating that infection with passage 5 is more severe than the infection 
with passage 6, and the infection with passage 6 is more severe than the infection with 
passage 7.  
Data obtained from groups of mice infected with 250 pfu of passages 5, 6 and 7 
confirmed the above conclusions. Among the mice infected with 250 pfu, only the 
passage 5 virus stock was able to cause clinical signs of disease. As can be seen in 
Figure  3.3.E and 3.3.F, mice started to recover from the clinical signs of infection with 
this stock from day 11 onwards. However, the rate of recovery was slow and the mice in 
this group did not fully recover by the end of the experiment. 
3.4 Analysing the effect of consecutive passages on virus genome 
nucleotide sequence 
Spontaneous mutagenesis is a characteristic of RNA viruses.  It has been 
calculated that the mutation rate for RNA viruses is between 10-3 to 10-6 per site per 
replication (Schrag et al., 1999). As a result, RNA virus populations evolve into 
genetically related but diverse subpopulations known as quasispecies. Here, it was 
decided to analyse the sequence of the PVM strain J3666 stocks used in the 
pathogenicity study described in Section  3.3. 
While it was desirable to determine the entire genome sequence of the stocks, 
the limited amount of the stock of PVM strain J3666 passages 5, 6 and 7 made this 
impractical. Therefore, an alternative technique was chosen to amplify large fragments 
of the genome and sequence the areas that are more prone to spontaneous mutagenesis. 
The complete sequence of PVM strains J3666, 15 (Warwick) and 15 (ATCC) have been 
determined (Krempl et al., 2005; Thorpe & Easton, 2005). Comparison between the 
sequences suggests little variation among the NS1, NS2 and L genes of PVM. 
Therefore, to concentrate on the parts of the genome that are more prone to 
mutagenesis, the rest of the genome except the NS1, NS2, and L genes were sequenced. 
The approach employed involved amplifying four fragments (F2, F3, F4 and F5; 
Figure  3.4). This would amplify from the N gene to the first third of the L gene. For this 
purpose, total RNA from PVM strain J3666 passages 5, 6 and 7 stocks (Section  3.3) 
was prepared. The synthesis of the cDNA for fragment 2 used primer pair P15FLN3.2  
and P15FLM2.2 (Appendix I), for fragment 3 primer pair P15FLSH3.2 and P15FLF2.2 
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(Appendix I), for the Fragment 4 primer pair P15FLM23 and P15FLM25 (Appendix I), 
and for the Fragment 5 primer pair P15FLL5 and P15FLL7 (Appendix I). The 
fragments were then sequenced in their entireties and the data assembled. A comparison 
with the sequence of PVM strain J3666 (Accession number: NC_006579) was made.  
 
Figure  3.4 The PVM genome and the location of primers on the genome. Primer pair 
P15FLN3.2 and P15FLM2.2 amplifying fragment 2 (F2) with 3083 bp in length are shown in 
black (F2), primer pair P15FLSH3.2 and P15FLF2.2 amplifying fragment 3 (F3) with 3446 bp 
length are shown in red, primer pair P15FLM23 and P15FLM25 amplifying fragment 4 (F 4) with 
874 bp in length is shown in cyan, and primer pair P15FLL5 and P15FLL7 amplifying fragment 5 
(F 5) with 3465 bp in length is shown in green. 
3.4.1 The fragment 2 region 
Primer pair P15FLN3.2 and P15FLM2.2 was used to amplify the fragment 2 
from cDNA templates. DNA amplification was carried out using KOD DNA 
polymerase (see  2.3.11) to reduce the possibility of causing random mutations during 
DNA amplification. As indicated in Figure  3.4, fragment 2 contains the N, P and M 
genes. The sequence of the fragment 2 was obtained using primers NS2B, N1, N5, N3, 
N4, P.3, P2F, P2R, P1, P.2, and P15FLM2.2 (Appendix I). No sequence conflict 
reflecting spontaneous mutations was identified. 
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3.4.2 The fragment 3 region 
Fragment 3 was amplified from cDNA made from PVM strain J3666 passages 5, 
6 and 7 using P15FLF2.2 and P15FLSH3.2 (Figure  3.4). The sequence of fragment 3 
was obtained using primers SH2, G7, P15FLSH3, G(4878)R, SH32, SH4360, G9, F14, 
F7, F9, F22, F11, P15FLSH3.2, F22, and P15FLF2.2 (Appendix I). Unlike the sequence 
of the fragment 2, several sequence changes were identified in the sequences of 
fragment 3 of the passages 5, 6 and 7 virus stocks when they were compared against the 
published sequence of the strain J3666 (Accession number: NC_006579). All three 
passages of the virus stock had the same sequences, though they differed from the 
published sequence of PVM strain J3666 (Accession number: NC_006579). The 
identified sequence differences are summarised in Table  3.1. 
Compared with the sequence of PVM strain J3666 (accession number: 
NC_006579), the SH gene from passage 5, 6 and 7 viruses carry 6 point mutations: a 
silent mutation at position 70 (CU), a mutation at position 269 (CU) resulting in an 
H87  Y87 change in the amino acid sequence of the SH glycoprotein, a mutation at 
position 283 (CU) causing a premature stop codon, two mutations at positions 292-
293 (CCUU) and a mutation at position 299 (CU). Table 3.1 summarizes the 
mutations affecting the sequence of SH gene in PVM strain J3666 passages 5, 6 and 7. 
The amino acid sequence of the SH glycoprotein is compared against the sequence of 
the SH glycoprotein of PVM strain J3666, 15 Warwick and 15 ATCC in Figure 3.5. 
The most striking difference in the G gene of the strain J3666 (Accession 
number: NC_006579) and strain J3666 passages 5, 6 and 7 was the mutation at 
nucleotide 65 of the G gene changing a UGA stop codon to AGA. As a result, the first 
ORF of the G gene (Sections  1.2.1.1 and  3.5) was placed in frame with the second ORF 
such that the G glycoprotein in strain J3666 passages 5, 6 and 7 is 18 amino acid longer 
at the N-terminal than that of PVM strain J3666 and PVM strain 15 (ATCC) (Section 
3.5). This feature of the G glycoprotein of the passages 5, 6 and 7 was investigated in 
more depth and the results are discussed in Section  3.5. The other mutations appearing 
in the G genes of the strain J3666 passages 5, 6 and 7 were at positions 68 (CU), 104 
(AG), 118 (CU), 165 (GU), 236 (GA) and 1121 (UA). The mutation at 
position 68 is in the noncoding region of the G gene of the strain J3666. The mutations 
at positions 104, 165, 236, and 1121 resulted in amino acid changes in the G 
glycoprotein. The amino acid sequence of the G glycoprotein of the strains J3666, 15 
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(ATCC), 15 (Warwick) are compared with the amino acid sequence of the G protein of 
PVM strain J3666 Passages 5, 6 and 7 in Figure  3.6. 
 
 
PVM strain J3666 
 
PASSAGE 5 
 
PASSAGE 6 
 
PASSAGE 7 
 
NUCLEOTIDE CHANGE 
C(4381) U U U 
SH.269 
His  Tyr 
C(4395) U U U 
SH.283 
SL 
C(4399) U U U 
SH.287 
Stop 
CC(4404-4405) UU UU UU 
SH.292-293 
NC* 
C(4411) U U U 
SH.299 
NC (Stop)* 
U(4575) A A A 
G.65 
Amber  Lys 
C(4578) U U U 
G.68 
NC  Leu† 
A(4614) G G G 
G.104 
Ser  Gly 
C(4628) U U U 
G.118 
NS 
G(4675) U U U 
G.165 
Gly  Val 
G(4746) A A A 
G.236 
Gly  Arg 
U(5631) A A A 
G.1121 
Ser  Thr 
U(6581) G G G 
F.721 
Ile  Glu 
U(6826) A A A 
F.966 
SL 
U(6852) C C C 
F.992 
Val  Ala 
Table  3.1 Nucleotide differences between PVM strain J3666 passages 5, 6 and 7 used in this 
study and PVM strain J3666 (Accession number: NC_006579). The antigenomic sequences of 
the viruses were compared together. The genomic positions of the nucleotides in strain J3666 
genome are provided in parentheses. The nucleotide changes in the passages 5, 6 and 7 are 
provided. The result of the nucleotide changes in the amino acid sequence of the SH protein is 
shown. The mutation site in the SH gene is shown in “gene.nucleotide position” format. The 
occurrence of the mutations in non-coding sequences of each gene is shown by NC and the 
silent mutations are indicated as SL. * The effect of mutation is shown after considering the 
mutation at position 299 of the SH gene. † The effect of mutation is shown after considering the 
mutation at position 65 of the G gene.   
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Figure  3.5 Alignment of the SH protein of PVM strain J3666 and PVM strain J3666 passages 5, 
6 and 7.   Differences in aminoacid sequences are indicated in black background. Mutated 
amino acids of the protein chains are shown in a black background the presence of a 
termination in the protein sequence is shown by a “*” sign in each sequence. Numbers on the 
right represent the length of the protein molecule. Each protein molecule indicated on the left. 
SH: SH protein of PVM strains J3666, SH P.5, P.6, and P.7: SH proteins of PVM strain J3666 
passages 5, 6, ad 7 respectively. 
 
Figure  3.6 Amino acid comparison between G proteins of PVM strain J3666 (Accession 
number: NC_006579), G protein of strain 15 (ATCC) (Accession number: AY729016), G protein 
of strain J3666 passages 5, 6 and 7. The differences between the aminoacid sequences are 
indicated in black. The consensus sequence among all of the viruses is shown in the last line of 
each row. Numbers on the right indicate the corresponding protein chain length. 
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3.4.3 The fragment 4 region 
Primer pair P15FLM23 and P15FLM25 (Appendix I) was used to synthesise the 
fragment 4. After obtaining the purified fragment 4, its sequence was obtained using 
P15FLM23, P15FLM25, and 22K7 primers (Appendix I). No nucleotide changes were 
identified between the sequenced fragment 4 and the sequence of PVM strain J3666 
(Accession number: NC_006579). 
3.4.4 The fragment 5 region 
Primer pair P15FLL5 and P15FLL7 (Appendix I) was used to amplify the 
Fragment 5. The sequence of Fragment 5 was obtained after being purified using PL1, 
PL23, L1D, L1F, L1H, L1J, L2C and PL29 primers (Appendix I). No changes were 
observed among the sequence of the fragment 5 of the passages 5, 6, 7 in comparison 
with PVM strain J3666 (Accession number: NC_006579). 
3.5 Analysing the SH gene end and G ORF start sequence consistency 
in PVM strain J3666 population 
The sequencing data presented in section  3.4 revealed that the sequences 
obtained from passages 5, 6 and 7 have a difference in the sequence of the G gene in 
comparison with the sequence of PVM strain J3666 which were reported by Randhawa 
et. al. (1995). These results were consistent with the sequencing results obtained from 
cDNA constructs which were amplified from PVM strain J3666 for use in the 
construction of G-GFP minigenomes (Chapter 5).  The sequences studied in Section  3.4 
and Chapter 5 did not contain the stop codon for the first ORF of the G gene 
(Section  1.2.1.1). Instead, a point mutation was present which resulted in a change of 
the stop codon “UGA” into “AGA” in the mRNA. This point mutation would have 
changed the structure of the G gene, resulting in the generation of a single ORF through 
the fusion of ORFs 1 and 2. The G protein arising from this would therefore contain an 
amino terminal sequence derived from the first ORF. A different type of PVM G gene 
which is lacking the first ORF at AUG29  was described by Krempl and Collins (2004). 
It was reported that the main ORF in PVM 15 (ATCC) contains a single ORF starting 
from position 83 (Figure 3.7). The data suggested that the sequence obtained from the 
virus resulted from a mixture of two subpopulations of PVM, one with two ORFs as 
described in Section  1.2.1.1.1 and reported by Randhawa and colleagues (1995) and the 
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other one containing one single ORF. A diagram representing these two G gene 
organisations is shown in Figures 1.5 and 3.7. 
 
Figure  3.7 Describing the G mRNA organisation in PVM strain 15 (ATCC), PVM strain J3666 
and PVM strain 15 (Warwick). In PVM strain 15 (ATCC) the presence of one unique ORF 
provides a longer N terminal for the G gene. In contrast, in the strain J3666 the stop codon at 
position 65 of the gene makes two separate ORFs. In the strain 15 (Warwick) a premature stop 
codon generates an ORF starting from AUG(83). Furthermore, an “A” insertion in the sequence 
of the ORF causes a frameshift mutation resulting in production of a stop codon at position 190. 
Subsequently, a start codon at position 190 of the G gene of the strain 15 (Warwick) is formed. 
For more details refer to the text. 
Because of the importance of the organisation of the G gene in our studies, it 
was decided to explore the G gene organisation in the Warwick PVM strain J3666 
working stock of passage 4 virus (Section 3.2) in more depth. For this, the G gene was 
amplified from total virus RNA extracts using RT-PCR with primers SH4360 and 
G4878(R) (Appendix I).  Primer SH4360 anneals to the SH gene (nucleotides 206 and 
227), and  primer G4878(R) anneals to the G gene nucleotides 304-324. This made it 
possible to amplify a fragment from the SH and G genes with 517 nucleotide in length 
which contained 150 nucleotides from the SH ORF (responsible for encoding 49 amino 
acids from the C terminal of the SH protein) and 296 nucleotides from the two G ORFs 
of the strain J3666 (Accession number: NC_006579) (responsible for encoding the first 
ORF and 81 amino acids from the N terminal of the second ORF of the G gene of PVM 
strain J3666).  A standard PCR was conducted amplifying the SH-G fragment using Taq 
polymerase. The SH-G fragment (Figure  3.8) was purified from an agarose gel. The “T” 
overhangs in the pGEM-T (Promega) and pBS-T vectors (Section  2.3.8) and the “A” 
sequence in the SH-G fragment added by Taq DNA polymerase were ligated together to 
construct the pBS-SHG and pGEM-SHG plasmids prior to transformation. 
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Figure  3.8 RT-PCR amplification, amplifying the SH-G fragment from cDNA of PVM strain 
J3666. Lane 1 Hyper ladder I, Lane 2 contains negative control, lanes 3, 4 and 5 contain the 
518 nt PCR product, designated as SH-G fragment, from the RT-PCR.  
The presence of the SH-G fragment in pBS-SHG clones was confirmed by XhoI 
and EcoRI restriction enzyme digestion of pBS-SHG (data not shown), and EcoRI 
digestion of pGEM-SHG (Figure  3.9). Prior to the sequencing, the presence of the SH-
G fragments was confirmed by PCR with primers SH4360 and G4878(R) (Appendix I). 
 
 Figure  3.9 EcoRI digestion of pGEM-SHG plasmids. Plasmids pGEM-SHG1-11 digested with 
EcoRI restriction enzyme. The pGEM vectors are designed in a way to release the insert when 
they are digested with EcoRI enzyme. The SH-G fragments are visible at 518 bp. Lanes 1 to 12 
in order contain ladder and pGEM-SH-G1-11. Plasmids pGEM-SH-G6 and pGEM-SH-G11 do 
not contain the 518 bp fragment. 
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The nucleotide sequence of 14 plasmids, 5 from one ligation reaction with pBS-
T vector and 9 from an independent RT-PCR/ligation reaction with pGEM-T vector 
were determined. The sequences were compared against the reference sequence of the 
strain J3666 in the GenBank (accession number: AY743909). It was found that 12 of 
the sequences represent a G gene containing only one ORF (Figure  3.7). In contrast, the 
sequences obtained from pBS-SHG2 and pB-SHG9 clones (15% of the clones) reflected 
the organisation of the G gene published by Randhawa and colleagues (1995).  
The results suggest the presence of at least two subpopulations of PVM strain 
J3666: a population containing two ORFs in the G gene as previously published 
(Randhawa et al., 1995) (from now on strain J3666-A), and a population containing a 
single ORF as described above (Figure 3.7) (from now on strain J3666-B). Two of the 
14 (15%) sequenced plasmids   (pBS-GSH2 and pBS-GSH9) reflected the organisation 
of the G gene of the subpopulation J3666-A, and the rest (85% of the sequenced clones) 
showed the organisation of the G gene for the subpopulation of J3666-B.  
Table  3.2 compares the sequences of the pBS-SHG2 and pBS-SHG9 with the 
sequence of PVM strain J3666 (accession number AY743909). Both pBS-SHG2 and 
pBS-SHG9 contain the first ORF preceding the main ORF of the G gene. The first ORF 
contains 12 codons and is terminated by a “UAG” stop codon as indicated. There is a 
gap of 15 non-coding nucleotides between the first ORF and the second ORF 
(Figure  3.7). 
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Gene 
Changes in the 
nucleic acids 
sequence 
Changes in the 
amino acids 
sequence 
SH U(262)  C SL 
 U(267)  C Lys  His 
 U(383)  C NC 
 U(387)  C NC 
G U(21)    C NC 
 C(118)  U SL 
 U(196)  C SL 
 U(229)  C SL 
Table  3.2 Sequence differences among the SH-G clones and PVM strain J3666 sequence. 
Sequence comparison was made among clones pBS-SHG2, pBS-SHG9 and PVM strain J3666 
(accession number: AY743909). The nature of each nucleotide change is indicated. The 
numbers in the parentheses indicates the nucleotides position in each gene. The effects of the 
mutation in the aminoacid sequences are shown. The occurrence of the mutations in non-
coding sequences of each gene is shown by NC and the silent mutations are indicated as SL.  
Table  3.3 compares the sequence of pGEM-SHG-1, 2, 3, 4, 6, 7, 8, 9, and 10 and 
pBS-SHG-5, 6 and 7, in which the G gene organisation was that of the subpopulation 
J3666-B, with the sequence of PVM strain J3666 (Warwick). 
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Gene 
Changes in the 
nucleic acids 
sequence 
Changes in the 
amino acids 
sequence 
Plasmids 
SH U(250)  A SL pGEM-SHG7 
 C(269)  U His  Tyr pGEM-SHG-1-4,6-10 
pBS-SHG-5-7 
 C(283)  U SL pGEM-SHG-1-4,6-10 
pBS-SHG-5-7 
 C(287)  U Gln  Stop codon pGEM-SHG-1-4,6-10 
pBS-SHG-5-7 
 A(291)  G NC * pGEM-SHG-6 
 C(299)  U NC * pGEM-SHG-1-4,6-10 
pBS-SHG-5-7 
G U(65)  A Stop codon  Lys pGEM-SHG-1-4,6-10 
pBS-SHG-5-7 
 A(66)  U Lys  Met * pBS-SHG-7 
 A(83)  G Met  Val pGEM-SHG-2 
 A(104)  G Ser  Gly 
pGEM-SHG-1-4,6-10 
pBS-SHG-5-7 
 A(113)  U Ile  Phe pBS-SHG-7 
 G(165)  U Gly  Val pGEM-SHG-1-4,6-10 
pBS-SHG-6 † 
 U(234)  C Val  Ala pGEM-SHG-4 † 
 G(236)  A Gly  Arg 
pGEM-SHG-1-4,7-10 
pBS-SHG-5 ‡ 
Table  3.3 Sequence differences among the SH-G clones and PVM strain J3666 sequence. 
Sequence comparison was among clones pGEM-SHG-1, 2, 3, 4, 6, 7, 8, 9, and 10; pBS-SHG-
5, 6 and 7; and PVM strain J3666. The nature of each nucleotide change is indicated. The 
numbers in parentheses indicate the nucleotide position in each gene. The possible effects of 
the mutation in the amino acid sequences are shown. The occurrence of the mutations in non-
coding sequences of each gene is shown by NC and the silent mutations are indicated as SL.  
(*) The result of the mutation was determined after applying the mutation affecting the ORF. (†) 
In pBS-SHG-5 and 7 remained undefined. (‡) In pBS-SHG-6 and 7 remained undefined. 
3.6 Conclusion and discussion 
As has been described for other viruses (Churchill et al., 1969; Cohen et al., 
1989; Dardiri, 1969; Hearn et al., 1966; Kwilas et al., 2009; Taylor et al., 1993), 
successive passage of a pathogenic stock of PVM in BS-C-1 cells generated attenuation 
in disease (Figure 3.3).  This may explain the different pathogenicity seen with PVM 
strain 15 (Warwick) (which was obtained from ATCC then extensively passaged in 
tissue culture) and PVM strain 15 (ATCC) which has been passaged only in mice. 
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The pattern in the onset of the clinical signs of disease and weight loss in the 
group of mice infected with PVM strain J3666 (Working stock) was consistent with 
what was reported by Krempl et al. (2007). In results presented here, for the group of 
mice that received 500 pfu and 250 pfu, the weight loss and signs of disease started 
from day 5 and extending to day 10 when mice were euthanatized (Figure  3.1). For the 
group of mice infected with 125 pfu of PVM strain J3666 initially the same pattern was 
observed, but mice started recovering after day 10. In Krempl et al. (2007), a group of 
mice infected with 500 pfu showed weight loss one day earlier than observed here, and 
the experiment was terminated at day 8 post infection. The slight difference between the 
data reported by Krempl et al. (2007)  and the results reported in this chapter could be 
explained by the 80 µl volume of the inocula used by Krempl et al. (2007). As shown by 
Cook et al. (1998), inoculum volume contributes to pathogenicity, as larger volumes are 
likely to deliver the virus deeper into the lungs. 
Comparison between results reported by Cook et al. (1998) and those here 
suggest an inconsistency. Cook et al. (1998) reported that mice infected with 60 pfu of 
PVM strain J3666 developed severe disease which resulted in death of 20% of the 
animals (Cook et al., 1998). However, the data reported here indicate that mice 
receiving 62.5 pfu developed mild disease. A significant difference in experimental 
protocol between the experiments here and those of Cook et al. (1998) was in the 
anaesthetic agent used; Cook et al. (1998) used ether and here mice were anaesthetised 
with ketamine (Section  2.1.5 2.1.5). The possible role of anaesthetic agents in mice 
infected with respiratory viruses cannot be neglected (Knight et al., 1983; Shope, 1934). 
In the experiments conducted with Cook et al. (1998) the virus was passaged 3 
times in the cell culture (Prof. Andrew Easton, personal communication), while in this 
research the experiments were conducted using the passage 4 of PVM which was 
prepared during the time of experiment and was derived directly from the passage 
number 3 which was used by Cook et al. (1998). The experiments conducted with 
passages 5, 6 and 7, the virus obtained from the available stocks in the laboratory, all 
derived directly from the stock used by Cook et al. (1998). 
Passage 5 virus was shown to be more pathogenic than passage 6 and 7 virus 
stocks. The passage 5 virus was able to produce clinical disease in the three 
administered doses (Figure 3.3). As expected the onset of infection with passage 5 was 
more rapid and produced more disease when 5000 pfu was administered, with 
progressively less severe disease seen when the inoculum was reduced to 500 pfu and 
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250 pfu. Passage 6 virus was capable of producing clinical signs of disease when the 
inoculum contained 5000 pfu, but not with 500 pfu or 250 pfu, as can be seen in 
Figure  3.3. When 5000 pfu of passage 7 virus was used, the clinical score peaked on 
day 8, after which the animals recovered.  
In pneumoviruses, production of defective interfering (DI) particles has been 
reported for HRSV strain Randall during passage of the virus in cell culture and when 
the moi for the virus was calculated between 1 and 5 (Treuhaft & Beem, 1982). While 
they are not competent to replicate alone, DI particles require factors provided by a 
helper virus to be able to replicate. A protective effect for DI particles against 
heterologous or homologous viruses in animal models has been reported (Doyle & 
Holland, 1973; Easton et al., 2011; Scott et al., 2011). This is due to interferon 
induction and interference with the viruses in their replication cycle (Doyle & Holland, 
1973; Easton et al., 2011; Scott et al., 2011). Although the presence of DI particles in 
batches of PVM strain J3666 passages 5, 6 and 7 was not directly examined the possible 
effect of DI particles in reducing the pathogenesis of the virus can’t be ignored. 
However, virus stocks were prepared using very low moi (typically 0.01-0.05 pfu/cell or 
lower). This significantly reduces the likelihood of DI virus production. It is likely that 
among the factors affecting the pathogenicity of PVM strain J3666, adaptation to 
growth in monkey kidney cells thorough consecutive passage of PVM in cell culture is 
one of the main determinants in the attenuation of the virus. The molecular cause of the 
attenuation remains to be determined. 
The genome sequence of PVM passages 5, 6 and 7 was determined and 
compared to understand its correlation with nucleotide changes and the differences in 
pathogenesis. As discussed above, the pathogenicity of PVM strain passages 5, 6 and 7 
reduced gradually from the highest (in the passage 5) to the lowest (in the passage 7). 
Surprisingly, no genome sequence changes among PVM strain J3666 passages 5, 6 and 
7 were identified. As mentioned in section  3.4, it was designed to sequence a part of 
genome divided into 4 fragments. The sequence of the NS1 and NS2 genes and the 
majority of the L gene remained undetermined. Thus, it is possible that the attenuation 
is due to mutations in the areas of the genome whose sequence remained unknown. 
Also, it wouldn’t be possible to identify the presence of mutations when they are in low 
frequencies. To identify such mutations different clonal isolates of the population of the 
virus need to be sequenced, although the cloning experiment increases the risk of 
nucleotide change. 
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 Comparing the sequences of passages 5, 6 and 7 with PVM strain J3666 
(accession number: NC_006579) indicated mutations across the fragment 3. Table 3.1 
summarizes the mutations in the fragment 3. Briefly, the coding mutations seen in the 
SH gene were C(4381)U changing a histidine residue to a tyrosine residue and 
C(4399)U mutating glutamine residue to a stop codon resulting in the synthesis of a 
SH protein with a truncated C terminal; the coding mutations in the G gene are 
U(4575)A changing an amber stop codon to a lysine residue resulting in the 
production of a G glycoprotein with a larger N-terminal, C(4578)U changing the 
noncoding sequence between the two ORFs to a leucine codon, A(4614)G changing a 
serine residue to a glycine residue, G(4675)U changing a glycine residue to a valine 
residue, G(4746)A changing a glycine residue to an arginine, U(5631)A  changing 
a serine residue to a threonine residue; in the F gene: U(6581)G changing an 
isoleucine residue to a glutamine residue and U(6852)C changing a valine residue to 
an alanine residue. 
In an attempt to investigate the possible presence of subpopulation of viruses in 
the working stock of PVM strain J3666, 14 independent clones containing parts of the 
SH and G genes derived from two separate RT-PCR amplifications from virus genomic 
RNA or antigenomic RNA were sequenced. The analysis showed that at least two 
distinct subpopulations of viruses were present. The minor subpopulation, (J3666-A) 
represented by 2 clones, had a G gene with two ORFs organised as reported by 
Randhawa et al. (1995). The remaining clones represented a major subpopulation 
generated a single, large ORF which would encode a G protein with an amino terminal 
extension (J3666-B). These data indicate that PVM stocks contain a population of 
viruses with some sequence variation. Using these stocks it is not possible to be 
confident about the role(s) of specific gene sequences in pathogenicity. It is therefore 
more desirable to generate homogenous populations using reverse genetics. 
A further possibility is that factors like post-translational processing of proteins 
including changes in the glycosylation patterns of glycoproteins and proteolytic 
cleavage may affect the pathogenesis. Recently, comparison of HRSV grown in HEp-2 
cells with HRSV grown in Vero cell lines showed that the HEp-2 grown virus contained 
a smaller G glycoprotein lacking its C terminal (Kwilas et al., 2009), and the progeny 
viruses recovered from Vero cells were inefficient in using cellular glycosaminoglycan 
(GAG) molecules as the receptor. However, these viruses were able to initiate an 
infection in well-differentiated human air-way cells that do not produce GAG molecules 
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at their apical sites. It is therefore possible that the attenuation seen in the passages 6 
and 7 was due to the accumulation of post-translational processing in the virus 
population. 
Sequence analysis of the SH gene (Section 3.5) revealed the presence of two 
subpopulations. The major subpopulation (J3666-B) expressed a truncated SH protein 
and a minor subpopulation (J3666-A) expressed a full length SH protein. The mutations 
discussed in Section  3.5 could affect the structure and function of SH protein, causing a 
defective virus particle. Considering that the SH protein of HRSV is a transmembrane 
protein and forms a transmembrane channel across the membrane (Carter et al., 2010) 
the hydrophobicity of the SH protein was determined to  analyse the effect of the 
mutations on the hydrophobicity (Kyte & Doolittle, 1982). To predict the possible 
effects on the hydrophobicity of the SH protein, the HMTOP sever was used (Kyte & 
Doolittle, 1982; Tusnady & Simon, 2001). Analysing the results (data not shown) 
suggested that the SH protein of PVM strain 15 (Warwick) may lack a transmembrane 
domain, while in the SH protein of PVM strain J3666, the amino acids 24 to 46 produce 
transmembrane helices. 
Unlike in PVM, the SH gene of HRSV strains has been reported to vary very 
little in coding capacity (Chen et al., 2000). In contrast, the SH gene of human 
metapneumovirus is very vulnerable to mutations when it is grown in vitro (Biacchesi et 
al., 2007). It is possible that the SH gene of PVM studied in this research has been 
mutated during passages in tissue culture. HRSV lacking the SH gene was only partially 
attenuated in chimpanzees’ lower respiratory tract (Whitehead et al., 1999). Studying 
the differences in the SH proteins of PVM strains could explain the importance of the 
SH gene in the virulence of the virus. 
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CHAPTER 4   
 
 
A REVERSE GENETICS APPROACH 
TO STUDY THE EFFECT OF THE G 
GENE ORGANISATION IN PVM 
PATHOGENICITY   
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4.1 Introduction 
A reverse genetics system for HRSV was first described in 1991 by rescuing 
synthetic HRSV genome homologue in which a CAT gene replaced virus genes in the 
genome (Collins et al., 1991). Soon after this achievement, Collins et. al. (1995) 
reported production of infectious virus from cDNA of HRSV strain A2. Since then, the 
technique has been used to investigate a wide range molecular aspect of HRSV in vitro 
and in vivo. However, the main obstacle in studying the pathogenesis of HRSV, lack of 
a suitable animal model, has hampered the study of pathogenesis. As discussed in 
chapter one, PVM is a versatile substitute to study molecular aspects of pneumoviruses, 
and employing a reverse genetics system for PVM would be beneficial in extending its 
ability as a model system. 
In chapter 3, the possibility of the contribution of genetic factors to the 
pathogenicity of pneumoviruses was analysed. A reverse genetics system for PVM was 
developed by Dibben (Dibben, 2006). However, the early attempts to obtain infectious 
virus from cDNA failed (Dibben, 2006). Another reverse genetics system for PVM 
from which virus could be generated was developed by Krempl et. al (2007). The work 
presented in this chapter, describes the establishment of a reverse genetics system for 
PVM and its use in studying the pathogenicity of the virus. Using this reverse genetics 
system, infectious viruses were rescued carrying either of the two organisations of the G 
gene (Section  1.2.1.1). To study the effect of the organisation of the G gene, the first 
ORF of the G gene was deleted and infectious viruses were rescued. The infectious 
viruses were used in a BALB/c mouse model to analyse the pathogenicity of the virus. 
The clinical scoring system (Section  2.5) was used to evaluate the pathogenicity. The 
differences between the results obtained from the reverse genetics system described in 
this section and the reverse genetics system developed by Krempl and colleagues (2007) 
are discussed below. 
4.2 Plasmid p15FL-2G 
The plasmid carrying a cDNA copy of the PVM strain 15 (Warwick) genome, 
p15FL-2G, was constructed by Dr. O. Dibben and was available in the pneumovirus 
Laboratory, University of Warwick (Dibben, 2006). This was constructed from  6 
different fragments with  four  (fragments 2 to 5) defined by  restriction enzyme sites 
inserted during the cloning process (SexAI at positions 1006, SalI at position 4089, 
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XmaI at position 7261 and NotI at position 8134),  and  one natural site (SexAI at 
position 11600) (Figure 4-1). The cDNA was cloned between a bacteriophage T7 
transcription promoter and the hepatitis delta ribozyme in such a way that T7 
transcription would result in the production of an antigenomic copy of the PVM genome 
shown to be required for efficient recovery of infectious virus for other negative sense 
RNA viruses. The construct has 2G residues at the 5’ end of the antigenome RNA to 
ensure efficient transcription by the T7 RNA polymerase. These are presumed to be 
eliminated during virus replication as seen for all other recombinant negative sense 
RNA viruses. 
 
Figure  4.1 Plasmid p15FL-2G (17944 bp). The genes, restriction sites, ribozyme and T7 
polymerase transcription promoter are shown. P2 and M2-2 overlapping genes are shown. 
Plasmid p15FL-2G was subjected to further modifications to synthesise pFL2G-
G15, pFL2G-G15∆ORF1, pFL2G-GJ3666 and pFL2G-GJ3666∆ORF1. The cloning 
procedure is explained in the text and summarized in Figure 4.2. 
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Figure 4.2 – The syntheses of p15FL2G-GJ3666, pFL2G-GJ3666∆ORF1, pFL2G-G15 and pFL2G-G15∆ORF1. To synthesise plasmid pF3-BSHTI-BGLII, the 
plasmid pSH120 was subjected to two Quick Change mutagenesis reactions using primer pair QCF3BGL2F and QCF3BGL2R (arrows shown in black) as 
indicated in step A. Plasmid pF3-BSHTI-BGL2 was subjected to a Quick Change PCR reaction using primer pair QCFL2GA4728F and QCFL2GA4728R  
(arrows shown in black) to synthesise the pF3-BSHTI-BGL2-A plasmid (step B). The fragment 3 from pF3-BSHTI-BGLII was excised using SalI and XmaI 
restriction enzymes and ligated into p15FL-2G double digested with SalI and XmaI restriction enzymes, leading to production of pFL2G-GJ3666∆ORF1 (step 
C). Primer pair G_Round(F) and G_Round(R), arrows shown in red, were designed to introduce the nucleotide differences between PVM strain 15 and strain 
J3666 into the first ORF of the G gene using the round the horn site directed mutagenesis PCR reaction (step D) to produce pFL2G-GJ3666. To produce 
pFL2G-G15, the fragment 3 from pF3-BSHTI-BGLII-A (obtained in step B) was excised using SalI and XmaI restriction enzymes and ligated into p15FL-2G 
double digested with SalI and XmaI (step E). Plasmid pFL2G-G15 was then mutated using primer pair 1stORFOut-15-F and 1stORFOut-15-R (arrows shown 
in black) and Quick Change mutagenesis reaction to synthesis pFL2G-G15∆ORF1 (step F). The black lines indicated with “G gene” define the organisation of 
ORFs in the various G gene constructs. 
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4.3  Complete sequencing of p15FL-2G 
Before starting the rescue process, the complete nucleotide sequence of the full 
length genome plasmid was determined. For this purpose the plasmid p15FL-2G was 
sequenced using G9, J1, J4E, J5, M1, M2, N1, N3, N5, NS1B, NS2A, NS2B, P2A, P3, 
P4, SH2, 22K7, F7, F9, F11, F14, F17, G7, J7, L1F, L1H, L1J, L2C, L2F, L10, PL23, 
PL29, L2G, L2H, L3C, L3D, L3E, L3F, L3G, PL48, and L50 primers (Appendix I). 
Sequencing data were analysed and 30 changes between the sequenced plasmid and the 
published sequence of PVM strain 15 (Warwick) (GenBank; accession number 
AY743910.1) were identified. These are shown in Table 4.1, and some, as indicated, 
confirmed the location of restriction endonuclease sites inserted during the cloning 
process of p15FL-2G. Two of those were introduced in the coding region of the second 
ORF of the M gene which caused sequence changes in a hypothetical polypeptide 
synthesised from a short second ORF [A(4048)  G (4089) resulting in the change of a 
histidine residue to a valine residue, A(4051)  C resulting in the change of a histidine 
residue to an asparagine residue, A(4063)  C resulting in the change of a threonine 
residue to a proline residue]. The rest of the restriction sites introduced by Dibben 
(2006) were placed in the noncoding regions (NTR) of the M, SH, F and M2 genes. 
Table 4.1 describes the changes found across the full length genome of PVM 
strain 15 (Warwick). Briefly, in the M gene, an  A(3690)C mutation changes a 
tyrosine residue to a serine residue, G(3705)A changes a glycine residue to asparagine 
residue; in the G gene G(5465)C changes a glutamic acid residue to a glutamine 
residue; in F gene A(5954)T changes of a tyrosine residue to a phenylalanine residue 
and C(7278)G changes  a phenylalanine residue to a leucine residue. These mutations 
were observed and reported by Dibben (2006) during constructing the p15FL-2G 
plasmid. 
 
Sequence of 
PVM 15 
(Warwick) 
Sequence of 
p15FL-2G 
 
Position 
 
Comments 
970 CA 1012 GT NTR of NS1 Introduction of SexAI restriction site 
3690 A 3731 C M gene, 1st ORF Tyr  Ser 
3705 G 3746 A M gene, 1st ORF Gly  Asp 
3796 A 3837 G M gene, 1st ORF SL 
4048 A 4089 G M gene, 2nd ORF His  Val 
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4051 A 4092 C M gene, 2nd ORF 
His  Asp 
Introduction of SalI restriction site 
4059 A 4100 C M gene, 2nd ORF SL 
4063 A 4104 C M gene, 2nd ORF Thr  Pro 
4065 A 4106 C M gene, 2nd ORF SL 
4218 C 4259 T SH gene SL 
5465 G 5506 C G gene Glu  Gln 
5548 A 5589 G G gene SL 
5954 A 5995 T F gene Tyr  Phe 
5958U 5999 C F gene SL 
6127U 6168 C F gene SL 
6531 C 6572 C F gene SL 
6720U 6761 C F gene SL 
7278 C 7319 G F gene Phe  Leu 
7296-7499 
AAAC 
7537-7540 
CGGG 
NTR of F gene. Non-coding region between F and G genes. Introduction of XmaI 
8370-8374 
AGUAA 
8409-8413 
GGCCG 
NTR of M2 gene. 
Non-coding region between M2-2 
and L gene. Introducing NotI 
restriction site 
8902 U 8943 C L gene SL 
12247 A 12288 G L gene SL 
13030 A 13071 G L gene SL 
13516 A 13557 G L gene SL 
Table  4.1 Comparison of sequence of PVM strain 15 (Warwick) and p15FL-2G.  Silent 
mutations are indicated as SL. 
4.4 Amending plasmid p15FL-2G 
The structure of the PVM G gene for the non-pathogenic strain 15 and the 
pathogenic strain J3666 was described in chapter one. To understand the effect of these 
different organisations of the G gene on the pathogenesis of PVM, it was necessary to 
amend the plasmid carrying the full-length PVM strain 15 viral genome in such a way 
to make it feasible to swap the G gene with G gene from other viruses such as PVM 
strain J3666. For this purpose, two further restriction sites were inserted, one before and 
one after the G gene. The presence of restriction sites would make it possible to remove 
the G gene entirely from the full length genome and replace it with the desired gene. 
Two restriction enzymes, BshTI and BglII were inserted into the plasmid 
pSH120 (Figure 4.2), the plasmid carrying fragment 3 used to create the full length 
PVM genome cDNA using the quick change mutagenesis technique. The use of plasmid 
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pSH120 as the template provided advantages including a wider choice from the 
restriction enzymes which are frequently present on the full length genome, use of pfu 
proof reading enzyme which potentially is not able to amplify very large constructs such 
as the full length genome, and the ease of confirming the sequence in the smaller 
construct. 
To insert the BshTI and BglII restriction sites into pSH120, two different Quick 
Change mutagenesis PCR reactions were performed. First, the plasmid pSH120 was 
used as the template and the quick change mutagenesis PCR primer QCF3BSHT1F and 
QCBSHT1R pair (Appendix I) designed to insert the BshTI restriction site used. Having 
been digested with restriction enzyme DpnI to remove the template, the PCR product 
was used to transform competent E. coli. Liquid cultures were grown from individual 
colonies and the presence of mutated pSH120 was confirmed by restriction digestion of 
the isolated DNA from the individual bacterial cultures by BshTI restriction enzyme. 
The mutated plasmid was named pF3BshT1. Plasmid DNA from four colonies was 
individually sequenced with QCF3BSHT1F, QCBSHT1R, SH95+, SH2, G4E, G7, G7, 
F7, F14, F9, and F11 primers (Appendix I) to confirm that no additional mutations had 
been inserted. The plasmid DNA mixture was then used as the template to insert the 
second restriction site (BglII) into the plasmid.  
Quick change mutagenesis PCR was performed with the primer pair 
QCF3BGL2R and QCF3BGL2F (Appendix I) designed to insert a BglII restriction site. 
Having been digested with DpnI to remove the template, the PCR product was used to 
transform competent E. coli. Plasmid DNA from individual colonies was prepared and 
the presence of the BglII site confirmed by digestion followed by nucleotide 
sequencing. The mutated plasmid was named pF3-BSHT1-BGL2 plasmid. Using J5 and 
F14 primers, a PCR fragment was amplified from the pF3-BSHTI-BGL2. Digestion of 
the DNA fragment with BshTI and BglII is shown in Figure 4.3.  
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Figure  4.3 Digestion of the 2718 bp fragment generated by PCR amplification from pF3-BSHT1-
BGL2 plasmid using J5 and F14 primers. Following digestion with BshTI and BglII restriction 
enzymes, three fragments were generated of 434 bp, 1339 bp and 945 bp (A); lane 1 
Hyperladder I DNA size markers, Lanes 2 – 6 the digested PCR fragment. The strategy was 
used to amplify the 2718 bp fragment and the position of the restriction endonucleases are 
shown in B.  
As discussed in Chapter 1, a significant difference in nucleotide sequence 
between PVM strain J3666 and PVM strain 15 (Warwick) is in their G gene 
organisation which in the strain 15, contains 2 overlapping ORFs, the second and largest 
of which encodes the G protein. In contrast, the strain J3666 G gene contains a short 
ORF upstream of the main ORF which encodes the G protein (Figure  1.5). Originally, 
plasmid p15FL-2G was amplified from PVM strain 15 (Warwick), so it was expected to 
have a genome structure similar to that published. However, sequencing data (Dibben, 
2006)  revealed that the major ORF of the G gene in the plasmid p15FL-2G had the 
same structure of the major ORF of the G gene in PVM strain J3666 i.e. it lacked the 
additional U residue. However, only one ORF was present.  To return the sequence to 
that of PVM 15 (Warwick) an A residue was inserted into the G gene in pF3-BSHT1-
BGL2 (from now on pF3BB). The presence of the A residue at position 169 of the G 
gene in the mutated plasmid (pF3BBA) would generate a G gene with a structure 
similar to that found in PVM strain 15 (Warwick) with two overlapping ORFs. This 
would generate two plasmids similar to each other with a difference only in the 
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organisation of the G gene, making it possible to compare the effect of the mutation on 
pathogenesis. 
To construct the mutation, pF3BB was used as the template and a primer pair 
(QCFL2GA4728F and QCFL2GA4728R) designed to insert the A residue at position 
4725 of p15FL-2G. After DpnI digestion, the PCR product was used to transform 
competent E. coli. Four colonies (designated as pF3BBA-C1, pF3BBA-C2, pF3BBA-
C3 and pF3BBA-C4) were selected and their sequence obtained using T7, J4, SH2, 
SH95+, G4E, G7, G9, F17, F7, F14, F9 and F11 primers (Appendix I). Following 
confirmation of the sequence, the plasmid pF3BBA-C3 was chosen to use in the 
experiments. 
4.5  Insertion of fragment 3 into p15FL2G 
In order to clone the fragment 3 into p15FL2G, the fragment 3 from the plasmid 
pF3-BB was digested with the restriction enzymes SalI and XmaI and was replaced with 
fragment 3 from either pF3-BB or pF3-BBA. The presence of BglII restriction site in 
the fragment 3 of the full length genome was confirmed by restriction double digestion 
of the full length plasmid with BglII and EcoRI, and NdeI and BglII (not shown). 
4.6 Description of the full length genomes 
The adenosine deletion in pF3-BB plasmid caused an extension in the open 
reading frame responsible for coding the G glycoprotein to achieve the same sequence 
of the G glycoprotein described for PVM strain J3666. However, because the rest of the 
full length genome is similar to PVM strain 15 (Warwick), the G gene lacked the first 
ORF found in the G gene of PVM strain J3666 (Randhawa et al., 1995). Therefore, the 
p15FL-2G construct carrying the F3-BB fragment was called pFL2G-GJ3666∆ORF1. 
On the same basis, the full length plasmid carrying the fragment 3 with the composition 
similar to that was found in the PVM strain 15 (Warwick) was called pFL2G-G15. 
For the purpose of this research it was necessary to synthesise two more full 
length genome plasmids based on the sequence of pFL2G-GJ3666∆ORF1 and pFL2G-
G15 plasmids which are different only in the presence or absence of the first ORF of the 
G gene in comparison with their parental plasmids. “Round the horn” site directed 
mutagenesis PCR (Section  2.3.14) was used to insert the nucleotide changes in the G 
gene of plasmid pFL2G-GJ3666∆ORF1. For this purpose the G_Round(R) and 
G_Round(F) primer pair (Appendix I) were designed to contain the sequence of the G 
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gene strain J3666. The position of the primers were chosen in such a way that annealing 
at their 5’ ends would  result in generation of a fragment spanning the beginning region 
of the G gene of PVM (Figure 4.4). The mutagenesis was carried out as explained in 
Section 2.3.14. The successfully mutated plasmid, designated as pFL2G-GJ3666, was 
identified by sequencing of the G gene. To make pFL2G-G15∆ORF1 the Quick Change 
mutagenesis PCR method (Section  2.3.12) was carried out to delete the first ORF in 
pFL2G-G15 using the primer pair 1stORFOut-15-F and 1stORFOut-15-R (Appendix I) 
which were designed to mutate the AUG codon of the first ORF to GCG. The 
successfully mutated plasmids were selected after analyzing the sequence of G gene.  
 
 
Figure  4.4 The position of the G_Round(F) and G_Round(R) primers to each other. The 
phosphorylated 5’ ends of the primers are indicated (Section 2.3.14). The G_Round(R) primer is 
shown in blue and G_Round(F) is shown in red. 
4.7 Rescue of plasmid p15FL-2G 
The sequence of p15FL-2G obtained in Section 4.3 showed that there were no 
significant changes between sequences of the  the p15FL-2G clone and PVM strain 15 
(Warwick) sequence submitted to the GenBank (Accession number: AY743910) that 
might hamper the process of rescuing infectious virus. The genome of negative stranded 
RNA viruses is not able to start infection de novo, and require the viral polymerase 
complex to synthesis antigenomic RNA to act as the intermediary RNA from the 
genomic RNA. Hence, it is necessary to provide the viral polymerase complex to 
support replication of the virus. In order to provide the polymerase complex, four 
plasmids encoding the PVM N, P, M2-1 and L proteins were co-transfected with the 
p15FL-2G plasmid. As discussed in chapter one, the stoichiometry of individual 
proteins in the polymerase complex is highly important to achieve successful replication 
and/or transcription. It was therefore necessary to find the right combination of 
concentrations for the polymerase complex plasmid to obtain a successful rescue. 
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Successful rescue systems for other members of pneumoviruses were reviewed and 5 
methods which had been used previously to rescue HRSV, BRSV and APV were 
considered.  Methods 1 and 2 were used to rescue BRSV from cDNA (Buchholz et al., 
1999; Yunus et al., 2001), and method 3 and 4 (Collins et al., 1995; Jin et al., 1998) 
were used to rescue HRSV from cDNA. Method 5 was employed by Dr. Roger Ling to 
rescue APV (Dr. R. Ling, unpublished data). Table 4.2 describes the concentrations of 
the helper plasmids which were used in these methods. 
The various amounts of DNA shown in Table 4.2 were mixed and BSR-T7/5 
cells were transfected as described in Section  2.2.4. The transfected cells were kept at 
31˚C and checked regularly for the presence of CPE. To passage the material the 
transfected BSR-T7/5 cells were subjected to a freeze and thaw cycle before being 
scraped into the medium and one third of the culture was transferred to a fresh BS-C-1 
cell culture. This point was considered as the first passage. Passaging of viruses was 
continued until extensive cell death was observed. Among the methods of rescue 
mentioned in Table 4.2, methods 1 and 5 resulted in successful production of 
recombinant viruses. The method 5 was used throughout as the method to rescue 
recombinant viruses and further experiments were planned based on the viruses 
obtained from this method. The process for passaging viruses following transfection is 
summarised in Figure 4.5. The recombinant viruses were defined as rPVM. Rescue of 
pFL2G-G15, pFL2G-G15ΔORF1, pFL2G-GJ3666, pFL2G-GJ3666ΔORF1 and p15FL-
2G resulted in production of rPVM-G(15), rPVM-G(15ΔORF1), rPVM-G(J3666), 
rPVM-G(J3666ΔORF1) and rPVM, respectively. The recombinant viruses were 
subjected to continuous passages until a titre greater than 1x105 pfu/ml for each was 
achieved. rPVM-G(J3666ΔORF1) and rPVM-G(15) were subjected to six continuous 
passages in BS-C-1 cells to obtain this titre. rPVM-G(J3666) and rPVM-G(15ΔORF1) 
were subjected to two passages in BS-C-1 cells to obtain the desired titre. 
Method used 
to rescue virus 
Full 
length 
pN pP pM2-1 pL References 
1 10 µg 4 µg 4 µg 2 µg 2 µg (Buchholz et al., 1999) 
2 0.4 µg 0.4 µg 0.2 µg 0.4 µg 0.4 µg (Jin et al., 1998) 
3 0.4 µg 0.4 µg 0.4 µg 0.1 µg 0.1 µg (Collins et al., 1995) 
4 1 µg 0.4 µg 0.3 µg 0.1 µg 0.2 µg (Yunus et al., 2001) 
5 3 µg 0.3 µg 0.3 µg 0.24 µg 0.15 µg Dr. R. Ling, unpublished 
data. 
Table  4.2 DNA concentrations used to rescue PVM from cDNA.  
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The presence of virus was confirmed by RT-PCR specific for the viral genome. 
The presence of XbaI and SalI restriction enzyme sites which are specific for the 
recombinant virus (obtained from using the method 2 mentioned in Table 4.2) was 
confirmed by amplifying the relevant part of the viral genome. For this, the 751 bp “M-
SH” fragment was amplified from nucleotide 3571 to 4322 of the PVM genome using 
M2 and SH2 primers and the cDNA of the virus as the template (Appendix I). The DNA 
fragment was purified and then digested with SalI restriction enzyme which would 
generate two fragments of 273 bp and 477 bp (Figure 4.6). This confirmed that 
recombinant PVM had been generated from the plasmid. 
In addition, to show successful infection of the cell by the PVM monoclonal 
antibody 26/C3/B5 was used to detect the PVM P protein in cell culture. Figure 4.7 
shows cells infected with recombinant PVM surrounded by non-infected cells and 
expressing the P protein. The full sequence of plasmids pFL2G-GJ3666 and pFL2G-
G15ΔORF1 which were generated using site directed mutagenesis were determined 
using the G9, J1, J4E, J5, M1, M2, N1, N3, N5, NS1B, NS2A, NS2B, P2A, P3, P4, 
SH2, 22K7, F7, F9, F11, F14, F17, G7, J7, L1F, L1H, L1J, L2C, L2F, L10, PL23, 
PL29, L2G, L2H, L3C, L3D, L3E, L3F, L3G, PL48, and L50 primers (Appendix I), to 
confirm that no mutations had arisen during the cloning procedure. A sequence conflict 
between their sequence and sequences of p15FL-2G, and pF3BBA was observed 
resulting in a LS423K  LN423K change in the F protein synthesised from the pFL2G-
GJ3666 and pFL2G-G15ΔORF1 plasmids.  
 
Figure  4.5 The rescue process to obtain infectious virus from cells. Each step of rescue of the 
recombinant viruses is indicated as a passage (pass.) number. Transfected BSR-T7/5 cells 
(pass. 0) were lysed and cell lysate obtained from BSR-T7/5 cultures was used to infect BS-C-1 
cells (pass. 1). 
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Figure  4.6 A. Digestion of the M-SH PCR fragment from the wildtype and recombinant viruses 
containing a SalI restriction site. The PCR fragments (751 bp) were amplified from the cDNA of 
the wildtype recombinant viruses (B). Following purification, the PCR fragments were digested 
with SalI restriction enzyme generating 477 bp and 273 bp fragments in the DNA fragment 
amplified from the recombinant viruses. The DNA amplified from the wildtype virus remained 
undigested. Lane 1, M-SH DNA fragment from wildtype virus, after being digested with SalI 
restriction enzyme; lane 2, the digested M-SH fragment; lane 3, DNA Hyperladder I size 
markers. The size of DNA markers are shown on the right of the gel. 
 
 
            A                                         B 
 
Figure  4.7 Detection of cells infected with the recombinant viruses using the 26/C3/B5 
monoclonal antibodies detecting PVM P protein. The infected cells are shown in green 
surrounded by the uninfected cells. The nuclei of cells were visualised using DAPI dye. A. Cells 
infected with rPVM-G(15) and B. Cells infected with rPVM-G(J3666). 
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4.7.1 Growth of recombinant viruses in cell culture 
The presence of the inserted mutations in the viral genome [including SalI, 
XmaI, NotI, BshTI, BglII and NotI restriction sites and deletion of the first ORF of the G 
genes in strains J3666 and 15 (Warwick)] raised the possibility that the mutations may 
reduce the growth rate of the viruses in vitro. An experiment was designed to test the 
growth of the recombinant viruses in cell culture. To do this BS-C-1 cells were cultured 
in 24 well plates in GMEM medium supplemented with 2% FCS. The cells were 
infected with either rPVM-G(15), rPVM-G(15ΔORF1), rPVM-G(J3666), rPVM-
G(J3666ΔORF1), rPVM passage 7, rPVM passage 8, or  PVM strain J3666 viruses 
(Section 4.7) with an moi of 0.05. The cultures were incubated at 31 and 37˚C. 
Samples were harvested by scraping the cells into the medium at 0, 24, 48, 72, 
96, and 120 hr post infection. Three individual samples were harvested from three 
different infected wells for each time point. All of the samples were kept at -70°C until 
titration using the micro-plaque assay technique (Section  2.2.7) to detect virus yield. 
Each titration was conducted in triplicate. An average was calculated for each time 
point. Results obtained from the titrations are depicted in Figure 4.8. 
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Figure  4.8 Growth of stock or recombinant PVM isolates in BS-C-1 cell culture system at two 
temperatures, 31˚C and 37˚C. The growth of the wildtype PVM strain 15, strain J3666, rPVM 
passages 7, rPVM passage 8, rPVM-G(15), rPVM-G(15ΔORF1), rPVM-G(J3666) and rPVM-
G(J3666ΔORF1) are shown in graphs A to H. The curve shown in blue indicates the growth of 
viruses at 37˚C and the curve shown in red indicates the growth of the viruses at 31˚C. 
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The yield of wildtype PVM strain 15 at both 31˚C and 37˚C was higher on day 0 
then for the other viruses tested. The reasons for this are unclear, but the final yield of 
viruses did not differ greatly from the others. As expected, wildtype PVM strain J3666 
showed a significant reduction in yield when grown at 37˚C. This virus has previously 
been shown to be temperature sensitive (Prof. A. Easton, personal communication). In 
general the yield of all of the viruses was less when grown at 37˚C. 
The growth rates of two consecutive passages of recombinant virus (rPVM) 
generated from plasmid p15FL-2G were very similar. For both virus stocks there was a 
small reduction in yield at 24 hr post infection followed by a rise thereafter when grown 
at 37˚C. The initial drop in yield was not seen when the viruses were grown at 31˚C. By 
day 4 post infection the viruses had reached maximum yields at both growth 
temperatures. These viruses contained a G gene encoding a protein equivalent to that for 
PVM strain J3666. This is similar to rPVM-G(J3666ΔORF1). 
Comparison of the titres of rPVM passage 7 and rPVM passage 8 virus with 
rPVM-G(J3666ΔORF1) at 31˚C showed that the latter achieved a final yield 
approximately 10-fold lower than the other two viruses. The only differences in genome 
sequence between these viruses is that rPVM-G(J3666ΔORF1) contains unique 
restriction enzyme sites for BglII and BshTI introduced to aid cloning. The differences 
in yield may indicate that the sequence alteration adversely affects the growth of rPVM-
G(J3666ΔORF1). 
The recombinant viruses carrying the PVM strain 15 G gene showed a similar 
growth curve to that of rPVM. rPVM-G(15) showed lower yields of virus when grown 
at 37˚C than at 31˚C but was propagated at 37˚C without difficulty. No substantial 
differences were seen in the growth characteristics in vitro of rPVM-G(J3666) and 
rPVM-G(J3666ΔORF1). 
Overall, the recombinant viruses all grew to similar levels in vitro with slightly 
higher yields achieved when grown at 31˚C. The recombinant viruses with a G gene 
originating from PVM strain J3666 reached slightly lower yields than those with G 
genes derived from PVM strain 15 (Warwick). 
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4.8 Testing the pathogenesis of recombinant viruses 
The infectivity of the recombinant viruses derived from p15FL-2G clones and 
rescued from BS-C-1 cells were tested in 4-8 weeks old BALB/c mice. Each virus will 
be considered in turn. 
4.9 rPVM-G(15) 
The virus was titrated in BS-C-1 cells and appropriate dilutions to make 250, 
500 and 5000 pfu in 50 µl of inocula were prepared. The inoculum was administrated 
intranasally to the animals (Section  2.5). In the control groups mice were inoculated 
with 50 µl of sterile PBS. Mice were checked and monitored daily. Figure 4.9 and 
Figure 4.9 show the change in the body weight and clinical signs, respectively for the 
mice. No weight loss was detected during the time course, and the clinical score of the 
animals was recorded (Figure 4.10) indicating that the virus was entirely non-
pathogenic. 
 
Figure  4.9 Change in body weight in groups of mice infected with rPVM-G(15). Each mouse 
was infected with 50 µl of the three levels of virus (5000 pfu, 500 pfu and 250 pfu). Body weight 
was monitored daily and the percentage of change in body weight normalised to the first day is 
shown. The data shown is representative of two independent experiments. The inocula were 
5000 pfu , 500 pfu , 250 pfu , PBS . 
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Figure  4.10 Clinical score for mice infected with the rPVM-G(15). Each mouse was infected with 
50 µl of the three concentrations (5000 pfu, 500 pfu and 250 pfu). Clinical score was monitored 
on a daily basis and expressed as an average for each experimental group. The data shown is 
representative of two independent experiments. The inocula were 5000 pfu , 500 pfu , 
250 pfu , PBS . 
4.10 rPVM-G(15∆ORF1) 
rPVM-G(15∆ORF1) was used to infect mice and differences in the weight of the 
infected mice and in the clinical score were monitored (Figure 4.11). Slight weight loss 
was observed only in the group of mice that received 5000 pfu of the virus (Figure 
4.11). Starting from day 6, weight loss reached a peak at day 9. The mice started 
recovering completely after the day 9. However, no changes in clinical signs of disease 
were seen Figure 4.12. Although no clinical signs of disease were observed during the 
infection, the weight loss suggests that deletion of the first ORF of the G gene of strain 
15 did alter the virulence of the virus. 
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Figure  4.11 Change in body weight in groups of mice infected with rPVM-G(15ΔORF1). Each 
mouse was infected with 50 µl of the three levels (5000 pfu, 500 pfu and 250 pfu) of rPVM-
G(15∆ORF1). Body weight was monitored daily and the percentage of change in body weight 
normalised to the first day is shown. The data shown is representative of two independent 
experiments. The inocula were 5000 pfu , 500 pfu , 250 pfu , PBS . 
 
Figure  4.12 Clinical score for mice infected with rPVM-G(15∆ORF1). Each mouse was infected 
with 50 µl of the three levels (5000 pfu, 500 pfu and 250 pfu). Clinical score was monitored on a 
daily basis and expressed as an average for each experimental group. The data shown is 
representative of two independent experiments. The inocula were 5000 pfu , 500 pfu , 
250 pfu , PBS . 
4.11 rPVM-G(J3666)  
Mice infected with 5000 pfu of rPVM-G(J3666) showed very mild signs  of 
disease and weight loss, but this was not seen with other doses. The level of weight loss 
was slightly greater at its peak (9.3 %) than seen with  rPVM-G(15∆ORF1) (Figure 
4.13). The weight loss in these animals started on day 6 and reached its peak at day 9. 
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The mice recovered completely after day 9. The mice recovered completely after day9.  
While the virus was not capable of producing lethal disease in the animals (Figure 
4.14), a low level of clinical signs were seen in the mice infected with 5000 pfu. As is 
normal, the appearance of clinical signs on day 8 followed the first sign of weight loss. 
Animals infected with 500 and 250 pfu showed no changes in weight or clinical signs of 
disease. These data indicated that rPVM-G(J3666) was more virulent than rPVM-
G(15∆ORF1). 
 
Figure  4.13 Change in body weight in groups of mice infected with rPVM-G(J3666) Each mouse 
was infected with 50 µl of the three concentrations (5000 pfu, 500 pfu and 250 pfu) of rPVM-
G(J3666). Body weight was monitored daily and the percentage of change in body weight 
normalised to the first day is shown. The data shown is representative of two independent 
experiments. The inocula were 5000 pfu , 500 pfu , 250 pfu , PBS . 
 
Figure  4.14 Clinical score for mice infected with rPVM-G(J3666). Each mouse was infected with 
50 µl of the three concentrations (5000 pfu, 500 pfu and 250 pfu) of rPVM-G(J3666). Clinical 
score was monitored on a daily basis and expressed as an average for each experimental 
group. The data shown is representative of two independent experiments. The inocula were 
5000 pfu , 500 pfu , 250 pfu , PBS .  
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4.12 rPVM-G(J3666∆ORF1) 
In the group of mice infected with rPVM-G(J3666∆ORF1) no clinical signs of 
disease or weight loss were observed (Figure 4.15 and Figure 4.16) with any dose of 
virus. 
 
Figure  4.15 Change in body weight in groups of mice infected with rPVM-G(J3666ΔORF1). 
Each mouse was infected with 50 µl of the three concentrations (5000 pfu, 500 pfu and 250 pfu) 
of rPVM-G(J3666∆ORF1). Body weight was monitored daily and the percentage of change in 
body weight normalised to the first day is shown. The data shown is representative of two 
independent experiments. The inocula were 5000 pfu , 500 pfu , 250 pfu , PBS
. 
 
Figure  4.16 Clinical score for mice infected with rPVM-G(J3666ΔORF1). Each mouse was 
infected with 50 µl of the three concentrations (5000µ pfu, 500 pfu and 250 pfu) of rPVM-
G(J3666ΔORF1). Clinical score was monitored on a daily basis and expressed as an average 
for each experimental group. The data shown is representative of two independent experiments. 
The inocula were 5000 pfu , 500 pfu , 250 pfu , PBS . 
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4.13 Discussion 
In the study presented in this chapter, the nucleotide sequence of the plasmid 
p15FL-2G was confirmed. The plasmid contained a full length cDNA copy of the PVM 
strain 15 (Warwick) genome. However, a single nucleotide alteration resulted in the 
presence of a G gene which expressed a protein similar to that described for PVM strain 
J3666 but which lacked a short upstream ORF found in the strain J3666 G gene. This 
plasmid was used to generate infectious virus. Using this genome as a base, four more 
plasmids were synthesized: pFL2G-G15 carrying the G gene of PVM strain 15 
(Warwick), pFL2G-G15∆ORF1 carrying the G gene of PVM strain 15 (Warwick) with 
its first ORF deleted, pFL2G-GJ3666 carrying the G gene of PVM strain J3666 and 
pFL2G-GJ3666∆ORF1 carrying the G gene of PVM strain J3666 with its first ORF 
deleted. The five cDNA named above were used in cell culture to recover infectious 
viruses, and respectively recombinant viruses rPVM-G(15), rPVM-G(15∆ORF1), 
rPVM-G(J3666) and rPVM-G(J3666∆ORF1) were recovered. 
Recombinant and wildtype viruses demonstrated a better growth rate at 31˚C  
than at 37˚C in tissue culture, but all could be propagated at 37˚C. The recombinant 
viruses rPVM-G(J3666) and rPVM-G(J3666∆ORF1) generated 10 fold less yield than 
the other recombinant viruses. The virulence of the recombinant viruses in mice was 
examined and showed that rPVM-G(15), which has the same G gene organisation as the 
non-pathogenic PVM strain 15 (Warwick) was not pathogenic when mice were infected 
with 250, 500 or 5000 pfu. However, when mice were infected with 5000 pfu of rPVM-
G(15∆ORF1) a small (4%) but significant weight loss was seen compared to the weight 
of the animals at the time of challenge. Control, uninfected, mice and animals infected 
with 250 pfu or 500 pfu of rPVM(15∆ORF1) showed a gain in weight, and no clinical 
signs of disease. Removal of the first ORF in PVM strain 15 (Warwick), which overlaps 
with the ORF encoding the G glycoprotein, results in a small but measurable increase in 
pathogenicity. 
The G gene of the pathogenic strain J3666 contains a short ORF upstream, but 
not overlapping, the ORF which encodes the G glycoprotein. The PVM strain J3666 G 
glycoprotein contains additional amino acids at the amino terminus compared to the G 
protein of strain 15 (Warwick). When mice were infected with rPVM-G(J3666), those 
receiving 5000 pfu showed weight loss which reached a maximum of 9% of the starting 
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weight on day 9 post infection and mild clinical signs of disease which followed the 
weight loss, beginning on day 8. 
Animals infected with 250 pfu or 500 pfu of rPVM-G(J3666) showed little 
change in weight and no clinical signs of disease. All animals challenged with any of 
the 3 selected doses of rPVM-G(J3666ΔORF1) remained clinically normal and showed 
no significant difference in weight. 
During this research, it was assumed that the low number of passages may 
reduce the possibility of generating DI particles. Taken together, the data suggest that 
the presence of the first ORF in the G gene of PVM may play an important role in virus 
virulence. A possible explanation may be that the upstream ORF affects the level of 
expression of the G protein from the downstream ORF. It is well known that the 
presence of an upstream ORF in cellular mRNAs frequently leads to a reduction in the 
level of protein produced by the downstream ORF (Child et al., 1999b; Kozak, 1984). 
Thus, pathogenicity of PVM may be affected by the nature and amount of G protein 
produced. The effect of the first ORF in the G gene of PVM was examined in more 
detail in Chapter 5. 
During construction of the plasmid p15FL-2G the area between nucleotides 900 
and 1300 of the F gene was reported to containing unclear sequences (Dibben, 2006). 
This conclusion was made after sequencing the plasmid with two individual primers (F9 
and F20) on several occasions (Dibben, 2006). In the work presented here, the 
sequences were obtained using the same primer (primer F9, Appendix I) which was 
used by Dibben (2006). Interestingly, the same ambiguous sequencing results with trace 
containing more than one peak at each nucleotide were achieved. The reason for the 
diversity in the nucleotide sequence of the F gene in this region remains unclear. Due to 
time constraints, the mutation in the F gene of plasmids pFL2G-G15∆ORF1 and 
pFL2G-GJ3666 was left unchanged. 
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CHAPTER 5  
 
 
EFFECT OF THE FIRST ORF ON 
PVM G PROTEIN EXPRESSION 
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5.1 Introduction 
As discussed in Section  1.2.1.1.1, the G gene of PVM strain 15 (Warwick) 
contains two overlapping open reading frames. In the G gene of PVM strain J3666, 
however, a shorter ORF precedes the main ORF of the gene, and the main ORF is 
longer than that of strain 15 (Warwick) (Section 1.2.1.1.1). In other systems it has been 
shown that the presence or absence of an upstream ORF can affect the translational 
level of the second ORF (Meijer et al., 2000; Peabody & Berg, 1986; Poyry et al., 2004; 
Wang & Sachs, 1997). The consistent presence of an upstream ORF in the G gene in 
PVM strains raises the question of the contribution of the first ORF in controlling the 
expression level of G glycoprotein from the larger second ORF. 
To analyse the contribution of the first ORF of the G gene in translation of the G 
glycoprotein, it was necessary to compare different levels of G protein in the absence 
and presence of the first ORF. For this purpose, a reverse genetics system using a 
synthetic minigenome was employed. A dicistronic minigenome system expressing two 
reporter genes was constructed for PVM. The first gene transcribed from the synthetic 
genome expressed the luciferase (Luc) protein. The second gene expressed the G 
glycoprotein from either PVM strain 15 (Warwick) or strain J3666. To measure the 
quantity of G protein expressed, the G gene was tagged at its 3’ end with green 
fluorescent protein (GFP) and the amount of GFP was measured using an ELISA, based 
on the assumption that the quantity of GFP would reflect the quantity of G protein 
expressed. The activity of luciferase protein coded from the sequence in the first cistron 
of the minigenome was used to normalise the data. Using these basic constructions it 
was possible to assess the effect of the presence and absence of the upstream ORF in the 
G gene. The normalised results were compared to each other to study the effect of first 
ORF in the translational control of the G gene in both strains of PVM. 
5.2 Construction of the PVM minigenome carrying G gene of PVM 
The plasmid was made based on the available dicistronic minigenome plasmid 
(pWt/NdeI) by using the presence of the naturally occurring restriction sites, and 
introducing a novel restriction site upstream of the CAT gene in the minigenome. The 
process used in the approach is summarised in Figure  5.1. 
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Figure  5.1 The synthesis of pG-GFP minigenome. The construction of pG-GFP was performed 
in 8 steps indicated in the diagram as steps A to H. In step A, the G gene was amplified using 
cDNA or plasmid DNA templates; in step B, GFP was amplified using pWt/NdeI as the template. 
For step C, the G and GFP genes were joined together using an overlap PCR technique. Step 
D, an NcoI restriction site was inserted in pWt/NdeI using quick change mutagenesis technique. 
Subsequently, in step E, the mutated pWt/NdeI was digested using NcoI and PstI restriction 
enzymes. Subsequently, in step F, the luciferase gene was amplified from pGL3 template DNA, 
and ligated (step F) into the digested pWT/NdeI DNA. Finally in step H, the products of steps G 
and C were ligated together to make the pG-GFP (see text for further detail). 
The plasmid pWt/NdeI (Figure  5.2) was constructed and optimised by O. 
Dibben and L. Thorpe to analyse the effect of gene leaders and gene trailers on the 
protein synthesis of PVM (Dibben & Easton, 2007; Dibben et al., 2008). It consists of 
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two genes expressing chloramphenicol acetyl transferase (CAT) and green fluorescent 
protein (GFP) each of them flanked by PVM gene start (GS) and gene end (GE) signals 
making them two individual genes controlled by PVM transcription regulation 
sequences. The genomic leader and trailer regions of the PVM genome RNA flank both 
genes, and the whole area was bounded by T7 transcription start and stop sequences. T7 
directed transcription produces an RNA molecule representing a synthetic (mini-) 
genome of PVM which can be replicated and transcribed by the relevant virus protein 
complexes. 
 
Figure  5.2 Schematic structure of pWt/NdeI. Naturally occurring restriction sites are shown in 
black and the recombinant restriction site introduced upstream of the CAT gene is shown in red. 
Gene start sequences are shown with vertical lines and in green, likewise gene end sequences 
are shown in red. The sizes (bp) of DNA between the restriction sites are shown.   
5.3 Quick change mutagenesis to make pWt/NcoI 
Due to lack of a suitable quantitative detection assay for CAT as the product of 
the first gene in the minigenome this was removed from the first cistron in the 
pWt/NdeI minigenome and replaced with the firefly luciferase gene which is readily 
detectable (Section  2.4.2). For this, two point mutations were inserted upstream of the 
translation initiation of the CAT gene in pWt/NdeI, to make an NcoI restriction site, 
using the quick change mutagenesis technique (Section  2.3.12). NCOIFOR and 
NCOIREV primers (Appendix I) were designed for this purpose to mutate TA to CC at 
position 55 and 56 of the pWt/NdeI (Figure  5.3). The mutated plasmid was designated 
pNcoI/PstI. Digestion of pNcoI/PstI with NcoI and PstI restriction enzymes was used to 
identify the successfully mutated plasmid. As indicated in Figure 5.2 digestion of 
pNcoI/PstI with NcoI and PstI restriction enzymes resulted in production of 516, 164, 
977 and 3263 bp fragments (Figure 5.4)(. 
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Figure  5.3 Quick Change mutagenesis reaction to introduce an NcoI restriction site before the 
start codon of CAT gene. A. The approximate position of the mutagenesis primers to mutate the 
nucleotides 55 and 56 of the plasmid pWt/NdeI. B. The mutagenesis site on the plasmid 
pWt/NdeI. C. Both nucleotides at residues 55 and 66 of the plasmid pWt/NdeI were mutated to 
cytosine. The primer pair used in the reaction is shown as two black arrows named NcoIRev 
and NcoIFor. 
5.4 The Luciferase gene region 
Amplification of the luciferase gene was conducted using plasmid pGL3 
(Promega) as the template and primers PstLucR and NcoLucF (Appendix I). The primer 
NcoLucF was designed in such a way as to amplify NcoI restriction site from the pGL3 
plasmid and the primer PstLucR was designed to add the PstI restriction site to the 3’ 
end of the 1653 base pair fragment. Gel purification of the PCR product was followed 
by digestion of the amplified luciferase gene with NcoI and PstI. The digested luciferase 
gene was then ligated into pNco/PstI which had also been digested with NcoI and PstI. 
Six colonies were randomly selected and the colonies containing pNcoI/PstI-Luc were 
identified after DNA purification and digestion of the purified DNA using PstI and NcoI 
restriction enzymes. Figure 5.4 shows a typical digestion result of three of the colonies; 
the 1653 bp fragment of the luciferase gene was released upon digestion with PstI and 
NcoI restriction enzymes. 
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Figure  5.4 Restriction enzyme digestion of pWt/NcoI and pNcoI/PstI with PstI and NcoI 
restriction enzymes. Lanes 1 to 7 contain DNA size markers, pWt/NcoI-Luc colony number 1, 
pWt/NcoI-Luc colony number 2, pNcoI/PstI colony number 1, pNcoI/PstI colony number 2, 
pNcoI/PstI colony number 3, and pWt/NcoI-Luc colony number 3, respectively. 
5.5 The G-GFP region 
To measure the quantity of expressed G protein, a GFP tag was inserted at the C 
terminus. To join the two genes together an overlap PCR technique was used. 
5.5.1 Amplifying the G gene from PVM strains; general features 
In the G gene of the PVM strains 15 (Warwick) and J3666, there are 14 
nucleotide differences including 13 point mutations and one single nucleotide deletion 
(Randhawa et al., 1995). For this analysis it was essential to include all of the gene 
differences in the minigenome. Therefore, it was decided to make two minigenomes 
each containing the G gene from one PVM strain. To achieve this, the gene was 
amplified from each strain individually. The plasmid pF3-BBA (Section  4.2) carrying a 
cDNA copy of the  relevant region of strain 15 (Warwick), was used as the template to 
amplify the G gene. A preparation of cDNA was generated from RNA of PVM strain 
J3666 (Section  2.3.10) and used as the template for amplification of the G gene for 
PVM strain J3666. 
The presence of a PVM gene start and gene end sequence was required to direct 
transcription of the G genes in the minigenome construct.  These were present on the 
minigenome pWt/NdeI. Digestion of pWt/NdeI with PstI and NcoI retained the gene 
start and stop sequence flanking the Luc gene. The authentic gene start of the G gene, 
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occurring naturally in the genome of the PVM, was retained in the amplified sequence 
of the G gene. A reverse primer (PstIRev: Appendix I) was designed based on the 3’ 
end of G gene, which is conserved between both strains. Three features were considered 
for the primer; first, it was necessary to remove the stop codon from the G gene to fuse 
together the reading frame of the G and GFP genes; second, for the overlap PCR 
reaction it was necessary to add the initial nucleotides of the GFP gene to the 3’ end of 
G gene. To achieve this, the reverse primer amplifying the G gene was designed to carry 
19 nucleotides of the complementary sequence from the beginning of GFP gene as a 
tag, and similarly 20 nucleotides from 3’ end of G gene was added to the forward 
primer to amplify GFP gene.  
5.5.1.1 Amplifying G gene from PVM strain 15 template 
Amplification of the G gene from pF3-BBA template (Section 4.2) with primers 
PstIFor and PstIRev (Appendix I) generated the expected product with a length of 1393 
nucleotides and a non-specific product with about 800 base pairs (Figure  5.5). The 1393 
base pair PCR product was excised and purified from the gel. 
 
Figure  5.5 PCR amplification of the PVM strain 15 (Warwick) G gene using primers PstIFor and 
PstIRev. Lane 1 shows the Hyperladder I size marker. The sizes of the markers are shown on 
the left. Lane 2 shows the 1393 nt product of amplification of the PVM strain 15 (Warwick) G 
gene. 
5.5.1.2 Amplifying the G gene from strain J3666 template 
To make a minigenome of the G gene with the organisation found in PVM strain 
J3666, the G gene was amplified from cDNA from PVM strain J3666 RNA. For this 
purpose, RNA extracted directly from 250 µl of cell culture harvested virus, and cDNA 
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was made from both sense and antisense RNA of the virus using random primers. The 
G gene was amplified using the PstIRev and the PstIGJ3666 primer pair (Appendix I) 
and used in an overlap PCR as described earlier. 
5.5.2 Amplification of the GFP gene 
The GFP gene was amplified from pWt/NdeI using GFP-For and GFP-Rev 
primer pair (Appendix I). The primer pair was designed to leave a tag complementary to 
the 3’ end of the genomic sense of the G gene at the 5’ end of the PCR product, as 
before. This would give the opportunity to use it in overlap PCR to join the G and GFP 
genes together. A PstI restriction site was placed at the 3’ end of the GFP gene for 
cloning purposes. The PCR products were separated by agarose gel electrophoresis 
(Figure 5.6) and the 779 nucleotide fragment was excised from the gel. 
 
Figure  5.6 Amplification of the GFP gene from pWT/NdeI DNA. Lane 1 shows the, Hyperladder I 
size markers. The sizes of the markers are shown on the left. Lanes 2 and 3 shows the PCR 
product with the expected 779 base pair size. 
5.5.3 The overlap PCR to join G and GFP together 
To conduct a successful overlap PCR it was necessary to design overlapping 
primers for both G and GFP genes. For this, the primer GFPFor was designed carrying 
23 nucleotides from the 3’ end of the G gene. As a result, the amplified fragment was 
expected to carry the 23 nucleotide of the G gene at the 5’ end of the fragment 
(Section  5.5.2). The second primer, PstIRev, was designed to carry the first 19 
nucleotides from the sense strand of the GFP fragment. This would result in 
amplification of a fragment from the G gene containing 19 nucleotides from the GFP 
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gene. It was assumed that in a PCR reaction the overlapped region of the fragments 
would anneal to each other and act as primers and synthesise the other fragment leading 
to the completion of the G-GFP fragment synthesis. Using the PstIFor primer, for the 
strain 15 (Warwick), or PstIGJ3666 primer, for the strain J3666, as the forward primers 
individually and GFPRev as the reverse primer would give the opportunity to further 
amplify the G-GFP fragment. The principle of the overlap PCR which was used here is 
explained in Figure  5.7. The overlap sequence in the sense strand of the G fragment 
annealing to the overlap sequence of the sense strand of the GFP fragment is shown in 
Figure 5.8. 
 
 
Figure  5.7 The overlap PCR method used to join the G and GFP fragments to synthesis the G-
GFP fragments for the strains 15 and J3666. A. Amplification of the G fragment using PstFor, 
for the strains 15 (Warwick), or PstIGJ3666, for the strain J3666, as the forward primers and 
PstRev as the reverse primer. The pF3-BBA was used as the template to synthesis G(15) for 
PVM fragment. The RT-PCR was used to amplify the G gene from genomic RNA isolated from 
strain J3666. B. Amplification of the GFP fragment using the GFPFor and GFPRev primer pair. 
C. The overlap PCR reaction. D. the fragment G-GFP. The PstRev and GFPFor primers are 
shown in blue carrying the overlapping region (shown in red). The G fragment is shown in blue 
with the overlap sequence at its 3’ end (red). The GFP fragment is shown in green with the 
overlap sequence at its 5’ end (red). 
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Figure  5.8 The overlap PCR reaction. The fragment G (blue) and the fragment GFP (green) are 
shown in the overlap PCR reaction. The overlapped regions between the sense G fragment and 
antisense GFP fragments are annealed together. The stop codon in G fragment was replaced 
with “CCC” and shown inside a blue box.  
To optimise the overlap PCR reaction for the G gene of PVM strain 15, an 
overlap PCR was conducted in buffers with either 2, 3 or 4 mM of Mg2+. The annealing 
temperature was set at 58°C and kept constant during optimisation of Mg2+ 
optimisation, based on the assumption that higher annealing temperature would 
eliminate the possibility of production of nonspecific inter- and intra-molecular 
secondary structures. The process was used to achieve correct annealing between 5’ and 
3’ ends of the GFP and G genes. The highest yield was achieved with concentrations of 
3 and 4 mM Mg2+ (Figure 5.9). The PCR product was gel purified and kept at -20°C 
until the time to be used. Equal concentrations of the G (Section  5.5.1) and the GFP 
fragments (Section  5.5.2) were used as the template. The GFPFor and PstIRev primers 
(Appendix I) were designed to overlap at their 5’ end. Therefore, it was expected that 
the fragments G and GFP contain overlapping ends at their 3’ (for the G fragment) and 
5’ (for the GFP fragment) ends. The primers PstIFor and GFPRev were used in the 
overlap PCR . 
 
Figure  5.9 The overlap PCR to join G and GFP fragments together. Gel purified G and GFP 
genes from previous PCR amplifications were used with different Mg2+ concentrations. Lanes 1, 
2 and 3 show the products of reaction in the presence of 2, 3 and 4 mM Mg2+ , respectively. 
Lane 4 shows the Hyperladder I size markers with the sizes shown on the right. 
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5.6 Ligation of G-GFP fragments into pNcoI/PstI-Luc 
G-GFP fragments obtained from the process explained above were digested with 
PstI restriction enzyme and ligated into PstI digested pNcoI/PstI-Luc vector (Figure 
5.10). Following transformation of  E. coli, plasmid DNA prepared from bacterial 
colonies was digested with PstI and the plasmids carrying the G-GFP fragment were 
selected and sequenced using primer G4878(R) (Appendix I) to confirm the orientation 
of the G-GFP fragment in the vector. 
 
Figure  5.10 Ligation of the G-GFP fragment into pNcoI/PstI-Luc. The PstI digested G-GFP was 
ligated into the PstI digested pNcoI/PstI-Luc vector. The PVM gene start and stop sequences 
are shown in green and red, respectively.   
5.7 Deletion of the first ORF in both constructs 
Both constructed G-GFP minigenome plasmids (pG-GFP-15 and pG-GFP-
J3666) were used in a single step quick change mutagenesis PCR reaction to mutate the 
start codon of the first ORF to GCG using primers 1stORFOut-J6-F and 1stORFOut-J6-
R (Appendix I)  for pG-GFPJ3666 and primers 1stORFOut-15-R and 1stORFOut-15-F 
for pG-GFP-15. This ensured that the first ORF in both constructs could no longer be 
translated and the transcribed mRNA contained only one single ORF (Section  1.2.1.1). 
The mutated plasmids were referred to as pG-GFP-15∆ORF-1 and pG-
GFPJ3666∆ORF-1 (Figure 5.11). 
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Figure  5.11 Deletion of the first ORF of the G gene in pG-GFP15 and pG-GFPJ3666. The 
primer pair 1stORFOut-15-F and 1stORFOut-15-R, for the strain 15, and the primer pair 
1stORFOut-J6-F and 1stORFOut-J6-R as indicated with black arrows, for the strain J3666, were 
used to mutate the start codon of the first ORF of the G gene to GCG. The Luc gene is 
indicated. The PVM gene start and stop sequences are shown with green and red vertical lines. 
The first ORF in each construct is indicated.  
5.8 Correction of the first ORF stop codon in pG-GFPJ3666 
As discussed in Chapter 4, the sequence of the G gene in strain J3666 did not 
contain the stop codon for the first ORF of the G gene. As a result, and because the aim 
the experiment was to analyse the effect of the first ORF in expression of the main ORF 
of the G gene, a Quick Change mutagenesis PCR primer pair [MG_STOP(F) and 
MG_STOP(R)] was designed to restore the stop codon for the first ORF. Following the 
mutagenesis PCR, the DpnI digested PCR products were used to transform competent 
E. coli. The sequence of the clones obtained and one of the clones contained the 
corrected stop codon was randomly selected. 
5.9 Cloning the G-GFP fragments under T7 promoter 
Before transfection of the pG-GFP plasmids into the BSR-T7/5 cells, it was 
decided to test the expression of the G-GFP ORF independent from the PVM 
transcription system. For this purpose, the G-GFP fragments were cloned into 
pBlueScript II plasmids (Figure 5.12). The presence of the T7 polymerase promoter 
upstream of the G-GFP ORF would provide the opportunity to control the ORF 
transcription in the presence of the T7 polymerase. BS-C-1 cells infected with a 
recombinant vaccinia virus expressing bacteriophage T7 RNA polymerase was chosen 
for this purpose. 
117 
 
 
Figure  5.12 Strategy used for constructing pBS-G-GFP plasmids. The multiple cloning site and 
the T7 promoter of pBlueScript II are depicted. The PstI restriction sites are indicated in 
pBlueScript II vector and G-GFP fragment. The digested G-GFP fragments were inserted into 
the digested pBlueScript II vector. The PVM gene end and start sequences are shown in red 
and green, respectively. The gene end and start sequences were inserted into the pBS-G-GFP 
plasmids during cloning procedure but was not in use during the experiment. 
The G-GFP fragment was digested from pG-GFP15, pG-GFP15∆ORF1, pG-
GFPJ3666 and pG-GFPJ3666∆ORF1 plasmids individually by digestion with PstI, and 
the fragments were purified. These fragments were inserted into pBluescripII, digested 
with PstI. The ligation mixture was transformed into competent E. coli (Sections  2.3.5 
and  2.3.6), and the transformed bacteria were cultured on LB agar supplemented with 
IPTG and X-Gal (Section  2.1.13 and Section  2.3.9). On the following day, 3 white 
colonies for each construct (pBS-G-GFP15, pBS-G-GFP15∆ORF1, pBS-G-GFPJ3666 
and pBSG-GFPJ3666∆ORF1) were selected and grown in liquid cultures to provide 
DNA. The presence of the G-GFP fragment in pBS-G-GFP15, pBS-G-GFP15∆ORF1, 
pBS-G-GFPJ3666 and pBSG-GFPJ3666∆ORF1 constructs was confirmed by digestion 
with PstI restriction enzyme. The orientation of the start codon of the G-GFP fragments 
in 3 plasmid stocks prepared from each of the pBS-G-GFP15, pBS-G-GFP15∆ORF1, 
pBS-G-GFPJ3666 and pBSG-GFPJ3666∆ORF1 plasmids was confirmed by sequencing 
the constructs using universal T7 and G4878(R) primers (Appendix I). 
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Figure  5.13 PstI digestion of the pBS-GGFP constructs. Lanes 4 and 8 contain DNA size 
markers. Lanes 1 – 3 contain pstI digested pBS-G-GFP15, lanes 5 – 7 contain pBS-G-
GFP15∆ORF1, and lanes 9 -14 contain pBS-G-GFPJ3666 and pBSG-GFPJ3666∆ORF1. The 
DNA size markers are indicated on the left. 
5.10 Expression of the G-GFP fusion proteins in Vaccinia Virus T7 
infected cells 
The pT7-G-GFP constructs were transfected into  BS-C-1 cells infected with 
recombinant vaccinia virus expressing bacteriophage T7 RNA polymerase (moi= 1). 
The lysate was used in a GFP ELISA to standardise loading on a polyacrylamide gel 
(Section  2.4.1).   
The expression of the G-GFP fusion protein was confirmed by western blotting 
(Section  2.4.1). Protein samples were incubated at 37˚C for 30 min prior to 
electrophoresis on an 8% polyacrylamide gel (Puffer et al., 2000). The results of the 
western blot analysis are shown in Figure  5.14. 
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Figure  5.14 Detection of G-GFP fusion protein using SDS-PAGE and western blot. GFP was 
detected as described in Section 2.3.18. Numbers on the left indicate the position of the protein 
weight markers (SpectraTM, Fermentas). Numbers on the top indicate the lane number. Lanes 1 
to 5 contain recombinant GFP, BS-C-1 cell lysates infected with T7 expressing vaccinia virus 
and transfected with pBS-G-GFPJ3666∆ORF1, pBS-G-GFPJ3666, pBS-G-GFP15∆ORF1, and 
pBS-G-GFP15, respectively. All samples incubated for 30 min at 37°C as explained in the text. 
The relative molecular mass (Mr) of GFP is 26900. GFP readily forms a dimer 
which can be seen in lane 1 in Figure 5.14. The non-covalently formed dimer is stable 
when incubated at 37˚C prior to electrophoresis. This was necessary as no GFP was 
detected on western blots when the protein samples were heated to 100˚C (data not 
shown). The molecular weight of non-glycosylated PVM strain J3666 G protein is 
predicted to be 43600 and the nonglycosylated PVM strain 15 G protein is predicted to 
be 39800 (Randhawa et al., 1995). Following glycosylation the G protein increases in 
size by approximately 40000. In Figure 5.14 the G-GFP fusion protein from both strains 
15 and J3666 G gene produced two bands one of approximately 58000 and a larger 
band of approximately 73000 with several bands between these two sizes. It is unlikely 
that the G-GFP fusion protein will be glycosylated and the 73000 protein is likely to be 
the full length fusion of the G and the GFP proteins. The smaller proteins are most 
likely to be cleavage products which have been degraded at the amino terminus. 
Degradation of fusion proteins is commonly observed. However, it is also possible that 
the PVM G protein contain a furin - like cleavage site which is responsible for the 
production of the smaller products discussed below (Section  5.11). The data clearly 
show that the G gene constructs are capable of directing the synthesis of the expected 
fusion proteins. 
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5.11 Measuring the G-GFP fusion proteins expression in BSRT-7 cells 
transfected with pG-GFP plasmids 
In Section 5.9, the expression of G-GFP fragments cloned in pBlueScript II 
vectors were shown. To achieve the expression of the G-GFP in the minigenome 
constructs, BSRT/7-5 cells, which constitutively express bacteriophage T7 RNA 
polymerase, were prepared in 6 well plates. Each of the pG-GFP15, pG-GFP15∆ORF1, 
pG-GFPJ3666 and pG-GFPJ3666∆ORF1 plasmids was transfected into BSR-T7/5 cells 
along with the plasmids coding for the RNP complex, P, N, L and M2-1 proteins which 
are necessary for controlling RNA transcription of PVM (Section  1.2.3). Table 5.1 
shows the optimised amounts of the plasmid DNA used in the transfection (Dibben & 
Easton, 2007; Dibben et al., 2008). In each experiment, three wells of the BSR-T7/5 
cells were not transfected with the plasmids and were designated as the negative 
controls. The negative controls were treated with the same amount of the transfection 
reagent. For each of the pG-GFP plasmids the transfection was performed in triplicate. 
The experiment was repeated on two different occasions.  
 
 pN pM2-1 pL pP Minigenome 
Concentration (µg) 0.4 0.1 0.2 0.2 0.4 
Table  5.1 The concentrations of the minigenomes and helper plasmids, coding for the RNP 
complex of PVM, used to transfect BSR-T7/5 cells (Dibben & Easton, 2007; Dibben et al., 2008). 
pP, pL, pM2-1 and pN indicate the name of plasmids coding for P, L, M2-1, and N proteins of 
PVM. 
The transfected BSR-T7/5 cells were incubated for 48 hr at 37˚C. Thereafter, the 
transfected BSR-T7/5 cells and the negative control cells were lysed in CCLR 1X lysing 
buffer (Section  2.4.1). The samples were used directly in the GFP ELISA to measure 
the level of the G-GFP fusion protein (Section 2.4.1). The GFP ELISA was performed 
in triplicate. The luciferase activity in the samples expressed from the Luc gene in the 
first cistron of the G-GFP minigenomes was determined as described in Section 2.4.2. 
Table 5.2 shows the mean of the luciferase activities in the sample, and Table 5.3 shows 
the means of the GFP concentrations in 100 µl of each of the samples. 
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A 
Minigenome Luc activity Luc activity Luc activity 
pG-GFP15 127.6 145.4 95.46 
pG-GFP15∆ORF1 97.17 99.54 93.58 
pG-GFPJ3666  28.41 27.79 36.21 
pG-GFPJ3666∆ORF1 51.08 34.6 40.4 
B 
Minigenome Luc activity Luc activity Luc activity 
pG-GFP15 193.7 76.66 190.9 
pG-GFP15∆ORF1 110.8 129.9 126.6 
pG-GFPJ3666  77.94 56.43 73.77 
pG-GFPJ3666∆ORF1 39.87 30.91 38.79 
Table  5.2 The luciferase activities achieved from two independent transfections (A and B) of 
BSR-T7/5 cells with the PVM support plasmids coding for the RNP complex and the 
minigenomes pG-GFP15, pG-GFP15ΔORF1, pG-GFPJ3666 and pG-GFPJ3666ΔORF1. The 
luciferase assay results were obtained from 3 separate wells derived from each of the two 
independent experiences. 
A 
Minigenome GFP Concentration (pg) GFP Concentration (pg) GFP Concentration (pg) 
pG-GFP15 4431.5 5971 2415 
pG-GFP15∆ORF1 5479.9 5000 4701.2 
pG-GFPJ3666 1099.8 916.47 1262.8 
pG-GFPJ3666∆ORF1 2142.9 1254.3 1360.5 
B 
Minigenome GFP Concentration (pg) GFP Concentration (pg) GFP Concentration (pg) 
pG-GFP15 4686.6 1369 4970 
pG-GFP15∆ORF1 6674.1 7500 9062.5 
pG-GFPJ3666  3389 1887.8 4329.4 
pG-GFPJ3666∆ORF1 1819.7 1238 507 
Table  5.3 The mean concentrations of GFP proteins achieved from two independent 
transfections (A and B) of BSR-T7/5 cells with the PVM support plasmids coding for the RNP 
complex and the minigenomes pG-GFP15, pG-GFP15∆ORF1, pG-GFPJ3666 and pG-
GFPJ3666∆ORF1. Each transfection experiment generated 3 separate cell sample. Each 
sample was tested three times to determine the level of GFP present to generate the mean 
values shown.  
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The ratio between the GFP concentration in each minigenome and its 
corresponding luciferase activity was calculated to normalise for transfection 
efficiencies. The ratios among the BSR-T7/5 cells are compared in Figure 5.15. 
The data in Figure 5.15 show that in the context of a PVM minigenome removal 
of the first, upstream, ORF from the G gene of PVM strain 15 results in a significant 
increase in expression of the G-GFP fusion protein (p= 0.03 with a paired t-test). In 
contrast, removal of the upstream ORF from the PVM strain J3666 G gene did not 
significantly affect the level of protein expression (p = 0.54). 
 
Figure  5.15 The ratio between the GFP expression and luciferase activity. The ratios calculated 
from BSR-T7/5 cells transfected with the minigenomes containing the sequence of PVM strain 
15 are shown as “Strain 15”. Likewise, “Strain J3666” refers to those transfected with the 
minigenomes of the PVM J3666. The cells transfected with the non-modified minigenomes (pG-
GFP15 and pG-GFPJ3666) are shown as  , and the cells transfected with the minigenomes 
with their first ORF deleted (pG-GFP15∆ORF1 and pG-GFPJ3666∆ORF1) are shown as . 
Error bars show the standard deviation from the mean and were calculated after the mean of 
GFP concentrations (Table 5.3) normalised against the luciferase activity (Table 5.2). The test 
was repeated at least three times. Data were found to be reproducible.  
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5.12 Discussion 
In eukaryotic systems, the 43 S ribosome subunit binds to the cap structure of 
the mRNA and scans until the first available AUG codon is found by the 43 S ribosomal 
subunit, and thereafter, following the association with specific initiation factors and the 
60 S ribosomal subunit the translation starts. This model, known as the scanning model 
explains the effect of the upstream ORF in suppression of a main and downstream ORF 
(Kozak, 1978). The efficiency of initiation of translation at the first AUG is affected by 
the nucleotide sequence in which it sits. The presence of a so-called strong translation 
initiation codon upstream of an ORF with a known and functional product may change 
the translation efficiency of a downstream main ORF (Kozak, 1989). When the 
upstream start codon is in a better context than the main ORF, translation of the main 
ORF is often suppressed. This effect has been shown for many eukaryotic and viral 
genes (Child et al., 1999b; Kozak, 1984; Meijer et al., 2000; Peabody & Berg, 1986; 
Wang & Sachs, 1997).  
In the work presented in this chapter, the effect of the first ORF in controlling 
the expression of the G protein of PVM in both strains 15 (Warwick) and J3666 was 
analysed. In Section  1.2.1.1 it was explained that the G gene of the strain 15 (Warwick) 
contains two overlapping ORFs (Thorpe & Easton, 2005). In contrast, in the strain 
J3666 G gene a small ORF consisting of 12 codons was shown to be present upstream 
of the major ORF (Randhawa et al., 1995).  Based on the model explained above, it was 
expected that the presence of these two ORFs in both of the strains might affect the 
translational efficiency of the main ORF. Considering the important role of the G gene 
in the inflammation resulting from the virus infection, it was hypothesised that the 
presence or absence of the first ORF in either of the strains may change the level of the 
expression of the G protein from the main ORF resulting in a change in the 
inflammatory response. 
To investigate the level of the G protein expression in vitro and the contribution 
of the first ORF to the expression level of the second ORF of the G gene, a minigenome 
system was developed. To control for the possibility that transfection efficiency may 
affect the results, a dicistronic system was developed in which the first cistron 
expressed the luciferase gene and the second cistron expressed the G gene. The G gene 
contained the second ORF coding the G glycoprotein fused with GFP at the C terminal 
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of the G protein (referred to as G-GFP). For each of the strains two variants were 
synthesised differing in the presence or absence of the first ORF of the G gene. 
Subsequently, the minigenomes pG-GFP15, pG-GFP15∆ORF1, pG-GFPJ3666 and pG-
GFPJ3666∆ORF1 were co-transfected with plasmids responsible for the synthesis of the 
RNP complex of PVM into BSR-T7/5 cells. Following the transfection, the 
concentration of the GFP and the activity of the luciferase protein were determined and 
the ratio between them was calculated.  The data suggested a significant difference in 
the ratio of G-GFP and luciferase gene expression between the pG-GFP15 and pG-
GFP15∆ORF1 constructs, while no significant difference between the ratios of the pG-
GFPJ3666 and pG-GFPJ3666∆ORF1 constructs was observed.  
The relative level of G-GFP expression in cells transfected with pG-
GFP15∆ORF1 was twice that of the cells transfected with pG-GFP15. The difference 
between the G-GFP level was shown to be statistically significant. In cells transfected 
with the constructs of the strain J3666 (pG-GFPJ3666 and pG-GFPJ3666∆ORF1), the 
level of the G-GFP expression was not significantly altered. 
The sequence context of the strain J3666 first ORF initiation codon is very poor 
(CAAAUGA), which suggests that ribosomes will not initiate strongly. This may 
suggest that ribosomes prefer to begin translation on the initiation codon of the second 
major ORF which is in a better context for translation (AGUAUGG). Removal of the 
first ORF may therefore have little effect. For the PVM strain 15 (Warwick) the 
initiation codon of the first Orf is also in a poor context (CAAAUGA) as is the initiation 
codon of the second ORF (AUAAUGU). The dramatic effect of removal of the first 
ORF may therefore be due simply to the major ORF becoming the first available site for 
translation initiation in the mRNA. Other possible reasons which must be considered 
could include the position of the first ORF, the length of the first ORF and the context 
of the main ORF versus the context of the first ORF. Alternatively, though less likely, it 
is possible that the effect of the first ORF in the expression of the G ORF is influenced 
by the cell type (Child et al., 1999a). To investigate this possibility, it would be 
necessary to analyse the consistency of the data in other cell lines that may support the 
minigenome expression. 
Expression of the G-GFP fusion protein was confirmed by western blot analysis. 
Protein from cells transfected with plasmids encoding the four G-gene constructs under 
the control of a bacteriophage T7 promoter was analysed by Western blot. The data 
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showed that all constructs generated a protein with a molecular mass expected for the 
G-GFP fusion proteins. The blots also indicated that there was a level of degradation of 
the fusion protein. 
Analysis of the amino acid sequence of the PVM G protein identified the 
presence of a potential furin-like cleavage site (RKKR) in the G protein of PVM 
between amino acids 362 and 365 in the strain J3666, and amino acids 329 and 332 in 
the strain 15 (Warwick). This raises the possibility of the cleavage of the G-GFP protein 
is due to this cleavage site. 
 Recently, it was shown that the G protein of HRSV grown in Vero cells is 
truncated, possibly due to cleavage at a C-terminal arginine residue (Kwilas et al., 
2009). It is possible that the putative furin cleavage site in the G glycoprotein of PVM is 
utilised to cleave the G glycoprotein in a similar way. The effect of this furin-like 
cleavage site in the maturation of the G glycoprotein remains to be determined. 
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CHAPTER 6  
 
 
DISCUSSION 
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HRSV, a member of pneumoviruses, is one of the most common causes of lower 
respiratory tract disease of infants, elderly and immunocompromised patients. After 
more than five decades since its discovery, many aspects of the molecular biology of the 
virus remain unclear. Most importantly, there is no safe vaccine available to prevent the 
disease. The only unsuccessful attempt in immunizing children with formalin 
inactivated viruses caused lungs sensitisation in vaccinated patients and led to a 
catastrophic situation of enhancement of disease when the patients encountered with the 
wildtype virus later in their life. Currently, passive immunization with human 
immunoglobulins or a recombinant humanized monoclonal antibody (palivizumab) is 
the only way of protecting high risk patients against the virus. 
A major barrier in HRSV research is the lack of a suitable model to study the 
interplay between the host and virus. Chimpanzees (Pan troglodytes) are the only highly 
permissive animal models in which to study HRSV in vivo (Belshe et al., 1977). There 
are several limitations in using chimpanzee as a research model including high cost of 
maintenance, their endangered status in the wild and ethical issues due to their genetic 
similarity to humans (Knight, 2008).  
Inbred mice have been extensively used to study the pathogenesis of HRSV. 
However, the semipermisive nature of mice to HRSV infection does not fully reflect all 
features of HRSV infection in humans. In particular, mice are not very permissive to 
primary isolates of HRSV, and HRSV infection in mice results in little or no 
inflammatory response. Another limitation of the HRSV – mouse model is the 
requirement of large inocula to infect mice to produce detectable signs of clinical 
disease (Rosenberg et al., 2005). 
Studying BRSV or PVM in their natural hosts have been considered as 
alternatives in studying the pathogenesis of HRSV.  The genome of BRSV strain 
A51908 is 15149 nucleotides in length and shares 73% of identity with HRSV and the 
genomic organisation of both HRSV and BRSV is similar (Collins et al., 1996b). 
Extensive cross reactivity between HRSV and BRSV proteins was reported. The genetic 
similarity between HRSV and BRSV makes BRSV an attractive candidate for the study 
of the molecular biology and pathogenesis of pneumoviruses. However, genetic 
diversity among cattle, the cost of maintenance and heterogenicity of the response of 
outbred cattle to BRSV infection are considered major limitations in using BRSV in 
cattle as a general model for pneumovirus infection in vivo models (Collins et al., 
1996b). 
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Using PVM in its natural murine host is considered as an alternative for studying 
the pathogenesis of pneumoviruses. PVM shares 52% nucleotide sequence similarity 
with HRSV, and they  share a similar genetic organisation except for the overlap of the 
M2 and L genes in HRSV which is absent in PVM. The pattern of disease of PVM in 
mice resembles the disease of HRSV in humans. Efficient replication of PVM in the 
mouse respiratory system is accompanied by an inflammatory response, mucous 
production and airway obstruction (Easton et al., 2004). The replication of PVM in lung 
epithelium leads to inflammatory cytokine production and granulocyte influx which is 
similar to the situation with HRSV. This similarity between the pathogenesis of HRSV 
and PVM in their hosts suggests that PVM is a potential powerful tool to study the 
pathogenesis of pneumoviruses in a natural host.  
In the research presented in this thesis, the pathogenesis of PVM was studied, 
and as the first step, the effect of consecutive tissue culture passages on the 
pathogenicity and genotype of PVM was analysed (CHAPTER 3). 
 Using the pathogenic strain J3666 it was shown that passage in tissue culture 
led to a loss of pathogenicity in mice .The results indicated that passages 6 and 7 were 
attenuated, but passage 5 was able to cause disease in mice. To investigate the 
molecular basis of the difference, the sequence of the virus genomes was determined. 
The NS1 and NS2 genes and most of the L gene were excluded from the study. The L, 
NS1 and NS2 genes are highly conserved among the strains of PVM and no genetic 
diversity between them has been shown. In particular, the NS1 and NS2 genes of the 
pathogenic strain J3666 and the non-pathogenic strain 15 were identical (Thorpe & 
Easton, 2005). Therefore, it was thought that the genetic diversity between the passages 
that are closely related to each other would be minimal.  
Surprisingly, no differences in the genome sequences were found between 
passages 5, 6 and 7. However, the sequence of passages 5, 6 and 7 were different from 
the published sequence of PVM strain J3666 (Accession number: NC_006579). The 
sequence differences between the published data and that obtained here were mainly 
located in the SH and G genes (Table 3.1). Briefly, in passages 5, 6 and 7, a C  U 
point mutation at nucleotide residue 269 caused a His  Tyr substitution and C  U 
mutation at SH gene position 283 introduced a stop codon resulting in shortening of the 
open reading frame. A comparison between the amino acid sequence of the SH protein 
encoded by the viruses from passages 5, 6 and 7 with the amino acid sequence of the 
SH protein of PVM strains J3666 and 15 (Warwick) revealed that the sequence of the 
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passages 5, 6 and 7 was similar to the sequence of the strain J3666 while its length was 
same as that of PVM strains 15 (Warwick) and 15 (ATCC). In the G gene, a U to A 
mutation at position 65 changed the stop codon of the first ORF of the G gene 
(Section  1.2.1.1.1) to a lysine residue resulting in an extension of the ORF and as a 
result production of a G glycoprotein with a larger N-terminal. The other changes 
observed in the G gene were: C(68)U in the noncoding sequence between the two 
ORFs, A(104)G changing a serine residue to a glycine residue, G(165)U changing a 
glycine residue to a valine residue, G(236)A changing a glycine residue to an arginine 
residue, and U(1121)A  changing a serine residue to a threonine residue. Two changes 
were observed in the nucleic acid sequence of the F gene U(721)G changing an 
isoleucine residue to a glutamine residue and U(992)C changing a valine residue to an 
alanine residue. 
 To investigate further the sequences present in the virus stocks, 14 independent 
clones from two separate RT-PCRs were prepared. These clones contained sequences 
from the SH and G genes of the PVM strain J3666 virus stock prepared after 5 passages 
in tissue culture. The sequence analysis showed that only 2 of the 14 clones contained a 
sequence of the G gene identical to that described by Randhawa et al. (1995). The 
remaining 12 clones contained a G gene in which the mutation in the stop codon of the 
first ORF made a single ORF extending from the first ORF to the second ORF. These 
data strongly suggest that the virus stocks used contain a mixed population of virus 
sequences. It is therefore not possible to determine which sequence(s) are responsible 
for the pathogenic phenotype. However, a major difference in the sequences lay in the 
organisation of the G gene encoding the G glycoprotein. The differences in organisation 
may play a role in G gene expression and this was investigated further. 
Collins et al. (1995) described a reverse genetics system for HRSV to study the 
replication requirements of HRSV in vitro. Soon after its first description, the reverse 
genetics approach was used to study the effect of gene deletion or gene modification in 
the pathogenesis of HRSV. It was identified that a point mutation in the gene start of the 
M2 gene is responsible for attenuation and temperature sensitive phenotype in vaccine 
candidate cpts248/404 (Whitehead et al., 1998a; Whitehead et al., 1998b). Using the 
reverse genetics approach, it was shown that the SH deleted recombinant viruses were 
attenuated in mice (Bukreyev et al., 1997), showing a moderate reduction in growth in 
the upper and lower respiratory tract of chimpanzees. In chimpanzees the ΔSH 
produced less disease than the wildtype virus (Whitehead et al., 1999). NS1 and NS2 
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deleted HRSV and also HRSV ΔNS2 are highly attenuated in the lower respiratory tract 
of chimpanzees (Whitehead et al., 1999).  The presence of other mutations including a 
missense mutation changing the TyrosineAlanine at amino acid 1321 of L gene 
caused attenuation in the virus (Whitehead et al., 1999; Whitehead et al., 1998b). Teng 
and Collins (1999) showed that the NS2 gene is not essential but is important for the 
efficient replication of HRSV, and the recombinant viruses with tandem stop codons in 
their NS2 gene produce revertant mutants to restore the NS2 gene function (Teng & 
Collins, 1999).  
Following the advances achieved in the study of HRSV, a reverse genetics 
system was employed to study the virulence of BRSV (Buchholz et al., 1999; Schlender 
et al., 2000). Using a recombinant vaccinia virus, Schlender et al. (2000) demonstrated 
that both NS1 and NS2 act together to suppress host interferon response. The function 
of NS1 and NS2 genes of PVM in antagonising the interferon α and β and interferon λ 
(IL-28) have also shown (Heinze et al., 2011). This suggests that both NS1 and NS2 
genes in pneumoviruses may act as interferon antagonists to modulate the innate 
immune response (Heinze et al., 2011; Schlender et al., 2000; Whitehead et al., 1999).  
More recently, a reverse genetics system was used to investigate the effect of the 
G gene of PVM in pathogenesis. It was shown that deletion of the G gene, or deletion of 
the cytoplasmic tail of the G protein resulted in virus attenuation in mice (Krempl et al., 
2007). 
The common feature in all of these studies was that the genetic backbone of the 
recombinant viruses was derived from a pathogenic virus. The studies therefore, 
employed a principle of establishing which mutations resulted in a loss of pathogenicity. 
While useful, this approach suffers from the problem that the role(s) of specific genes in 
reducing pathogenicity is not directly addressed. In the work described here the genetic 
backbone for the reverse genetics studies was that of PVM strain 15 (Warwick) which is 
not pathogenic in mice even when large doses are administered (Cook et al., 1998). 
Thus any mutation introduced into the virus genome are assessed by the appearance of 
pathogenicity and resulted in the gain of function. Having established a robust reverse 
genetics system based on work by Dibben (2006) and Thorpe and Easton (2005), it was 
used to specifically investigate the role of the G protein of PVM and its expression in 
pathogenesis. The structures of the G gene and the G glycoprotein of HRSV and PVM 
were reviewed briefly in Section  1.2.1.1.1. While the absence of the G protein in vitro 
does not have any significant effect on HRSV replication, its role in the virus 
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immunogenicity and pathogenicity in vivo has been a major topic in the pneumoviruses 
molecular biology (Teng et al., 2001). It has been reported that a recombinant HRSV in 
which the G gene was deleted was highly attenuated in the respiratory tract of mice 
(Teng et al., 2001). In the same study, it was shown that HRSV containing only the 
secreted form of the G glycoprotein is less attenuated (Teng et al., 2001). These data 
suggest an important role for the G glycoprotein in the virus replication in vivo.  
The G gene in both HRSV and PVM contain two ORFs (Wertz et al., 1985). In 
PVM strain J3666 the two ORFs are placed close to each other and in PVM strain 15 
(Warwick) the ORFs are overlapping each other (Randhawa et al., 1995; Thorpe & 
Easton, 2005). The presence of an upstream ORF has been shown to modulate the gene 
expression of a downstream ORF for many eukaryotic genes (Child et al., 1999b; 
Kozak, 1984; Meijer et al., 2000). The possible effect of the presence or absence of the 
first ORF of the G gene in PVM strains 15 (Warwick) and J3666 in the expression of 
the downstream ORF of the G gene was analysed. It was shown that in recombinant 
viruses with a common genetic backbone derived from the non-pathogenic strain 15 
(Warwick), the gene organisation of the G gene in PVM strain J3666 can affect the 
pathogenicity of the virus. The recombinant viruses in which the G gene was based on 
that from PVM strain 15 (Warwick) observed no signs of pathogenesis even when 5000 
pfu was inoculated into mice. Surprisingly, removal of the first, overlapping ORF of the 
PVM strain 15 (Warwick) G gene resulted in transient weight loss in mice inoculated 
with 5000 pfu. The transient weight loss is indicative of mild pathogenesis. The 
recombinant virus containing the PVM strain J3666 G gene showed clear signs of 
infection and weight loss in mice infected with the highest dose of virus. When the first 
ORF in this construct was removed the virus became non-pathogenic. These results 
indicate that the presence of the first ORF upstream of the main ORF encoding the 
PVM G glycoprotein has an effect on pathogenesis. 
To examine whether amending the organisation of the G gene affects the 
expression levels of the G protein, a series of minigenome replicons was designed. The 
dicistronic minigenome replicons, known as pG-GFP minigenomes, were designed to 
express the luciferase gene from their first gene and the G-GFP fusion protein from 
their second cistron. Both cistrons were designed to be controlled by the viral 
transcriptional system, and to minimize the possible effects of the SH-G intergenic 
region and the G gene start sequence in the expression of the G gene to contain the same 
intergenic region and G gene start of the G gene in PVM. The analysis of the expression 
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levels of the G-GFP fusion protein indicated that deletion of the first ORF in the 
constructs resembling the organisation of the G gene in the strain 15 (Warwick) is 
associated with a significant increase in the expression of the G protein. This is 
consistent with the pattern frequently seen in eukaryotic genes. In contrast, deletion of 
the first ORF in the strain J3666 G gene was associated with little or no effect. The level 
of expression of the G protein may be affected by the sequences surrounding the AUG 
intiation codon as discussed in Chapter 5.  
The central role of the G protein in HRSV virulence and in modulating the 
immune system was reviewed in Section 1.3.1.2. The immunomodulatory function of 
the G glycoprotein has been associated with the presence of a domain which mimics the 
fractalkine CX3C ( 1.3.1.2) (Tripp et al., 2001). Fractalkine (also known as CX3CL1) 
was reported as a new class of chemoattractants found in various non-lymphoid tissues, 
such as the small intestine, colon, heart, brain, lung, kidney and pancreas, of healthy 
individuals (Bazan et al., 1997). It consists of a 373 amino acid chain in which the 
chemokine domain is located at the end of a mucin-like stalk and a transmembrane 
domain through which it is anchored to the plasma membrane (Bazan et al., 1997). The 
receptor for fractalkine, CX3CR1, is found in high levels on NK cells and to a lesser 
extent on monocytes and T cells (Imai et al., 1997; Umehara et al., 2001). The 
triggering of the receptor results in release of perforin and granzymes from NK cells in 
a cytolytic response (Umehara et al., 2001; Yoneda et al., 2000). It has been shown that 
exposure of NK cells to the soluble form of fractalkine (s-fractalkine) increases the 
cytotoxicity of the NK cell activities (Yoneda et al., 2000) and granular exocytosis of 
NK cells responds in a dose dependent manner (Yoneda et al., 2000). The chemokine 
mimicry function of the G glycoprotein of HRSV might contribute in attracting NK 
cells, adhesion to the cellular membranes of infected epithelial cells expressing the G 
glycoprotein, and result in the damages of the lungs, and the levels of G protein 
expressed by the virus may affect the intensity of this response. 
The effect of HRSV G and/or SH proteins in reducing the number of pulmonary 
NK cells and the expression of IFN-γ was shown by Tripp et al.  (1999). The CX3C 
region of the G glycoprotein was reported to be associated with a reduction in the 
number of CX3CL1+, HRSV-specific and IFN-γ expressing lymphocytes, while in the 
same population the number of IL-4 expressing cells increased (Harcourt et al., 2006). 
These data emphasize the chemokine mimicry role of the G glycoprotein in controlling 
and affecting cytokine and chemokine production in the infection sites.  
133 
 
There are numerous examples of using animal models to study the pathogenesis 
of human viruses. Such models include those in which the virus replicates in its natural 
host. The models have been extensively used to explore different feature in molecular 
biology of pathogenesis and the mechanisms involved in host defence. Woodchuck 
hepatitis virus is one such system which has been employed to elucidate the molecular 
biology and pathogenesis of hepatitis B virus (HBV) (Shafritz & Lieberman, 1984; 
Snyder et al., 1982; Summers et al., 1978). Studying the interaction between PVM and 
the mouse and extrapolating and evaluating the data to a larger model (BRSV and 
bovine) may facilitate the discovery of the factors influencing the pathogenesis of 
pneumoviruses. Availability of a reverse genetics system for PVM could facilitate 
studying of virus pathogenesis. A clear description of the pathogenesis of PVM could 
be extrapolated to explain the pathogenesis of HRSV. 
The data presented here have shown that the PVM system is available for 
manipulation to explore the mechanisms of pathogenesis of pneumoviruses. Further 
studies are likely to identify additional factors which play a role in the disease process. 
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APPENDIX I: Primers sequence 
 
The sequences are listed 5’ to 3’. 
 
1stORFOut-15-F 
CCACAAGCTGACTTCACCTAGTGCGGGAAGAACTTAGAAGTGAGTGGCAG 
 
1stORFOut-15-R 
CTGCCACTCACTTCTAAGTTCCTTCCCGCACTAGGTGAAGTCAGCTTGTGG
  
1stORFOut-J6-F 
AGTACTATCCTATTGGAATCAAGCGAGACC TGTAGAGCAGCTCATAC  
 
1stORFOut-J6-R 
GTATGAGCTGCTCTACAGGTCTCGCTTGAT TCCAATAGGATAGTACT  
 
22K7 
CGATGGGTCTGGACCATCC 
 
F11 
ACTGTTTACTATCTTAGCAA 
 
F14 
ACAGTCTATAGAACTTCTTA 
 
F17 
TCCACTGCACTACTATAGAT 
 
F20 
GTCAACGCTGACACACTGGTTTAT 
 
F7 
TATTGAGTCATGCAAGAGCA 
 
F9 
CATTGTAGGCGGCATGGCTG 
 
G(4878)R 
GGAGGGGTGGATGTGCTGTTC 
 
G_Round(F) 
AGTTGACTTCACTTAGTATGGGAAGGAACTTTGAAGTGAGTGGCAGCATTA
CCAATTTG AACTTTGAGAGAACTCAGCATCC  
 
G_Round(R) 
AGTAGTTCTCTTGTATGAGCTGCTCTACAGGTCTCATTTGATTCCAATAGGA
TAGTACT TATCC 
 
158 
 
G4E 
GGCCAGGATAAGTACTATCCTATTGG 
 
G9 
CCCGAATTCATTAACTACTGATAAGGTT 
 
GFPFor 
TTCCAAGGAGGTCTAATTCTCCCATGGTGA GCAAGGGCGAGG 
 
GFPRev 
AATTTACTGCAGTTATGATCTAGAGTC 
 
J1 
ACGCGAAAAAATGCATAACAAAAC 
 
J4 
CTGCTGGTCATGTTGATCTCGA 
J5 
GATTTCACACAGCACAACAACC 
 
J7 
AAGTACACCTGGCCTCACAGTT 
 
L1D 
GGTCATCTGCTCAGTAAGTTGT 
 
L1F 
CTAGAGTTTGCCTTACACCAAC 
 
L1H 
CATCCTGCAATTCTTTCCGG 
 
L1J 
CTCTTTGAGGCTTATATCAGCTG 
 
L2C 
GAAGGACACCAGATTTCTTGAC 
 
L2F 
CAGCTCTGTTGCAAACATAGAC 
 
L2G 
ACTGAGAGGTTTGGAGACGA 
 
L2H 
CTGAGTAGTAAACAGTTCCACTC 
 
L3C 
CTCACTACAGGAAGTTCAGTG 
 
159 
 
L3D 
CGTTCTCGATGACGGACATGT 
 
L3E 
TCATAGGTGAAGGTGCTGGA 
 
L3F 
TAGTGGTGTTAAGCACTGGTTG 
 
L3G 
TACAGCGAGGTATTGCACTC 
 
L3H 
GCCCTGTTTACCATAACAAATGG 
 
L50 
CTTACAACTCTTCCTCTCTAGC 
 
M1 
CAGCCAACATATCACTAACTGTG 
 
M2 
CACTGTACCCAGCATTACTCCCA 
 
MG_Stop(F) 
CCTGTAGAGCAGCTCATACAAGAGAACTACTAGTTGACTTCACTTAGTATGG
GAAGG 
 
MG_Stop(R) 
CCTTCCCATACTAAGTGAAGTCAACTAGTAGTTCTCTTGTATGAGCTGCTCT
ACAGG 
 
N1 
GTAAAATGTGTGGACACACAG 
 
N3 
GGATTCTATCACATCAGAAAT 
 
N5 
TGAAAGCCGAGAAAGCCAGGT 
 
N4 
GCGAAGAAGTGGCAGAAATAG 
 
NcoIFor 
CCTGAAAAAAGTTAGGATAAATAACCATGG AGAAAAAAATCACTGG  
 
NcoIRev 
CCAGTGATTTTTTTCTCCATGGTTATTTAT CCTAACTTTTTTCAGG 
 
160 
 
NcoLucF 
AGCCACCATGGAAGACGCC 
 
NS1B 
CTTGCCCTGTAGAACTAAACACG 
 
NS2A 
CCGAGCCTACAAAACATCACTAG 
 
NS2B 
GAGCTGACTCAGATCACTCCAA 
 
P15FLSH3.2 
ACCAACGTCGACATGACAACCACACATACACACCCAC 
 
P15FLF2.2 
AATTATGCCCGGGTACAATTGTCATGATAAAACTGTGAGG 
 
P15FLL5 
TTTAATATTTGCGGCCGCTCAGTTATTAACCCAAAATTGTTAATTATGTAG 
 
P15FLL7 
GGAGGAGACCTGGTTTCATTATTCTTGTCAGC 
 
P15FLL7.2 
GTGTCTGCACCTGGTTTCATTATTCTTGTCAGC 
 
 
P15FLSH3 
GGAGGAGTCGACATGACAACCACACATACACAC 
 
P15FLSH3.2 
ACCAACGTCGACATGACAACCACACATACACACCCAC 
 
P15FLM2 
GGAGGGGTCGACGTTGGTGGCGGTGGTTGT 
 
 
P15FLM2.2 
GTGTGGTTGTCATGTCGACGTTGGTGGCGGTGGTTGTTGTG 
 
P15FLM23 
GGAGGGCCCGGGCATAATTGAGTTAGTTAA 
 
P15M23.2 
GACAATTGTACCCGGGCATAATTGAGTTAGTTAATTAAAAACTTAGG 
 
P15FLM25 
GGGAAAGGAGGCGGCCGCAAAAAAAGGAATACAG 
 
161 
 
P15FLN3.2 
CTCAGATCACTCCAACCAGGTGAGAGATCCACCACCTATAGC 
 
P2A 
CTTTGTGGAACCCGAGGAG 
 
P2F 
CGTCGAATTCACCATGTCACCAAATATAACATGCCCCC 
 
P2R 
CGTCTCTAGACTACAGATGAAGAACCCGGCTCTTGG 
 
P3 
GAGTCTGATGTTGACATTGAGAC 
 
P4 
CAAGTCTGACATCTTGACTGTC 
 
PL1 
CACATTAACTTCTTGTTCATCA 
 
PL23 
GGAAAATTATACAAAGAAGTGTTG 
 
PL29 
GTCAATATGGTGTCTGGAAC 
 
PL48 
CTAGACATGTGAGAAGGTCCCA 
 
PstIFor 
GGGGGGCTGCAGTCCTTCAATAAACCCCAG GC 
 
PstIGJ3666 
GGGGGCTGCAGCAGCCTTTGCAGTATGTCGTCTA 
 
PstIRev 
CCTCGCCCTTGCTCACCATGGGAGAATTAG ACCTCCTTGGAA 
 
PstLucR 
CCCCCCTGCAGTTACACGGCGATCTTTCCG C 
 
QCF3BSHT1F 
CCTTCAATAAACCCCAGGCCAGACCGGTTTACCCTGCTAGACG 
 
QCF3BSHT1R 
CGTCTAGCAGGGTAAACCGGTCTGGCCTGGGGTTTATTGAAGG 
 
QCF3BGL2F 
AGGAGGTCTAATTCTTAAGAGATCTATTCCTGAATTAACTTCAG 
162 
 
 
QCF3BGL2R 
CTGAAGTTAATTCAGGAATAGATCTCTTAAGAATTAGACCTCCT 
 
QCFL2GA4728F 
CCTGACACATTTAGGACTGTTGTAAAAAGTGAACCAAATGTGTAAGC 
 
QCFL2GA4728R 
GCTTACACATTTGGTTCACTTTTTACAACAGTCCTAAATGTGTCAGG 
 
SH2 
AACTGTGCATTGGCTGCTGAC 
 
SH4360 
GTTCATCCCAATCACCCTCCAC 
 
T7 
TAATACGACTCACTATAGG 
 
 
